Characterisation and strategic treatment of dystrophic muscle by Laws, Nicola

















A Dissertation submitted by: 
 
 
Nicola Laws, BVSc (hons) (UQ), 
Cert. Small Animal Medicine (Royal College of Veterinary Surgeons), 






For the award of 
 






  The mdx mouse is widely used as a model for Duchenne Muscular 
Dystrophy, a fatal X-linked disease caused by a deficiency of the sub-sarcolemmal 
protein, dystrophin This dissertation reports characterisation of the features of 
dystrophy in the mdx mouse, including parameters such as electrophysiological and 
contractile properties of dystrophic cardiac tissue, quantitative evaluation of 
kyphosis throughout the mdx lifespan, and contractile properties of respiratory and 
paraspinal muscles. Following these characterisation studies, the efficacy of 
antisense oligonucleotides (AOs) to induce alternative mRNA splicing in mdx 
skeletal muscles (diaphragm and paraspinal muscles) was evaluated. 
 
 The left atria of younger (<6 weeks) and older (>15 months) mdx mice 
showed consistently lower basal forces and responsiveness to increased calcium, 
while action potential duration was significantly shorter in young mice (3 weeks) 
and older mice (9 and 12 months) (P<0.05). Cardiac fibrosis increased with age in 
mdx atria and ventricles and was elevated in young (6-8 weeks) and old (15 months) 
mdx compared to control mice (P<0.01). This study provided insights into DMD 
cardiomyopathy, and suggested that very young or old mdx mice provide the most 
useful models. 
 
 Mdx mice show thoracolumbar kyphosis like boys with Duchenne Muscular 
Dystrophy. A novel radiographic index, the Kyphotic Index (KI), was developed 
and showed that mdx mice are significantly more kyphotic from 9 months of age, an 
effect maintained until 17 months (P<0.05). At 17 months, the paraspinal and 
respiratory muscles (latissimus dorsi, diaphragm and intercostal muscles) are 
significantly weaker and more fibrotic (P<0.05). 
 
Administration of AOs at four sites within the diaphragm at 4 and 5 months 
of age significantly increased twitch and tetanic forces compared to sham treated 
mdx (P<0.05). However, no difference in collagen was evident and dystrophin was 
not detected, possibly due to the low concentration of AO utilised. This study 
suggested that AOs can provide functional improvement in treated skeletal muscles. 
 
 Monthly injections with AOs into the paraspinal muscles from 2 months to 
18 months of age alleviated kyphosis, without significantly altering twitch and 
tetanic forces of latissimus dorsi, diaphragm and intercostal muscles. There was 
evidence of less fibrosis in diaphragm and latissimus dorsi muscles (P<0.05) and 
reduced central nucleation of the latissimus dorsi and intercostal muscles (P<0.05). 
Again, dystrophin was not detected by immunoblot.  
 
These studies indicate that very young and old mdx mice display previously 
uncharacterised dystrophic features, and are useful models for testing new therapies 
such as AOs. Low doses of AOs were shown to be safe and efficacious for long-
term use, however there remains a need for testing higher concentrations and 
improved delivery strategies.   
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LAYOUT OF DISSERTATION 
A chapter format has been used for the presentation of data within this thesis as it 
was felt that individual studies were complete projects in their own right, with 
differing objectives and sometimes scientific methods. For this reason each chapter 
included a brief Introduction, Aims, Methods, Statistics, Results and finally 
Discussion. To prevent excessive repetition of methods these sections were kept 
brief and explained in greater detail in Appendix B. Likewise, a lengthy review of 
the published literature for each topic was avoided in Chapter 1, but relevant 
information was included (where applicable) as individual chapter introductions or 
within the chapter discussions. Chapter 7 provides an overview of the dissertation, 
highlighting important conclusions, shortcomings and implications for future study. 
The objective at all times was to present experimental data in context with the 
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CHAPTER 1. INTRODUCTION: DUCHENNE 
MUSCULAR DYSTROPHY, LITERATURE REVIEW 
AND SCOPE OF STUDY. 
The disease is one of the most interesting and at the same time most sad…  
       Sir William Gowers, Lancet 1879 
1.1 Duchenne Muscular Dystrophy 
Muscular dystrophies are a heterogenous group of hereditary diseases 
characterised by muscle necrosis, progressive muscle wasting and weakness. 
Phenotypically, they are the result of uncompensated deficiencies in metabolites or 
proteins, exceeding muscle’s demands for differentiation, maturation, growth and 
repair (Infante and Huszagh, 1999). Abortive cycles of necrosis and repair follow, 
leading to the eventual loss of satellite cells, endomysial fibrosis and adiposis. The 
majority of the dystrophies, but not all, are disorders of the dystrophin-glycoprotein 
complex that spans the sarcolemma, with Duchenne Muscular Dystrophy (DMD) 
the most prevalent and severe, usually leading to the death of affected males by their 
third decade. 
For the purposes of this review the term dystrophic applies to muscles lacking 
the protein dystrophin, including the disease in man and several animal models.  
 
1.1.1 Brief history of Duchenne Muscular Dystrophy 
Clinical descriptions of boys with progressive muscle wasting and weakness,  
enlarged calves and muscle contractures appeared in the 18th and 19th Centuries, 
authored by physicians Charles Bell (Edinburgh, 1774), Gaetano Coste (Naples, 
1836), Mr Partridge (London, 1847) and W.J. Little (London, 1853). However, the 
most complete early description of the disease came from Dr Edward Meryon 
(London, 1851), whose dissertation on 8 affected boys from 3 families suggested a 
genetic link and gender predilection. He concluded from microscopic analysis that 
the condition involved muscle tissue, and spared the nervous system. Duchenne de 
Boulogne reported some 40 cases in the 1850’s and 1860’s, including more detailed 
histology obtained from muscle biopsies. (Early history reviewed by (Gowers, 




description of ‘Pseudo-hypertrophic Muscular Paralysis’ in a series of Lancet 
papers published in 1879 (Gowers, 1879). He brought attention to the common 
manifesation of muscular dystrophies now known as ‘Gower’s manoeuvre’, where 
affected individuals have difficulty rising, using their hands to incrementally walk 
up their thighs until able to stand (Figure 1.1), and the strong inheritance  from the 
maternal side ‘like haemophilia’. 
 Since these times the classification of different forms of muscular 
dystrophies, as well as identification of rare forms, has been performed. Becker 
Muscular Dystrophy (BMD), an allelic form of DMD with a milder phenotype was 
recognised (Becker and Kiener, 1955). Gene specific probes were developed and the 
cDNA was cloned and sequenced (Koenig et al., 1987), and the protein dystrophin 
was identified (Hoffman et al., 1987). Studies on the localisation (Koenig et al., 
1988) and function of dystrophin were then undertaken in earnest, most involving 
the murine model of DMD; the mdx mouse, discovered in a colony of 
C57Bl/10ScSn (Bulfield et al., 1984). The dystrophin-like protein, utrophin, was 
discovered in 1992 (Tinsley et al., 1992). 
 Early gene or myoblast transfer studies began in the 1990’s and are ongoing. 
Muscle is a vast organ presenting serious challenges to any somatic gene or cell 
replacement strategy. Adeno-viral associated mini-dystrophin research holds 
promise for the future (Xiao et al., 2000; Gregorevic et al, 2004). Aminoglycoside 
antibiotics such as gentamicin can be used to circumvent premature stop codons, 
and it is hoped new derivative drugs with a wider margin of safety can be used in 
the 10-15% of boys with this form of genetic defect (Barton-Davis et al., 1999). 
Anti-sense oligoribonucleotides offer exciting future prospects for safe and effective 
‘patching’ of mis-sense mutations, allowing a read-through of genetic information 
and production of functional dystrophin-like protein (Wilton et al., 1999; Aartsma-
Rus et al., 2002). The anticipation of a number of Stage Ι clinical trials, provides 
hope to patients and their families, although researchers agree a genetic ‘cure’ may 
realistically be one or two decades away (Scheuerbrandt, 2004). New genotyping 
techniques will allow tailoring of treatments to specific genetic lesions (Flanigan et 
al., 2003). 
 Perhaps the most recent advances in DMD research is into cardiomyopathy 




2004), (Quinlan et al., 2004),(Yue et al., 2004), and the recognition that best 
practice treatment guidelines for cardiac monitoring and care (as promoted for 
respiratory care) can improve longetivity and quality of life (Bushby et al., 2003), 
(McNally and Towbin, 2004).  
 
 
1.1.2.Clinical features of DMD 
Boys with DMD are normal at birth, and clinical signs are not usually detected 
until after they become ambulatory. There is often delayed motor development 
(delays in sitting, standing or walking unsupported) or an abnormal gait when 
walking, running or climbing stairs. Despite an increasing understanding of DMD 
and better diagnostic testing, the average age at diagnosis in the United Kingdom is 
4 years 10 months, almost identical to that of the 1980’s (Bushby et al., 1999).  
Intellectual milestones can sometimes be delayed, in particular speech 
development, with 50-70% of DMD children having a delay in speech at 
presentation. A proportion of boys have behavioural or emotional disturbances, or 
have intellectual impairment (Emery and Muntoni, 2003). 
Enlargement of the calf muscles is a typical early sign, and this hypertrophy 
can sometimes extend to masseters, deltoids, serrati anterior and quadriceps. Muscle 
weakness is bilateral and symmetrical, resulting in well-defined physical features 
including a broad-based waddling gait, pelvic tilting, lumbar lordosis and toe 
walking. Gower’s manoeuvre is often elicited by 4-5 years of age. Shortening of the 
Achilles tendons and occasionally hip flexors and hamstrings occur (Figure 1.1). 
Respiratory muscles are never evidently weak in ambulatory children, with forced 
vital capacity measurements > 70%. 
Eventually a child with DMD will become confined permanently to a 
wheelchair, with the age that this occurs varying from 7-13 years (Emery and 
Muntoni, 2003). Functional tests, such as the Hammersmith Scale, show a 
progressive loss in motor function. As the disease progresses and muscle weakness 
becomes more profound, flexion contractures occur, and a severe kyphoscoliosis 
develops unless spinal support is provided (Smith et al., 1989).  
There is a progressive decline in pulmonary function with age, leading to 




strong marker of subsequent mortality (5 year survival <8%) (Phillips et al., 2001). 
Sleep-disordered breathing and nocturnal desaturation are common and severe in 
DMD patients (Bourke and Gibson, 2002). Cardiac manifestations range from 
subclinical, progressing to dilated cardiomyopathy and early death from heart 
failure. Clinically apparent cardiomyopathy is present in all patients over 18 years 
of age (Nigro et al., 1990), and shortens life expectancy significantly (Eagle et al., 
2002).  
Sir William Gowers poignant early descriptions of boys with DMD, with its 
accompanying illustrations (Gowers, 1879) are unfortunately still relevant today. 
DMD remains a relentlessly progressive disorder causing significant morbidity and 
early mortality, however the clinical course is altering due to improved 
physiotherapy, early introduction of antibiotics, influenza vaccination, 
glucocorticoid regimes, assistive respiratory devices and spinal stabilisation 
techniques. In particular, nocturnal ventilation has improved survival markedly from 
19 years for non-ventilated patients to 25 years for those receiving ventilation 
(Eagle et al., 2002). Improved delivery and organization of care has meant the 
difference between death in childhood and achieving an independent (although 








Fig 1.1 Illustrations from early treatises on Duchenne Muscular Dystrophy.  
A. Two young boys showing calf hypertrophy and wide based stance 
characteristic of DMD.  
B. During Gower’s manoeuvre, a boy typically uses the strength of his arms    
and hands pushing against his thighs to help him rise from a sitting position.  
C.  A patient displaying progressive weakness and lordosis.  
D.  An advanced case with severe spinal deformity and ligament contractures. 





1.2 The dystrophin gene: room for error 
1.2.1 Incidence of DMD 
DMD is the most frequent of the lethal X chromosome-linked recessive 
disorders, with an occurrence of approximately 1 per 3,500 male births (Emery, 
1993). The mutation rate of 1 in 10,000 for the dystrophin gene is one of the highest 
mutation rates reported, and means 1 in 3 cases of DMD are the result of new, 
sporadic mutations (Muller et al., 1992).  
 
1.2.2 Gene structure and isoforms 
The dystrophin gene spans 2.4 megabases at Xp21.1 and comprises at least 85 
exons (including at least 7 promoters) that have been well conserved throughout 
vertebrate evolution (Koenig et al., 1987; Koenig et al., 1988).  
The genomic locus is nearly 200 times greater in size than the 14kb final RNA 
transcript, with a mean size of exons of 200bp and a mean size of introns of 35kb. 
The DNA encoding the DMD locus represents 1/1000 of total human DNA, and it 
has been suggested that the high frequency of DNA mutations is a direct 
consequence of the sheer size of the gene (Koenig et al., 1987). 
Dystrophin exists in a number of isoforms, with three full length transcripts 
referred to as Purkinje (P), Muscle (M) and Brain (B), reflecting those tissues in 
which they are predominately represented, and at least five other shorter transcripts 
generated by internal promotors (retina, heart, spinal cord, peripheral nerves and 
ubiquitous) (Culligan et al., 1998; Pearce et al., 1993; Emery, 2002). Figure 1.2 
shows a schematic representation of the human dystrophin gene. 
 
1.2.3 Mutation ‘hot spots’ in DMD 
  The high mutation rate and large size of the dystrophin gene has led to the 
characterisation of hundreds of independent mutations, with approximately 65% of 
patients with DMD having large deletions within the gene, centred around two 
mutation ‘hot spots’(Koenig and Kunkel, 1990). The first is located approximately 
1200kb from the 5’ end, clustered around Exons 45-55. The second is located 500kb 




The size and position of the deletion does not often correlate with the clinical 
phenotype observed, an observation largely explained by the reading frame 
hypothesis (Monaco et al., 1988). The majority of frame-shift deletions in these hot 
spots result in severe DMD, as no dystrophin is produced. In-frame deletions of the 
central region of the gene that removes almost 50% of the dystrophin can result in a 
mild phenotype. 
One third of DMD mutations are estimated to arise from point mutations or 
very small deletions that introduce premature stop codons, and these are not always 
centred on the mutation hot spots (Lenk et al., 1993). 
 
1.2.4 Becker Muscular Dystrophy 
DMD is also allelic with a milder condition of similar, but slower clinical 
course, known as Becker Muscular Dystrophy (BMD) (Becker and Kiener, 1955; 
Kingston et al., 1983). BMD usually results from mutations that maintain the 
reading frame, resulting in a partially functional dystrophin transcript (Monaco et 
al., 1988), however exceptions can occur sometimes with frame shift deletions, 
truncation mutations or splice site mutations also being described in BMD patients. 
(See also Sections 1.3.1, 1.3.2) 
 
1.2.5 Utrophin 
The dystrophin coding region also demonstrates homology with other classes 
of genes, and the entire dystrophin sequence is similar to that of utrophin (Pearce et 
al., 1993). The autosomal utrophin gene, located on chromosone 6, is another large 
gene of over 1 Mb in size, encoding the protein utrophin. This protein is present in a 
wide variety of tissues, with the highest levels in lung and kidney. In developing 
skeletal muscle it is localised around the entire sarcolemma, however in adults it 
becomes restricted to the myotendinous junctions and neuromuscular junctions. It 
has sequence homology to dystrophin of over 80% (Tinsley et al., 1992). The 






Fig 1.2 Schematic representation of the dystrophin gene 
a) The size occupied by the gene in kilobases (kb) 
b) The location of the various first exons and promoters (represented by the 
boxes above the vertical bars that show the dystrophin exons) 
c) Names of the resultant isoforms. B1, M1 and P1 indicate Brain, Muscle and 
Purkinje cell promoters, encoding for 3 full-length isoforms. They are 
located before Exon 2 
d) Tissues in which the various isoforms are preferentially expressed 
(from (Emery and Muntoni, 2003)) 
 
 
1.3 Dystrophin : more than a scaffold. 
1.3.1 Structure of dystrophin 
Dystrophin is a minor component (by mass) of skeletal, cardiac and smooth  
muscle, comprising only 0.002% of its total protein content (Beam, 1988). Despite 
its low abundance, it is an integral part of the large group of transmembrane and 
associated proteins known collectively as the dystrophin-glycoprotein complex 
(DGC). The DGC forms a direct link between the actin cytoskeleton and the 
extracellular matrix, and breaks in this link at one or more levels give rise to 
muscular dystrophy phenotypes. Figure 1.3 illustrates the arrangement of dystrophin 
serving as a bridge between the sarcolemma and sub-sarcolemmal actin filaments. 
  
 
Full-length dystrophin is a very large molecular weight protein (427 
kilodaltons), that is described as having four structural domains (Hoffman et al., 
1987). The N-terminal domain shows homology to α-actinin and binds F-actin in 
vivo and in vitro. One trangenic mouse study indicated that an intact actin-binding 
domain is not essential  (Corrado et al., 1996), however deletions of the amino 







Central rod domain 
Fig 1.3 The dystrophin-glycoprotein complex of skeletal muscle. The diagram 
shows the arrangement of DGC constituents in the sarcolemma and sub-
sarcolemmal areas. Abbreviations: ss = sarcospan, DB= dystrobrevin, syn= 
syntrophin, nNOS= neuronal nitric oxide synthase. 







A large central rod domain with 24 spectrin-like repeats follows this. The 
entirety of this domain appears not to be critical, as many mild Becker patients may 
have large in-frame deletions (for example from exon 17-48) that results in lengthy 
deletions in the rod domain (England et al., 1990).  
 The WW region, which separates the rod from the cysteine-rich domain is 
involved in the interaction of dystrophin with β-dystroglycan, and is a motif found 
in proteins with signalling and regulatory functions. Next comes the cysteine rich 
domain containing sequences involved in calcium binding, and calmodulin binding 
in a calcium dependant manner. Deletions within the cysteine rich regions disrupt 
the interaction between dystrophin and the glycoprotein complex and leads to severe 
dystrophic pathology (Rafael et al., 1996). 
Coiled-coil regions forming the C-terminus bind dystrobrevin, and the 
alternatively spliced region binds syntrophin. The exact function of dystrobrevin 
and syntrophin have not been entirely elucidated, however there is evidence they 
have roles in cell signalling through their binding with neuronal nitric oxide 
synthase (nNOS), sodium channels and various kinases. Deletions of the extreme C-
terminus and alternatively spliced region have no apparent effect on the function of 
dystrophin (Rafael et al., 1996). 
Analysis of dystrophin-deficient mdx mice and DMD patients shows that 
critical mutations causes a loss of the DGC at the myocyte membrane and de-
stabilisation of the whole complex, even though the DGC genes are still transcribed 
and translated (Ervasti et al., 1990). 
 
1.3.2 Evidence for a mechanical role for dystrophin 
The characterisation of the DGC has provided considerable evidence for 
dystrophin acting as a link between the glycoprotein complex and the sub-
sarcolemmal actin cytoskeleton. The linkage between the cytoskeleton and the 
extracellular matrix via dystroglycan is a likely mechanism for anchoring muscle 
cells, stabilising the membrane and protecting the sarcolemma from the stresses 
involved in muscle contraction  (Campbell, 1995). 
Dystrophin is localised to the sarcolemma at those areas of muscle under 
maximum longitudinally and radially transmitted stresses, and at the myotendinous 




 There is conflicting evidence whether dystrophic muscle is more 
susceptible to contraction induced injury using in vivo and in vitro methods. Mdx 
mice subject to markedly increased respiratory muscle workloads by tracheal 
banding did not show an expected increase in severe diaphragm pathology 
(Krupnick et al., 2003). Limb muscles subject to eccentric contractions however, 
did show fibre damage, measured by fluorescent dye leakage (Petrof et al., 1993a; 
Petrof, 1998a). 
 Leakage of muscle enzymes (pyruvate kinase and creatine kinase) into the 
serum occurs in mdx mice, DMD patients (and sometimes non-manifesting carriers) 
and occasionally BMD patients. Mdx muscle fibres also show an increased 
permeability to Evans Blue and Procion Orange, indicative of significant membrane 
lesions (Matsuda et al., 1995).  
 
1.3.3 Cell signalling role for dystrophin 
The DGC is a multifunctional protein complex, and there are strong 
arguments that its primary role is transmembrane signalling (Rando, 2001). The 
mechanisms of cell death due to mutations of the DGC are related to cell survival 
pathways and cellular defence mechanisms regulated by those signalling cascades. 
Components of the DGC are not muscle specific, but are widespread, suggesting 
universal and vital functions. 
There are numerous signalling molecules associated with the DGC, and the 
list continues to grow. They include calmodulin (which binds dystrophin and 
syntrophin), calmodulin-regulated kinases, Grb2 and nNOS. nNOS binds to 
syntrophin, which binds to dystrophin and  α-dystrobrevin. The product of nNOS, 
nitric oxide (NO) has cell protective properties, including actions as a free radical, 
the induction of cGMP-dependant cell survival pathways and a local vasodilatory 
effect on vascular smooth muscle, resulting in less ischaemic injury to skeletal 
muscle cells. nNOS is absent in the sarcolemmal or cytoskeletal fractions of mdx 
mice (Brenman et al., 1995b), however mice deficient in dystrophin and nNOS do 
not have an exacerbation of muscle pathology (Crosbie et al., 1998);(Chao et al., 
1998). 
Evidence from transgenic mouse studies expressing the Dp71 isoform 




membrane, however a severe phenotype still results, suggesting that the N and C 
terminal domains are required for normal dystrophin function, including cell 
signalling (Cox et al., 1994). 
 
1.3.4 Calcium homeostasis 
Early studies showed increased deposits of calcium (demonstrated by 
alizarin red stain) in muscle biopsies of DMD patients (Bodensteiner and Engel, 
1978). The processes of this calcium entry remain controversial. There is an 
increased activity of plasma membrane Ca2+ channels in myotubes of DMD patients 
and the mdx mouse at a time when dystrophin is first expressed (Fong et al., 1990), 
although other researchers could not verify these findings in the muscles of young 
mice (Head, 1993). Patch clamp studies demonstrated calcium entry through novel 
stretch inactivated ion channels in mdx myotubes, which could account for 
sufficient Ca2+ influx to elevate intracellular Ca2+ to pathological levels (Franco and 
Lansman, 1990). Recently new fluorescent techniques showed higher calcium in 
mdx myotubes and adult mdx fibres. These effects can be inhibited by the ion 
channel blockers nifedipine and amiloride(Hopf et al., 1996; Tutdibi et al., 1999).  
While some researchers argue that calcium accumulation is secondary to the 
degenerative processes occurring in dystrophin-deficient muscle, and not an 
inherent property of it (McArdle et al., 1995; Reeve et al., 1997), there is growing 
evidence using patch clamp techniques that subsarcolemmal accumulation of 
calcium in mdx muscles is high enough to induce Ca2+-induced-K+ release upon 
depolarisation. In addition there is passive influx of Ca2+ and an increased number 
of entry sites in dystrophic muscle (Mallouk and Allard, 2002; Mallouk et al., 2000) 
While it is unlikely that the DgC is an integral component of  Ca2+ channels 
itself, it could play a role in the proper organisation of such channels within the 
membrane, as well as the transmission of mechanical signals to channel gating 









1.4 Pathophysiology of dystrophin deficient muscle 
1.4.1 Initiation of necrosis 
Cell death in dystrophic muscle is not inevitable, but reflects a propensity 
that varies between muscles, changes with age and differs between species. Many 
characteristics of dystrophic muscle are stereotypic for necrotic processes, including 
raised intracellular Ca2+, increased volume of the sarcoplasmic reticulum, abnormal 
morphology of mitochondria and inflammation  (Bulfield et al., 1984; Anderson et 
al., 1988);  (Cullen M.J. and Jaros, 1988); (Stedman et al., 1991). The initiating 
event in the dystrophic process remains contentious, with arguments for and against 
elevated Ca2+, membrane damage or apoptosis acting as triggers (Tidball et al., 
1995).  
There appears to be no close connection between mechanical loading and 
cell death, with one study showing decreased degeneration in the limb muscles of 
exercised mdx mice (Dupont-Versteegden et al., 1994b), while another contrasting 
study employing immobilisation of mdx hind limbs by splinting also resulted in a 
significant reduction in degeneration (Mokhtarian et al., 1999). Recent cardiac 
studies showed that mechanical stress such as exercise or aortic banding was 
necessary to cause significant heart pathology (Danialou et al., 2001b; Nakamura et 
al., 2002).  
Myonuclear studies demonstrating fragmented double stranded DNA, and 
abnormal chromatin in mdx muscles lends weight to a primary apoptotic process 
followed by necrosis (Tidball et al., 1995). This scenario does not rule out the role 
of high intracellular Ca2+, as raised calcium is a common occurrence in well-
documented models of apoptosis (Cohen and Duke, 1984). High Ca2+ can cause 
necrosis, but may also be an initiator of apoptosis (Tidball et al., 1995). 
 
1.4.2 Downstream events 
The abnormally high Ca2+ content of dystrophic muscle activates calcium 
dependant proteases (especially calpains) that cause widespread proteolysis (Turner 
et al., 1988; Turner et al., 1993). Proteases can themselves modify calcium leak 
channels, thus a vicious cycle of disorded calcium homeostasis ensues (Alderton 




reduction in oxidative phosphorylation and eventual cell death. Additional 
mechanisms play a role in the pathogenesis of DMD, including defective glucose 
utilisation, a blunted vascular response to exercise, increased susceptibility to 
cytokines and oxidative stress, and aberrant cell signalling (Rando et al., 1998; 
Thomas et al., 1998; Heydemann and McNally, 2004). A schematic representation 
of the patho-physiological sequences in dystrophic muscle is shown in Figure 1.4. 
 
1.4.3 Myocyte regeneration and fibrosis  
Normal muscle is post-mitotic, but is capable of regenerating due largely to 
the proliferation of a population of mononuclear muscle precursor cells (satellite 
cells) within the basement membrane of fibres (Ferrari et al., 1998). In dystrophic 
muscle, regeneration fails to keep up with necrosis, so that atrophy eventually 
results. DMD muscle precursor cells in culture show fewer replications than age 
matched controls, thought to be due to shortened telomere lengths from prior 
replication cycles in vivo (Decary et al., 2000). There may also be a role for insulin-
like growth factor 1, as mice over-expressing this cytokine show decreased 
myonecrosis, improved muscle regeneration and protection against apoptosis 
(Barton et al., 2002).  
Chronic accumulation of fibrous tissue is a hallmark of dystrophy in both 
boys with DMD and the mdx mouse. Studies have demonstrated the role of T 
lymphocytes in this process, particularly in the diaphragm (Morrison et al., 2000). 
Transforming growth factor-β1 has also been mooted as a mediator of fibrosis in 
DMD (Bernasconi et al., 1999) and the canine model of DMD (Passerini et al., 
2002). 
 
1.4.4 Gene expression  
In recent years there has been interest in screening muscle cDNA arrays 
from DMD patients. Upregulation of 4 mitochondrial mRNA transcripts were found 
in one study, despite diminished mitochondrial enzyme activity. This upregulation 
of mRNA in response to low protein levels may be a short-term compensatory 
response, or due to oxidative damage, which is particularly important in 
mitochondrial compartments (Tkatchenko et al., 2001). Titin mRNA was markedly 




formation of thick filaments, could contribute to sarcomere disorganisation and 
myofibril fragility during contractions. Another study found 80 downregulated 
genes, 36% of which were mitochondrial genes, while 12% involved cell signalling 
or cell growth and differentiation. The largest group of upregulated genes were 
developmentally regulated genes such as  cardiac α-actin, embryonic myosin heavy 
chain, acetylcholine receptors and others (Chen et al., 2000). Noguchi and 
coworkers were the first to highlight differences between individual DMD patients 
at a molecular level, noting differences in gene expression for HLA-related proteins, 
myosin light chains and troponin T (Noguchi et al., 2003). Temporal gene 
expression studies from mdx diaphragms provided evidence that secondary factors 
are important in dystrophies, with coordinated increases of many cytokines, 
chemokines, leucocyte adhesion factors and complement system activators (Porter 
et al., 2002)  
 
 The multitudinous complex pathways involved in the progression of DMD 
pathology still require extensive unravelling. Debates over initiating events, 
exacerbating factors, the relative importance of cell signalling pathways, up- or 
downregulated genes, and oxidative damage are ongoing. Far from being solely 
academic arguments, the elucidation of these hierarchical or causal relationships 
will go a long way to influence the development and targeting of future therapies. It 
is likely that further gene expression profiling will facilitate this process. The lack 
of inevitability of early and widespread necrosis in all models of dystrophy means 
novel pharmaco- or genetic therapies could have an eventual role in modifying 
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1.5  Dystrophin deficiency in species other than man 
1.5.1 Range of animal models for DMD 
 There are a number of naturally occurring dystrophin deficient animal 
species, and many more transgenic models. The most widely used is the muscular 
dystrophy X-linked mouse (mdx), discovered in a colony of C57Bl/10ScSn mice in 
Scotland when screening the colony for the serum enzymes pyruvate kinase and 
creatine kinase (Bulfield et al., 1984). The canine model for DMD, the Golden 
Retriever Muscular Dystrophy dog (GRMD) was recorded a few years later 
(Kornegay et al., 1988). The first dystrophin-deficient cats were shown to have 
remarkable muscle hypertrophy and histological features of necrosis and 
regeneration, but not fibrosis (Carpenter et al., 1989). These 3 species will be 
discussed in greater detail below. 
 There are a variety of other models including the dystrophic chicken 
(Dawson, 1966), sheep (Paulson et al., 1966), cow (Poukka, 1966), zebrafish, Danio 
reio, (Chambers et al., 2001; Bolanos-Jimenez et al., 2001; Lu et al., 2003), and 
nematode, Caenorrhabditis elegans, (Mariol and Segalat, 2001). The use of these 
models is not widespread, due largely to their phenotypic or genetic dissimilarity to 
DMD.   
 
1.5.2 Hypertrophic Feline Muscular Dystrophy cat 
 The first description of X-linked muscular dystrophy in cats was of two male 
littermates at 23 months of age (Carpenter et al., 1989). Both animals showed 
pronounced hypertrophy of tongue, neck, trunk, limbs and diaphragm, hypertrophic 
cardiomyopathy and evidence of muscle fibre necrosis on histological examination. 
Two domestic shorthair cats with stiff gaits, salivation and lingual hypertrophy were 
diagnosed with muscular dystrophy based on severe histopathological changes in 
their skeletal muscles (myocyte hypertrophy, splitting of fibres and calcium 
deposition) and absence of dystrophin, and were subsequently used to establish a 
colony of HFMD cats at the University of Berne, Switzerland (Gaschen et al., 
1992). Their muscle hypertrophy is a true hypertrophy (rather than 
pseudohypertrophy as seen in DMD), there is little muscle weakness and, with the 
exception of diaphragm muscles in older animals (6-9 months of age), they tend not 




muscle and Purkinje promoter (Winand et al., 1994). This tends to be a lethal 
genetic defect due to secondary complications such as megaoesaphagus (due to 
constriction by the hypertrophic diaphragm), failure to eat or drink, and renal failure 
(Gaschen et al., 1992). Figure 1.5 shows examples of histopathological and clinical 
features of FHMD. 
 
1.5.3 Golden Retriever Muscular Dystrophy dog 
  The GRMD dog has been recognised as an excellent model for research into 
DMD for several decades, and there are now colonies established throughout the 
world, including the United States, Japan, France and Italy. Like DMD, affected 
animals show muscle weakness, elevated serum creatine kinase levels, features of 
multifocal muscle fibre necrosis and regeneration as well as significant fibrosis with 
contracture (Figure 1.5). Electron microscopy showed disruption of myofibrillar 
architecture, particularly in the subsarcolemma, and increased numbers and size of 
mitochondria (Kornegay et al., 1988).  
The genetic defect is a splice site mutation in Exon 6, leading to deletion of 
Exon 7 (Fletcher et al., 2001). Interestingly, although no dystrophin is detected by 
immunohistochemical methods, GRMD dogs may show low level, widespread 
dystrophin using Western blotting.  This suggests that some dogs may use a 
mechanism of alternative processing of mRNA to overcome their mutation to 
produce truncated, but functional dystrophin (Schatzberg et al., 1998). This 
hypothesis could explain the variation in clinical severity noted even within litters 
(Cooper et al., 1988);(Nguyen et al., 2002), and possibly some boys with DMD 
where low level dystrophin is also present (Nicholson, 1993). 
GRMD dogs develop dilated cardiomyopathy. Echocardiographic studies 
show reduced fractional shortening and left ejection fractions, and marked left 
ventricular free wall dysfunction (Chetboul et al., 2004). 
There are a number of reported therapy trials using the GRMD dog, 
including prednisolone studies (Liu et al., 2004), adenoviral vectors expressing 
utrophin (Cerletti et al., 2003), chimeric oligonucleotide injections (Bartlett et al., 
2000); (Fletcher et al., 2001) and haemopoietic stem cell studies (Dell'Agnola et al., 




future years as research into promising new therapies hurry towards Stage 1 
clinical trials. 
 
Fig 1.5 Feline and canine muscular dystrophy 
A B
C D
A: Feline hypertrophic muscular dystrophy (FHMD) cat, showing muscle 
hypertrophy and stiffness of head and neck muscles, failure to groom and tongue 
protrusion. B: Histology of FHMD animals shows regeneration with central nuclei. 
C. Golden Retriever Muscular Dystrophy (GRMD), with pronounced quadriceps 
and biceps femoris atrophy. In contrast the semimembranosus, semitendinosis and 
cranial sartorius muscles are spared (arrows).* denotes femur D. The histological 
features tend to be more severe than FHMD, with endomysial and perimyseal 
fibrosis prominent. (From A.(Shelton, 1999), B (Carpenter et al., 1989), 




1.5.4 The mdx mouse 
1.5.4 i The natural history of the mdx 
It is now realised that the mdx progresses through distinct stages throughout 
its lifespan, and demonstrates varying degrees of skeletal muscle pathology and 
cardiomyopathy depending on age and muscle type (Fig 1.6). These stages impact 
on research into the pathophysiology of DMD, and the timing of therapies targeting 
dystrophic muscle. 
 
1.5.4ii  Skeletal muscle necrosis 
Mdx muscles exhibit early necrosis from day 5 after birth, but only in 
muscles of the head, trunk and girdle. There is an onset of limb muscle degeneration 
around 2 weeks, with a peak between weeks 5 and 8 weeks (Coulton et al., 1988) or 
3 weeks (Grounds  and Torrisi, 2004). The number of centrally nucleated fibres 
increases progressively to reach 50% of all fibres by 2 months and 90% by 3 months 
as the muscle regenerates. A very high centrally-nucleated fibre count is not 
general, however, and some muscles such as the diaphragm have a much lower 
count (Gillis, 1999). Although split fibres are not uncommon in the mdx, the 
presence of connective or adipose tissue is not prominent in mice up to 52 weeks of 
age (Pastoret and Sebille, 1995b). That study found that histologically degenerating 
fibres were seen until 104 weeks of age, and in these older mice large areas of 
muscles were comprised of atrophied fibres surrounded by fibrosis. Evidence of 
regeneration was rare after 90 weeks.  
This evidence of cycles of chronic degeneration of mdx muscles is supported 
by the continual leak of cytosolic enzymes throughout life (Bulfield et al., 1984; 
Coulton et al., 1988) and the high protein turnover observed in adult animals 
(MacLennan and Edwards, 1990). 
Some muscles are more selectively affected by dystrophinopathy, especially 
the diaphragm (Stedman et al., 1991) and postural muscles such as the soleus, 
intercostals and paraspinals (Lefaucheur et al., 1995). There appears to be a relative 
sparing of small fast twitch muscles (Lefaucheur et al., 1995), and extraocular 






















































Fig 1.6 The natural history of the mdx mouse. 
The dystrophin-deficient mouse model of DMD undergoes various stages 
throughout its life, including an acute necrotic period at weaning age, muscular 
hypertrophy between approximately 5-12 months and weight loss and skeletal 
muscle atrophy between approximately 15-24 months. Diaphragm degeneration is 
most pronounced, and begins early in life. Mdx mice do not display overt heart 





1.5.4iii Muscle hypertrophy in the mdx  
Generalised muscular hypertrophy peaks between 6 and 12 months, then 
regresses to the point where 18 month old mice show atrophy (Pastoret and Sebille, 
1995b). Muscle hypertrophy can be due to fibre hypertrophy, hyperplasia (fibre 
neosynthesis) or connective tissue proliferation, although none of these theories 
alone explain the increase in muscle weight or cross-sectional area in the adult mdx 
(De La Porte et al., 1999). Compensatory hypertrophy may occur due to viable 
fibres contracting synergistically against fibres damaged by the dystrophic process, 
with observations that the extensor digitorum longus (EDL) and soleus muscles 
sustain a hypertrophy of 17% and 22% greater respectively than control mice 
(Lynch et al., 2001). Although various authors state that adult mdx muscles are 
‘bigger and stronger’ than age matched C57 muscles (Coulton et al., 1988; 
Partridge, 1997; Pastoret and Sebille, 1995a; Pastoret and Sebille, 1995b; Bobet et 
al., 1998), when forces are normalised for weight and cross-sectional area, the 
forces generated are actually less (Lynch et al., 2001). 
 
1.5.4 iv The mdx diaphragm: the ‘gold standard’ 
Of the skeletal muscles studied in the mdx mouse, only the diaphragm 
exhibits marked and progressive degeneration, fibrosis and functional deficits 
commensurate with limb muscles of boys with DMD (Stedman et al., 1991; Lynch 
et al., 1997; Lefaucheur et al., 1995; Anderson et al., 1998; Coirault et al., 1999). 
One study found that impaired diaphragm strength was associated with qualitative 
and quantitative changes in myosin molecular motors that are responsible for 
generating force, and consequently reduced force per contractile element (cross 
bridge) contributes to weakness (Coirault et al., 1999). There is also a regional 
difference in pathology supportive of contraction-induced injury, oxidative damage 
and muscle use, with those that work harder showing more severe disease, at least in 
the mouse (Anderson et al., 1998). 
 
1.5.4v  Cardiomyopathy in the mdx 
Data concerning the dystrophic involvement of mdx cardiac muscle is both 
limited and conflicting. There is evidence for substantial cardiac muscle necrosis 




(Torres and Duchen, 1987). Lefaucher et al 1995 found foci of inflammation and 
advanced fibrosis in older (at least 20 months) mdx hearts. 
Cardiac functional studies lend weight to significant heart pathology, 
including altered contractility and half relaxation times, and response to exogenous 
calcium in 12 week old mice (Sapp et al., 1996), and electrocardiographic changes 
(Chu et al., 2002; Bia et al., 1999). There are also age and sex related differences in 
cardiac β-adrenoceptors (measured by sensitivity to drugs that either stimulate or 
block these receptors) between 3 month mdx compared to C57 (Lu and Hoey, 2000). 
Altered action potentials are evidence of changes in membrane ion channels 
(Pacioretty et al., 1992), and mdx animals were found to have a significantly higher 
intracellular calcium concentration in ventricular cells, suggesting a defective 
control of calcium may have a role in electrophysiological and contractile properties 
of cardiomyocytes, as well as a noxious effects on cellular integrity (Alloatti et al., 
1995). 
Echocardiography of mdx hearts demonstrated significant differences in 
heart rate and left ventricular dimensions from control mice after 40 weeks of age, 
but not earlier. Fibrosis was seen as a late consequence of dystrophin deficiency 
(Quinlan et al., 2004).  
 
1.5.4vi  Genetic mutation in the mdx  
 The molecular basis of the disorder in mdx mice is a point mutation causing 
a frameshift and a premature stop codon in exon 23 of the dystrophin gene 
(3185C>T) (Sicinski et al., 1989). Despite this termination codon, approximately 
1% of mdx fibres show the presence of dystrophin (so called ‘revertant fibres’), 
possibly as a result of an exon skipping mechanism that restores the in-frame 
reading of the gene (Wilton et al., 1997a). 
More recently mice have been generated with point mutations or deletions in 
various parts of the dystrophin gene, to aid further understanding of critical 
functional domains of dystrophin (Im et al., 1996). 
 
1.5.4 vii Shortcomings and strengths of the mdx model 
 Researchers have questioned the validity of the mdx as a model for human 




regeneration, and lack of significant widespread fibrosis and fatty changes 
following muscle necrosis. It is said to be a better model for regenerative myopathy 
than degenerative processes. However, it remains the most readily available and 
economic model for research into DMD. 
 Dystrophinopathies show a lack of correspondence between phenotype and 
genotype. As commented by (Partridge, 1991), the ability of dystrophin-deficient 
animal models, such as the mdx mouse, to maintain a considerable muscle mass 
with a large resistance to pathogenesis offers ‘a considerable experimental asset, for 
it must be accommodated by any coherent theory of pathogenesis of dystrophin 
deficiency’.  
 Gene knockouts based on the mdx background are useful for loss-of- 
function or gain-of-function studies. Various transgenic strains, again on the mdx 
background, provide useful insights into the pathogenesis of the disease. The mdx 
mouse is proving to be a useful model for screening compounds for potential 
treatment of DMD patients. Compounds considered to be showing a positive effect 
in the mdx mouse are being considered for clinical trials.  
 There is increasing recognition of the importance of cardiomyopathy in 
DMD, and also recently in mdx mice. Like boys with DMD, mice show skeletal 
muscle degeneration and fibrosis before the onset of significant heart disease, which 
does not occur until much later in the lifespan. The gradual onset of 
cardiomyopathy, as well as inherent dysfunction in cardiomyocyte calcium 
handling, makes it a valid model of DMD cardiomyopathy. 
 New gene correction therapies will require extensive testing prior to clinical 
trials, including optimisation of dose, delivery methods and determination of 
transduction efficiency and safety. The short generation time and lifespan of the 
mdx mouse, as well as its close genetic homology to a large percentage of DMD 










1.6 Drug therapy for Duchenne Muscular Dystrophy 
There is no cure for DMD, and current palliative therapies are centred on 
long-term corticosteroid administration (prednisolone or deflazacort), and drugs 
aimed at treating or alleviating heart failure or respiratory tract complications. The 




Following almost two decades of use in patients with DMD, it is clear that 
glucocorticoids can provide short-term functional improvements such as increased 
muscle strength and prolonged ambulation (Wong and Christopher, 2002). 
The precise mechanisms by which glucocorticoids benefit dystrophic muscle 
are unclear. The possible mechanisms include a benefit to myogenesis (Passaquin et 
al., 1993); (Anderson et al., 1996), increased muscle mass due to anabolic effects 
(Rifai et al., 1995), reduction in apoptosis (Lim et al., 2004), stabilisation of the 
sarcolemma (Jacobs et al., 1996), regulation of intracellular calcium (Metzinger et 
al., 1995) and possibly immunosuppressive actions due to a reduction of 
mononuclear cells, although the latter is controversial (Kissel et al., 1993). Gene 
profiling of mdx suggested that genes involved in the immune response are down-
regulated, while structural protein genes were up-regulated after treatment with 
prednisolone (Muntoni et al., 2002). 
 The systemic effects of steroids are problematic, with a proportion of boys 
unable to continue treatment due to weight gain, mood swings and cataract 
development. These changes were found to be significantly less with the oxazolone 
derivative of prednisolone, deflazacort (Biggar et al., 2001). Boys treated with 
deflazacort or prednisiolone can walk significantly longer, have improved cardiac 
and respiratory function and delayed timing for scoliosis surgery (Biggar et al., 
2001; Silversides et al., 2003). The mechanisms are again unknown, but in vitro this 
agent has shown to augment expression of the membrane stabiliser laminin and 
satellite cell activity and muscle repair (Biggar et al., 2002). Deflazacort is 
unavailable in some Western countries, such as the United States and Australia, due 




dose rates for either glucocorticoid, or optimum age at which treatment should 
commence.  
 
1.6.2 Creatine monohydrate 
 Phosphocreatine is an important source of quick energy production in 
muscle, particularly those used for sprinting. Creatine monohydrate is used as a 
nutritional supplement by athletes, and has shown promise for the treatment of 
people with neuromuscular disorders. Its beneficial effects are attributed to 
antioxidant properties, reduction of protein breakdown and enhancement of 
sarcoplasmic reticulum calcium uptake. In mdx mice administered creatinine from a 
young age, the first wave of acute muscle necrosis was markedly reduced in the 
extensor digitorum longus (fast twitch muscle), but not the soleus (slow twitch 
muscle) (Passaquin et al., 2002). Creatine supplementation in DMD patients is more 
controversial. A four-month trial on boys with DMD showed increased handgrip 
strength and an increased fat free mass (Tarnopolsky et al., 2004). Another trial 
provided evidence of increased resistance to fatigue, and improved maximal 
voluntary contractions of patients (Louis et al., 2003). However a double blind, 
cross-over trial showed no improvement in quantitative strength tests (Walter et al, 
2002). Creatine monohydrate is still commonly used as a supplement for boys with 
DMD. 
 
1.6.3 Alternative pharmacological agents 
 Although gene therapy will likely provide the cure for DMD, success still 
remains on the distant horizon. In the meantime there is emphasis on developing 
therapies that alleviate the deleterious consequences of dystrophin deficiency such 
as muscle necrosis, inflammation and scarring. With a better understanding of the 
complex pathophysiology of dystrophic muscle and appreciation of downstream 
events, comes research into new agents such as anti-tumour necrosis factor α, 
(Remicade®), myostatin blocking agents and others.  
Table 1.1 lists current or recently completed clinical trials studying 
alternative pharmaceutical agents, and Table 1.2 lists some recent drug studies in 
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1.7  Gene therapy for Duchenne Muscular Dystrophy 
1.7.1 Dystrophin expression cassettes 
The muscle isoform of dystrophin is encoded on a 14kb mRNA, which is 
considerably shorter than full-length dystrophin, and effective at preventing 
dystrophy in mdx mice (Cox et al., 1993). It is important that gene regulatory 
regions are included in dystrophin expression cassettes, including the muscle 
creatine kinase gene, a polyadenylation signal and an intron.  
Despite their reduced size, these cassettes are still too large to fit in most 
vectors, so much research has focussed on developing mini- or micro dystrophin 
(dys) genes, omitting non essential areas of the gene such as the central rod region 
and the C-terminal. Micro-dys with less than 3 spectrin-like repeats show little 
function, however clones with 4 or more repeats show normal function (Sakamoto 
et al., 2002). Successful mini-dys transfer encoded by recombinant plasmid DNA 
has been performed in mdx diaphragms and hind limb muscles (Decrouy et al., 
1997), showing some protection of injury to muscle fibres.  
 
1.7.2 Vectors for gene delivery 
The four classes of vectors of most interest in DMD research are 
adenoviruses (Ad), adeno-associated viruses (AAV), retroviruses and plasmids, 
although recently equine infectious anaemia lenti-virus has also been utilised for in-
utero gene delivery (Gregory et al., 2004).  
Conventional Ad vectors suffer the limitation of giving rise to transient 
expression of recombinant genes, with levels declining by 1 week and usually 
undetectable by 4 weeks. There appears to be recruitment of immune cells 
(cytotoxic T cells) marking virus-infected cells for destruction (Yang et al., 1995). 
Improved adenoviruses, the so-called gutted adenoviruses, have emerged and show 
less immunogenecity, with greater capacity for larger therapeutic genes such as 
dystrophin (Allamand and Campbell, 2000); (Matecki et al., 2004). Muscle gene 
therapy utilising Ad vectors will likely require repeat delivery to be effective. 
Recent reports of intravascular delivery of Ad mediated reporter genes to mdx 
muscles also show promise for the future (Cho et al., 2000). 
Retroviral vectors are limited to carrying mini- or micro-dys. They are 




incorporated into the host genome, potentially allowing persistent gene transfer 
(VandenDriessche et al., 2002). 
Adeno-associated vectors (AAV) are capable of integration into muscle cells 
and may persist for years (Xiao et al., 2000). It is theoretically possible to 
administer these agents, then provide booster doses to maintain high levels of  
expression. They can accommodate only 4.8kb of exogenous sequence (Flotte et al., 
1995). 
Widespread muscle-specific expression of functional micro-dystrophin in 
mdx was acheieved using vasculature permeabilising agents and delivery via AAV 
pseudotype 6 vectors, with such methods applicable to a variety of genes in addition 
to dystrophin (Gregorivic et al, 2004). 
Naked plasmid DNA shows a remarkable ability to transfer genes to muscle. 
Plasmids have the advantages of minimal immunogenecity and toxicity, and a large 
cloning capacity. They should overcome most viral-vector mediated problems, and 
may be safer. A drawback is their low transfection efficiency when administered by 
intramuscular injection. Advances in electroporation technology will potentially 
assist in high level or long lasting gene expression using this method, at least in 
animal models (Vicat et al., 2000; Murakami et al., 2003). Pre-treatment of muscles 
with bovine hyaluronidase prior to electroporation greatly enhances transfection 
(McMahon et al., 2001). Intravascular delivery of these agents also shows potential 
(Liu et al., 2001a); (Zhang et al., 2004). 
Retention of plasmids may be a limitation, and they will either require repeat 
administration (as for Ad‘s) or modification to enable better integration and 
persistence. 
 
1.7.3 Cardiovascular gene therapy 
There have been few studies examining gene transfer into dystrophic cardiac 
muscle. The challenges for successful gene therapy of cardiac tissue include safe 
and effective delivery, duration of transgene expression, safety of the vector and the 
intrinsic properties of cardiac cells. Cardiomyocytes replicate very slowly, and 
because of their syncytial nature transfection will likely be limited to the immediate 
vicinity, rather than dispersed via a long length of fibre as occurs in skeletal muscle. 




potential for treatment of patients at a young age (Gregory et al., 2004). AAV 
mediated micro-dys persisted for 10 months post injection.  A recent study indicated 
that dystrophin expression in 50% of heart cells of mdx mice would be sufficient to 
treat cardiomyopathy (Yue et al., 2004). 
1.7.4 Clinical trials into gene therapy for DMD 
There are two landmark clinical trials currently underway, or close to 
commencement. 
The first study in France included a completed Stage I trial using 
intravenous administration of a large number of plasmids containing dystrophin 
cDNA into the forearms of patients. It has proved to be safe, but dystrophin 
expression was of the order of 1-10% of myocytes. In the second phase of the trial 
with Duchenne patients, it is planned to inject large volumes of the naked DNA into 
the forearm (Thioudellet et al., 2002; Scheuerbrandt, 2004). At present transfection 
levels are too low to draw conclusions of the validity of these methods. 
The second trial, supported by the Muscular Dystrophy Association of 
America, uses a modified AAV of serotype 2, called AAV 2.5. It contains a mini-
dys construct, lacking the rod regions R3-R21, and C-terminal end, making it one 
third as long as normal dystrophin (Wang et al., 2000). A Phase I/II trial will 
commence in late 2005 after toxicity and biodistribution studies are completed. The 
trials will involve 6 boys with DMD, older than 10 years. Placebo or vector 
injections will be administered into biceps muscles, with muscle strength testing and 
biopsies performed 6 weeks later (Scheuerbrandt, 2004). 
 
1.8 Ex vivo strategies using myoblasts or stem cells  
1.8.1 Myoblast transplantation 
The basic tenet of myoblast transfer is that its benefit would arise from a 
generation of significant amounts of donor muscle containing normal dystrophin, 
and the long-term survival of these donor muscle fibres within the patient’s muscles 
(Partridge et al., 1998). Early trials on myoblast (immature muscle cell) transfer into 
dystrophic mouse muscles showed some functional benefit in protecting adjacent 
fibres against necrosis, however effects were limited to a small region surrounding 
the injection site and there was evidence of immunological rejection of implanted 




outcomes, but may have significant side effects. Autologous myoblast 
transplantation could overcome rejection problems (Floyd et al., 1998); (Moisset et 
al., 1998), however myocytes from patients with DMD are not characteristically 
prolific in cell culture and may not be suitable for this approach. 
A family of genes including myoD has been identified that converts non-
muscle cells (eg fibroblasts) into muscle cells, and these may provide new sources 
of cells for gene therapy applications (Weintraub et al., 1989). There are also 
problems with cell survival that need addressing, however studies examining 
manipulation of telomerase expression may expand the replicative lifespan of 
myoblasts from normal and DMD patients (Biggar et al., 2002). 
 
1.8.2 Stem cell therapy 
New approaches involve stem cell recruitment via bone marrow 
transplantation techniques (Gussoni et al., 1999), or intra-arterial administration into 
mdx limbs (Torrente et al., 2001). Transplantation of myogenic progenitor cells into 
immunosupressed mice show that they can migrate to necrotic muscle and 
participate in its regeneration (Ferrari and Mavilio, 2002). Low efficacy of current 
stem cell approaches will require development of new strategies for expansion and 
active recruitment to myogenic differentiation. 
 
1.9  Strategies to upregulate utrophin 
Utrophin is a promising candidate for DMD therapy. Like dystrophin, it is 
capable of providing cytoskeletal linkage between actin and the extracellular matrix 
via DGC binding. It shows four structural domains like dystrophin. Mdx mice 
overexpressing a truncated utrophin transgene have reported to show reduced 
pathology as well as improved muscle function (Deconinck et al., 1997b). Utrophin 
has the advantage of not being recognised as a neo-antigen in dystrophin-deficient 
muscle, so cell-mediated immunity problems seen with dys transfer should be 
largely circumvented (Ebihara et al., 2000). 
An alternative approach is to increase expression of utrophin to the 2-3 fold 
increase in protein level required to prevent dystrophic pathology at the translational 
level via promoter activation, either via the use of small diffusable chemical 




drugs (Perkins and Davies, 2002). Heregulin, L-arginine, NO or hydroxyurea are 
thought to act by utrophin promoter activation mechanisms, although there is 
contention regarding the efficacy of L-arginine in this role (Krag et al., 2004; 
Chaubourt et al., 2002). 
 
1.10 Gene repair strategies  
1.10.1 Aminoglycosides 
Aminoglycoside antibiotics can suppress nonsense mutations in mammalian 
cells by the same action as they disrupt translational fidelity in bacteria. They bind a 
specific site in ribosomal RNA and disturb codon-anticodon recognition (Kaufman, 
1999). As mdx mice show a nonsense mutation in their dystrophin gene, the 
aminoglycoside gentamycin can be used to promote translation read-through of the 
nonsense codon in this species. Initial trials showed a restoration of between 10-
20% of normal levels of dystrophin in mdx muscles, at a level sufficient to protect 
against contraction-induced injury (Barton-Davis et al., 1999). This class of 
antimicrobials cause nephrotoxicity and ototoxicity, especially with long-term use, 
and more investigation is required regarding optimum dosage and interval between 
dosages before treatment of the estimated 15% of boys with DMD with premature 
stop mutations. 
 Negamycin, a dipeptide antibiotic said to be less toxic than gentamycin, 
restored dystrophin to skeletal and cardiac muscles of mdx mice in one study 
(Arakawa et al., 2003). Its mechanism of action is binding to a partial sequence of 
the eukaryotic rRNA decoding A-site.  
There have been several clinical trials using these agents. Effect may vary 
according to position of the stop codon, with some boys demonstrating greater 
dystrophin expression than others (Politano et al., 2003). Further clinical trails are 
anticipated, involving the use of gentamycin analogues, PTC124 and geneticin. 
   
1.10.2  Antisense oligonucleotides (AOs) 
1.10.2i The theoretical basis to AO use: 
Genes are organized in genomic DNA with exons (coding sequences) 
separated by introns (non-coding sequences). Exons contain open reading frames 




and a stop codon. For normal gene function to occur two exons in a series must 
have triplet codon breakpoints that maintain the correct translational ORF during 
splicing of intron sequences to form messenger RNA (mRNA). (Fig 1.7) 
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Fig 1.7 Simplified depiction of events involved in mammalian gene expression. 
 
Analysis of gene sequences of DMD patients revealed that the majority (but not all) 
showed deletions or point mutations of the gene causing a consequential shifting of 
the ORF, and the translation to a truncated, abnormal dystrophin (Fig 1.8A). If the 
deletion were in the area of the gene that maintained the ORF, the resultant protein 
would be shorter and semi-functional, a so-called Becker Muscular Dystrophy 
(BMD) protein causing a milder phenotype (Monaco et al., 1988) (Fig 1.8B). 
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Fig 1.8 Mutations of the dystrophin gene leading to A. Duchenne Muscular 
Dystrophy (DMD) or B. Beckers Muscular Dystrophy (BMD), depending upon the 
site of deletion, and whether the reading frame remains intact or is disrupted. These 
simplified diagrams apply to point mutations and short deletions and may not apply 




In the mdx mouse the nonsense mutation of the dystrophin gene results in 
termination of translation within Exon 23. Theoretically there should be no 
functional dystrophin expressed in mdx muscles, however occasional (<1%) 
dystrophin-positive fibres are found. Such fibres are also found in many DMD 
patients (Fanin et al., 1995). It is proposed that dystrophin arises in these fibres by 
alternative processing and exon skipping causing in-frame gene transcripts (Wilton 
et al., 1997a; Wilton et al., 1997b). 
Studies have shown that synthesized antisense oligonucleotides (AOs) may 
operate to induce exon skipping in a similar manner to that occurring in the mdx 
mouse (Wilton et al., 1999; Dunckley et al., 1995).  AOs have been utilised to block 
motifs involved in normal pre-mRNA splicing in mdx myoblasts. This causes 
skipping of exon 23 without disrupting the reading frame, thus potentially allowing 
synthesis of a shorter, but still functional protein when delivered to mdx muscles. 
(Figure 1.9) 
Fig 1.9 Use of antisense oligonucleotides in mdx mice to induce exon-skipping 
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Oligonucleotides have been used for the downregulation of cancer or 
disease genes, most commonly by base-pairing with a mRNA target and mediating 
its destruction by RNase H. AOs can also be used to silence mutations that cause 
aberrant splicing (for example β-Thalaassemia and some cystic fibrosis mutations), 
thus restoring correct splicing and gene function (Sazani and Kole, 2003). The 
requirements for the second generation AO’s are different - they must not activate 
RNase H, which would destroy the pre-mRNA target prior to splicing, and they 
must also be able to compete with splicing factors for access to pre-mRNA located 
in the nuclei of cells. AO’s with modifications to the 2’position, such as 2’-O-
methyl, or those with backbones based on phosphorothioate or morpholino 
derivatives are suitable candidates (Sazani and Kole, 2003).  
Delivery agents that allow AOs to accumulate in nuclei of cells and bind to 
the pre-mRNA markedly enhance their efficacy. Cationic liposome formulations or 
commercial vectors, such as Lipofectin, Eufectin or Lipofectamine are designed to 
enhance delivery and uptake. These vectors, because of their positive charge, have 
high affinity for negatively charged cell membranes (Dias and Stein, 2002).  
  
1.10.2iii  Development of AOs and potential applications  
 AOs applicable to mdx dystrophin were synthesized after sequencing of 
purified PCR products following long range PCR across introns 22 and 23. Splice 
sites flanking these introns were identified and 2’O-methyl dys 3’ and dys 5’ AOs 
were designed that would anneal to the 3’ and 5’ splice sites of the mouse pre-
mRNA respectively. These consistently induced skipping of Exon 23 in 
immortalised mouse myoblast lines (Wilton et al., 1999). Since then vast 
improvements in AO design and efficiency has occurred, including design of AO’s 
directed specifically against the 5’ (donor) splice site of intron 23. AOs as small as 
17 nucleotides induced strong and consistent exon skipping, with evidence of a 
Becker-like protein produced in cell lines and in vivo (Mann et al., 2002; Mann et 
al., 2001). Figure 1.10 shows immunohistochemical evidence of successful 
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Fig 1.10 Examples of successful antisense oligonucleotide (AO) treatment, detected 
by immunostaining. A. Wild-type mice with dystrophin located on the periphery of 
all fibres. B Mdx muscle cells with some revertant fibres showing positive staining. 
C. Mdx muscles following electrotransfer of AO with many fibres staining positive 
for dystrophin. (Wells et al., 2003) 
 
Optimisation of oligonucleotide composition and delivery methods is vital to 
the application of this methodology in both the mdx mouse model (Wilton et al., 
1999; Mann et al., 2001) and in DMD cultured muscle cells (Aartsma-Rus et al., 
2002; van Deutekom et al., 2001). Modification of AO’s to a morpholino chemistry 
is also possible, which creates a neutral molecule with biological stability that can 
be tethered to a sense ‘leash’ and delivered as a cationic lipoplex (Gebski et al., 
2003). The aim of structural modifications is to create optimal safety, delivery and 
efficacy of both AO and delivery agent. 
Further developments include the application of multiexon skipping 
strategies using a combination of AOs to skip two or more exons (including an 
entire stretch from Exon 45-51 in cultured myotubes from one DMD patient) 
(Aartsma-Rus et al., 2004). Improved delivery using hyaluronidase enhanced 
electrotransfer was investigated in injected mdx limb muscles, with increased 
dystrophin expression resulting (Wells et al., 2003). Repeated administration and 
higher dosages of AO’s enhanced dystrophin expression (Lu et al., 2004). Linkage 
of antisense sequences to short nuclear (sn) RNA allows for subcellular localisation 
and inclusion into spliceosomes, and U7 (a non-spliceosomal snRNA) can be 
engineered to bind and deliver antisense sequences. AOs linked to U7 sn RNA have 




muscle. Administration into mdx tibialis anterior muscles showed prolonged 
expression, reduction of exercised-induced damage, and improved contractility 
(Goyenvalle et al., 2004). 
The advantages of an AO approach to therapy are that it is tissue specific 
and highly sequence specific (Bremmer-Bout et al., 2004). AOs are small 
compounds, and do not elicit an immune response. The apparent specificity of 
current AOs suggests that systemic delivery may be possible with targeted exon 
skipping only occurring in those tissues expressing dystrophin. There is the 
potential for repeated delivery as there appears to be a natural ability of muscle cells 
to take up these compounds, as well as a slow turnover of muscle cells in vivo 
(Wilton et al., 1999).  
The shortcomings of AO therapy at present are the challenges of widespread 
delivery to many muscle groups, and ensuring persistence in tissues. While some 
experiments suggest dystrophin persistence following AO treatment is up to 2 
months (Lu et al., 2003), other studies suggest it may be considerably shorter than 
this (Wells et al., 2003). The development and refinement of vectors for systemic 
delivery may overcome these problems. 
Unfortunately dystrophinopathies caused by large deletions of the gene will 
not be amenable to this method of correction, however a hospital database in France 
indicated that 43% of patients could benefit from skipping a single exon 
(Goyenvalle et al., 2004), and this proportion may be increased if multiple exon 
skipping can be accomplished (Aartsma-Rus et al., 2004).  
It must also be recogised that BMD is not a benign disorder, and can result 
in serious cardiomyopathy and death. However, many BMD patients lead active 
lives well into middle age (or beyond), and do not suffer the debilitating 
consequences of respiratory failure or generalised muscle wasting seen in DMD. 
 Despite these limitations the future for incorporation of AO technology into 
the treatment of DMD looks promising. The dystrophin gene is uniquely suited to 
therapeutic exon skipping due the modular and repetitive nature of some of its 
domains, and the high incidence of point mutations or short deletions. There are 
now pathways in place for vector mediated delivery and potential rescue of multiple 





1.11 Aims and Scope of study  
 The overall aim of this research project was further characterisation of the 
mdx mouse model of DMD, to enable strategic treatment with antisense 
oligonucleotides. Particular muscles were targeted in this study, including cardiac 
muscle, diaphragm, paraspinal and accessory respiratory muscles. Knowledge 
gained from preliminary characterisation studies were used to optimise methods and 
choose ages and numbers of mice for subsequent experiments utilising AO’s (see 
Fig 1.11). The exception to this was the cardiac experiments, as it was felt that an 
in-depth cardiac AO study was beyond the scope of this PhD because of time 
constraints. The aims and scope of each individual project are listed below. 
 
1.11.1 Atrial function and cardiac fibrosis in aging mdx  
The mdx heart has been characterised to an extent previously, and in recent 
years there have been functional studies using in vitro isolated hearts and in vivo 
catheterised hearts. New knowledge has been gained from these studies that 
confirms the mdx mouse as a useful model for DMD cardiomyopathy under certain 
conditions, notably exercise induced stress, following aortic banding or 
pharmacologically induced stress (dobutamine or isoprenaline), or perhaps older 
age. This latter point was published only in late 2004, with reports of 
echocardiographic data from 40 week old mdx suggesting ventricular function was 
impaired and dilation was present in these older mice, but not before (Quinlan et al., 
2004). Prior to these studies there was limited functional data available, mostly from 
young mdx atria. The older mouse may be a realistic model for heart disease in 
DMD, as cardiomyopathy also develops gradually in DMD, often towards the end 
of the patient’s lifespan. Artificially induced heart failure (such as from aortic 
banding or acute catecholamines challenge) may provide a less realistic model than 
gradually occurring pathology with compensatory physiological responses and 
progressive fibrosis.  
The aim of this study was to characterise changes in atrial function and 
cardiac fibrosis throughout the lifespan of the mdx mouse. This project used 9 ages 
of mice (from 3 weeks to 24 months), and measured cardiac morphometry, atrial 
contractility, responses to exogenous calcium and development of fibrosis as 




documented in the mdx, despite it being a significant contributor to DMD 
cardiomyopathy, and fibrosis in general being a hallmark of dystrophy in any 
muscle type. This project used two measures of cardiac fibrosis; the first was the 
colorimetric assay of hydroxyproline, an amino acid constituting some 8% of the 
total protein content of collagen, the second using collagen specific staining and 
percentage flourescence of heart sections.  
Electrophysiological data was also measured across the age groups of mice, 
using transmembrane action potentials from isolated left atria. Again, there is little 
available data from mdx mice, and none across the lifespan. There is also conflicting 
ECG data available in the literature with reports indicating QT intervals as similar, 
less or greater in mdx compared to control mice, and it was hoped action potential 
data would resolve this. Electrophysiological disturbances may be an inate property 
of dystrophic muscle, as there is a high incidence of arrythmias and ECG 
abnormalities in boys with DMD, even at a young age before clinical signs of heart 
failure. 
 
 1.11.2 Monophasic action potential measurements and trabeculae contractility 
Monophasic action potential measurements using Langendorff preparations 
and trabeculae contractility was also planned in a separate set of experiments, as it 
was felt that these parameters would add considerably to our knowledge regarding 
dystrophic cardiac muscle. There have been no MAP studies reported from mdx 
mice, despite this technique being widely used in transgenic murine models of 
human cardiomyopathy (especially arrhythmias). There have been few mouse 
trabeculae or small papillary muscle functional studies, and none in mdx mice. 
Ventricular experiments may provide additional information, especially if there is 
unequal chamber involvement in the dystrophic process.  
Unfortunately there were technical difficulties with these studies, which 
meant there were too few results to draw conclusions or provide tests of statistical 
significance. These results are included as Appendix A, including establishment of 









1.11.3 Diaphragm function and fibrosis in aging mdx 
 The diaphragm is recognised as the muscle that best resembles the severe 
dystrophic pathology seen in DMD. This study utilised the same age groups of mice 
as outlined in 1.11.1, and served as a useful preliminary study for a future 
experiment examining the effects of AOs injected into the diaphragm. Protocols 
were established, and expertise gained, in skeletal muscle contractility experiments, 
histology and surgery for diaphragm injections.  
 
1.11.4 Progression of kyphosis in aging mdx mice 
 Boys with DMD develop severe kyphoscoliosis unless spinal surgical 
stabilisation is undertaken. The aim of this study was to characterise the progression 
of kyphosis in mdx mice by monthly radiographs, and development of a novel 
Kyphotic Index to measure this objectively. Further aims were to assess the 
contractility of paraspinal and respiratory muscles not previously examined in mice, 
including latissimus dorsi muscles and an intercostal muscle segments. Fibrosis was 
also quantitated in these muscles, in addition to the longissimus dorsi muscles and 
diaphragm. These paraspinal and accessory respiratory muscles were deemed 
important for both the progression of kyphosis and possibly respiratory dysfunction 
in mdx mice. It was anticipated that knowledge gained from these experiments 
would further understanding of the dystrophic phenotype, and serve as useful 
preliminary data for a later experiment administering AOs into paraspinal muscles. 
 
1.11.5  AO administration into mdx diaphragm muscle 
 AOs show promise as a gene correction strategy in the treatment of DMD, 
but for this to be considered successful they must be shown to ameliorate the signs 
of dystrophin deficiency, including necrosis, fibrosis and muscle weakness. This 
study examined the effects of two administrations of AOs into mdx diaphragms, 
given one month apart.  The aim was to determine if AOs injected into a muscle 
with known severe dystrophic tendencies is rescued by such therapy, using the 
endpoints of muscle function in vitro, collagen accumulation and dystrophin protein 






1.11.6 Long term administration of AO’s into paraspinal muscles of mdx 
 Any potential therapy for a genetic disorder such as DMD is likely to be 
given long term, and by repeat administration. Current AO strategies are limited to 
direct intramuscular injections, and previous studies have looked only at single 
treatments in young animals. The aim of this study was to examine the efficacy of 
monthly AO injections into the paraspinal muscles of mdx mice for 16 months 
(following on from 1.11.5). Mice were radiographed once monthly to follow 
progression of kyphosis in injected, sham-injected and wild-type mice. At the end of 
the experiment muscles were mounted in organ baths for contractility studies, and 
fibrosis was measured by hydroxyproline assay and specific collagen stains of 
histological sections. Western blotting was used to assess efficacy of AO 
transduction and dystrophin protein expression. This study is unique in applying a 
dynamic parameter that changes with age (the Kyphotic Index), and measures of 
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CHAPTER 2. THE AGING MDX MOUSE: ATRIAL 
FUNCTION AND CARDIAC FIBROSIS 
2.1 Introduction 
Boys with DMD often exhibit cardiomyopathy in addition to serious 
respiratory complications due to diaphragm weakness, thoracic deformity and 
chronic hypoventilation. A recent survey on survival in DMD patients highlighted 
that early death from heart failure reduced average life expectancy significantly 
(Eagle et al., 2002). Symptomatic cardiomyopathy increases with age, with all 
DMD patients over 18 years having detectable cardiac disease (Nigro et al., 1990). 
The spectrum of cardiac involvement includes sudden death, isolated conduction 
defects and dilated or hypertrophic cardiomyopathy. Autonomic imbalance has been 
demonstrated in DMD patients at an early stage of the disease when 
cardiopulmonary function is still well preserved (Yotsukura et al., 1995). 
Cardiac involvement in mdx was noted in early histological studies. 
Myocardial lesions were observed in 5/10 male mdx mice ranging in age from 8-30 
weeks (Bridges, 1986). Coulton et al., (1988) found evidence of cardiac 
myonecrosis and cellular infiltration in 13/65 ventricles examined in mice of 26-303 
days old. Foci of inflammation and fibrosis were also found in old mdx hearts 
(greater than 20 months old) (Lefaucheur et al., 1995),  while another histological 
study reported the absence of pathological changes in mdx hearts examined at 
different ages (Torres and Duchen, 1987).  
Two studies have suggested that mdx hearts may be hypertrophic (Danialou 
et al., 2001b; Megeney et al., 1999), although it has been pointed out that these 
studies had small sample sizes (5 and 12 mice respectively) that were not large 
enough to reveal a statistically significant hypertrophy (Yue et al., 2004). Other 
studies have shown that heart weight normalised to body weight is similar between 
mdx and control mice (Yue et al., 2004), and that left ventricle/bodyweight is 
significantly less in younger and similar in older mice (Lu and Hoey, 2000). There 
have been no studies to evaluate heart weights in relation to body weight 
systematically across throughout the mdx lifespan, although echocardiographic 
studies of 8, 29 and 42 week old mice showed the development of dilated 
cardiomyopathy in 42 week old mdx, with increased LV end systolic and diastolic 




Studies of isolated left atria in 12-week-old mice showed mdx also have 
contractile dysfunction compared to wild types (Sapp et al., 1996). These young 
mice also displayed a reduced responsiveness to calcium and altered atrial twitch 
characteristics, including delayed relaxation times. Ex vivo perfused hearts from 
young mdx provide direct evidence for severe contractile dysfunction and non-
ischaemic tissue damage correlated with cardiac workload, indicating dystrophin 
functions to guard cardiomyocytes from mechanical stress (Danialou et al., 2001b). 
It has been suggested that 50% dystrophin expression is sufficient to improve heart 
function in mdx mice, as measured by Evans blue dye uptake and left ventricular 
functional parameters (Yue et al., 2004). 
Autonomic nervous system dysfunction occurs in mdx as well as boys with 
DMD. There is a marked deterioration in cardiac β1-adrenoceptor function in aged 
(12 month old) male mdx, evidenced by a reduced potency and efficacy of (-)-
isoprenaline (Lu and Hoey, 2000). Heart rate variability studies on conscious mice 
suggested an elevated sympathetic tone and blunted parasympathetic activity in mdx 
(Chu et al., 2002). 
Quantitative studies of cardiac fibrosis in mdx are few. One study revealed a 
four-fold increased fibrosis in 17-month-old mdx hearts compared to controls, with 
no predilection for the five regions analysed (right ventricle, anterior wall, posterior 
wall, lateral wall and septum)(Quinlan et al., 2004). 
There is a requirement for further cardiac phenotype characterisations of the 
mdx as it increases the knowledge base to help understanding of the 
pathophysiology of DMD cardiomyopathy. Furthermore, this is important for 
therapeutic trials involving anti-inflammatory, immune-modulating agents or gene 
therapy studies that may improve cardiac function.  
 
2.2 Aims  
The primary aim of the present study was to determine whether cardiac 
function and electrophysiological properties of mdx mice change across their 
lifespan and vary significantly from wild type mice. In addition, cardiac collagen 
was measured to assess if mdx heart fibrosis increases with age, as occurs in hearts 






2.3.1 Mouse numbers and groupings 
In the initial series of experiments (Study 1), groups of 7-8 male control 
C57BL/10ScSn (C57) and mutant C57BL/10ScSn mdx (mdx) mice were utilised for 
functional studies at 3, 6 and 12 weeks, 6, 9, 12 and 15 months of age. In addition 
two groups of mdx mice only were used at 18 and 24 months of age (because of the 
unavailability of control mice at these ages). For hydroxyproline assays and 
morphometry measurements additional age, sex and strain matched tissues were 
utilised to give an n=10-14 per group. 
 Following examination of the results of these experiments two age groups 
of C57 and mdx mice (6-8 weeks and 15-17 months) were utilised for a more 
detailed analysis of cardiac fibrosis (Study 2). There were 7-8 mice/age group/ 
strain for this part of the study. It was anticipated that measuring cardiac fibrosis at 
3 different cross-sectional levels of the heart, and an increased n number would 
improve accuracy, as would performing hydroxyproline assays on ventricular tissue 
from mid-heart rather than just the tip of the heart apex. 
 Mdx mice were obtained from the USQ Animal House, and C57’s from 
Animal Resource Centre, Nedlands, Western Australia.  
















































Morphometry, cardiac function and 
fibrosis across the lifespan of mdx
Ages 3, 6, 12 wks, 6, 9, 
12, 15, 18 +  24 mths 
for all studies 
Numbers (/ age group /strain) 
n=7-8 (functional studies) 
n=7-14 (hydroxyproline assays) 
n=4 (histology) 
Ages 3, 6, 12 wks, 6, 9, 12, 15, 
18  +  24 mths (morphometry ) 
3, 6, 12 wks, 6, 9, 12, 15 mths 
(functional studies, histology 
and hydroxyproline assays) 
MDX C57 
Study 2 
Cardiac fibrosis in young and old mdx 
and C57 mice
Ages 6-8 wks and 15-17 mths 
Numbers (/ age group / strain) 
n=7-8 (hydroxyproline assays) 
n=7-8 (histology) 
Ages 6-8 wks and 15-17 mths 
Fig 2.1 Diagram detailing the mouse numbers and groups for the series of 






2.3.2 Transmembrane action potentials and contractility of isolated atria 
At the commencement of each experiment mice were weighed, anaesthetised 
using Tiletamine/Zolazepam at 35 mg/kg subcutaneously (Virbac Laboratories, 
Australia), then euthanased by exsanguination. Lungs and hearts were removed, and 
the lungs were rinsed of blood clots, blotted for 3 seconds and weighed. 
Each heart was dissected quickly in ice-cold pre-carbogenated (95% O2/5% 
CO2) Tyrode physiological salt solution (TPSS; mM: NaCl 136.9, KCl 5.4, 
MgCl2H20 1.05, NaH2PO4.2H2O 0.4, NaHCO3 22.6, CaCl22H2O 1.8, glucose 5.5, 
ascorbic acid 0.3, Na2EDTA 0.05). The right atria, right ventricular free wall and 
left ventricle (LV) plus septum were dissected, blotted for 3 seconds and weighed.  
The left atria (LA) was removed and a stainless steel hook was positioned 
into the pulmonary vein opening, before transferring into a 1 ml Perspex organ bath. 
The LA was pinned onto a small rubber mat, and the hook connected to the force 
transducer (model AE801, SensoNor, Horten, Norway). The tissue was perfused 
continuously with carbogenated TPSS at a flow rate of 3mL/min and a temperature 
of 35±0.5oC. The LA was held at an optimum preload of 3.5±0.5 mN throughout the 
experiment, and field stimulated via platinum electrodes at 0.5ms pulse width and 1 
Hz, 25% above threshold (Grass SD9 stimulator, W. Warwick, RI, USA).  
 After a 30-minute equilibration period the LA was impaled 4-5 times at 
different sites with a 3M KCl filled glass microelectrode (World Precision 
Instruments, New Haven, CT, USA, 150F glass, 10-50MΩ resistance). Data was 
recorded using a PowerLab and Chart 4.1.1 software (A.D. Instruments, Castle Hill, 
Australia), at 1000 samples/sec and then an average of the 4-5 recordings was 
calculated. A concentration response curve (CRC) to CaCl2 was generated following 
transmembrane action potential (TAP) recordings. Details of the apparatus required 
for these experiments are provided in Appendix B. 
2.3.3 Collagen measurements 
At the end of the experiment the LA was blotted briefly and weighed. LA 
and LV apex were stored at –70oC. For Study 2 the right atria were also stored for 
hydroxyproline assays. The remainder of left ventricle and septum was fixed 
sequentially in Telly’s fixative (formaldehyde, glacial acetic acid-ethanol fixative, 




24 hours) and 70% ethanol, prior to paraffin embedding, cutting and staining of 10 
micron sections, using 0.1% w/v picrosirius red solution (Sirius Red F3B, Chroma 
Dyes, Germany in saturated picric acid).  
Analysis was performed blinded to the strain or age. Interstitial and 
perivascular collagen was included, while capsular collagen was excluded from 
analysis. For Study 1 sections were viewed on a Biorad MRC 1024 confocal 
scanning microscope with a krypton/argon laser and subjected to a 
Rhodamine/Texas Red filter of 568nm wavelength. Images were captured using a 
Biorad Lasersharp 2000 program. Photomicrographs of 4 sections per heart were 
analysed and averaged for saturated pixel intensity corresponding to collagen fibres, 
using Scion Image software Beta 4.0.2 (http://www.scioncorp.com). Results are 
expressed as collagen as a percentage of area of view. An n of 4-6 mice per group 
was compared in this manner.  
For Study 2 examining fibrosis in young and old mice, entire hearts were 
sectioned at 3 levels a) apex, b) mid portion and c) base. Fluorescent microscopy 
images were acquired from these heart sections using a digital camera (Q imaging 
Micropublisher 5.0 RTV) coupled to an epifluorescence microscope (Eclipse E600, 
Nikon, Japan). Four sections per tissue were photographed and analysed using the 
image analysis program DocuAnalySIS (Soft Imaging System), then averaged. 
Collagen was expressed as a percentage of the total area of tissue. Good correlation 
was found between results of slides examined previously using the confocal 
microscope, and those captured and analysed with this analysis system. 
Hydroxyproline (HP) content was also used as a measure of total collagen as 
described previously (Stegemann and Stalder, 1967), with the following 
modifications. Tissue was thawed, then hydrolysed in sealed 2 ml cryotubes with 
6M HCl overnight at 110oC and dried completely using filtered air under pressure 
and heat (50oC). Values are expressed as µg HP/mg tissue wet weight. Appendix B 
shows details of HP assays, modified for tissue samples less than 20mg, to fit a 2 
mL total volume. 
2.4 Statistics 
Results are expressed as means ± S.E. Responses between groups of same aged mdx 




differences were determined initially by ANOVA, with post hoc application of 
unpaired Student’s t-tests in the event of significant ANOVA. P values less than 




 Differences in body weight between mdx and C57 were evident at various life 
stages as depicted in Fig 2.2a. At 3 weeks of age, corresponding to the acute muscle 
necrotic stage, mdx mice were significantly lighter (P<0.001), and then became 
heavier than wild type mice with development of muscle hypertrophy (significant at 
12 weeks of age (P<0.05)). Older mdx (at 15 months of age) demonstrated a weight 
decline relative to C57 mice (P<0.01). 
 Lung weights were less for mdx mice at all age groups except 15 months (data 
not shown), however when adjusted for bodyweight there was no significant 
difference between mdx and wild type mice, except for the 3 week old and 9 month 
old age groups (Fig 2.2b). Importantly there was no evidence of increased 
lung/body weight ratios indicative of pulmonary congestion as mdx aged. 
Total mdx heart weights (calculated by addition of individual heart 
chambers) were less at 3 weeks, and at all ages exceeding 12 months (Fig 2.2c). In 
contrast heart weight/body weight ratio was higher in mdx at 3 weeks (when body 
weights were less than controls) and lower at 12 weeks when they are undergoing 
muscle hypertrophy. At all ages exceeing 12 months mdx exhibited a lower heart 
weight/body weight ratio, despite lower body weights (Fig 2.2d). At no time point 




Fig 2.2 Morphometry data from aging mice. Mdx and C57 mice a) Body weights of 
mdx mice are less at 3 weeks of age, and then became significantly less than 
controls from 15-24 months. b) Lung weight/body weight ratio was greater in mdx 
at 3 weeks when mice were of low body weight, and were then less than control 
mice (significant at 9 months only). c) Heart weights were greater in control mice, 
with significance at 3 weeks, then from 12 months to 24 months. d) Heart weight/ 
body weight ratio was less for mdx mice (significant at 3months, then from 12-18 
months), however at 3 weeks of age mdx showed an increased heart/body weight 
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2.5.2 Transmembrane action potential recordings 
The criteria for TAP inclusion were a stable wave-shape with a sequence of 
more than 10 action potentials, a horizontal diastolic interval, amplitude greater than 
70 mV, and an overshoot greater than +10 mV.  
APDs were measured at 20, 50 and 90% of repolarisation (APD20, APD50 and 
APD90 respectively). There was a strong trend of shorter APD90 values in all age 
groups of mdx, with significance at 3 weeks, 9 months and 12 months (Fig 2.3). 
Waveform shape differed between strains as mice aged, with APD50 increasing in 
mdx older than 15 months, despite a tendency for a shorter APD90 (Fig 2.3 and 2.4) 
APD increased over the lifespan of both mouse strains 
 Action potential amplitudes (APA) were not significantly different (C57, 88.5 ± 
2.8: mdx 87.4 ± 2.1 mV). Rate of upstroke (dV/dtmax) were not different between 
strains (C57, 86.3 ± 2.1: mdx 91.9±3.7 V/sec). There was no difference in resting 
membrane potentials at any age groups compared (C57, -76.7 ± 0.73mV: mdx, 
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Fig 2.3 Transmembrane action potential durations (APD) across age ranges of mdx 
(open circles) and control mice (filled circles), measured from left atria. APD 20,50,90 















Fig 2.4 Action Potential waveforms in aged (15 month old) mdx (broken line) 
and C57 (solid line). Action potential amplitudes, and resting membrane 
potentials were the same for both strains, but APD50 was prolonged and APD90 
shorter in dystrophic atria. 
 
 
2.5.3 Atrial isometric force and calcium induced inotropy 
 Basal isometric force production was measured at 1.8 mM CaCl2 (Fig 2.5a). 
Young mdx showed reduced basal force compared to controls, which was 
significant at 3 and 6 weeks, and redeveloping again at 15 months. In the 
intervening period force production was not different except for 9 months when C57 
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Fig 2.5 Isometric twitch forces in aging mdx (open symbols) and C57 (closed 
symbols).n=7-8 mice per strain/age group.**P<0.01,*P<0.05 a. Basal atrial force of 
contraction at 1.8mM CaCl2 (mN) b. Concentration Response Curves to CaCl2 for 4 




 There was a significant difference between increases in force of contraction in 
young mdx mice relative to their age-matched controls, with mdx showing 
diminished inotropic responsiveness at 3, 6 and 12 weeks of age, and again at 15 
months. As previously noted for basal force generation, 9 month old mdx showed 
increased responsiveness to exogenous calcium. Shapes of CRCs varied, 
demonstrating a plateau or usually a decline in contractility with maximum calcium 
loading. 
 Isometric twitch characteristics varied between mouse strains at ages greater 
than 12 weeks (Fig 2.6). After this age mdx mice showed a prolonged time to 50% 
relaxation (TR50: P<0.01)) and time to 90% relaxation (TR90: P<0.01), and mice 
from 9 months of age showed a delayed time to peak force (TPF: P<0.05) also. 
These parameters increased irrespective of the peak force generated. 
           
              
       *
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TPF, TR50 and TR90 similar 
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Fig 2.6 Changes in isometric twitch waveforms with age (C57 solid line, mdx 
dashed line). Young mdx mice show similar twitch shape to control mice despite a 
reduced force, but as mdx age time to peak force and time to 50% and 90% 





2.5.4 Collagen measurements 
2.5.4a Study 1  
LA and LV apex hydroxyproline values across the age ranges are shown in Fig 2.7. 
There was a 2-4 fold more hydroxyproline (and hence collagen) in atrial compared 
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Fig 2.7 Left atrial and left ventricular hydroxyproline (HP) values for aging mice. 
There was a tendency for greater fibrosis (measured by HP ) in mdx for both tissues, 





The mean ventricular collagen percentage as detected by picrosirius red 
fluorescence was increased for mdx mice, but due to large standard error of means 
in this strain, this only reached statistical difference at two ages (6 weeks and 15 
months) (Fig 2.8a). The box and whiskers plot portrays the trend for increased 
fibrosis in aging mdx hearts, and the spread of data for both strains across their life 
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Fig 2.8a Left ventricular collagen expressed as percentage of area, as determined by 
picrosirius red staining and confocal imaging. Results based on 4 sections/heart, n= 
4 per strain/age. Fig 2.8b Box plot using the same data as 3.8a, demonstrating 
progression of fibrosis in older mdx hearts. Median value shown by bar, 1st and 3rd 






Figure 2.9 shows representative photomicrographs of myocardial sections in young 
and aged mdx and C57 mice. Some mdx mice showed marked collagen deposition 
compared to others of the same strain, or control mice of the same age. This 
collagen was predominantly localised to interstitial areas in mdx, although regions 
of accumulated perivascular collagen was also noted. An occasional young animal 
with dramatically increased capsular fibrosis was seen, however this type of 
collagen was not included in the final analysis due to the sporadic incidence. 
 
Fig 2.9  Representative photomicrographs of mdx and C57  left ventricular sections 
cut  at 10 microns and stained with picrosirius red. 40X magnification. A.6-week- 
old C57. Collagen deposition, shown by orange-red staining, is minimal. Collagen 
averaged over all sections for this animal was 0.13% B. 6-week-old mdx (0.69% 





2.5.4b Study 2 
 HP values were greater for mdx right atria in young mice (P<0.01), left atria 
in both young  (P<0.05) and old mdx (P< 0.001), and left ventricles in young 
(P<0.05) and old mdx (P<0.01). Left ventricular hydroxyproline tended to be 5-10 
times less than atrial hydroxyproline. Figure 2.10 shows results of HP assays from 
atrial and mid ventricular sections.  
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Fig 2.10 Left atrial, right atrial and left ventricular hydroxyproline (HP) values for 
young and aged mice. Mdx showed greater HP in all tissues except the right atria in 





The results of collagen analysis at 3 different levels are shown in Figure 
2.11. There was significantly more fibrosis in old compared to young mice of both 
strains, and mdx showed more fibrosis than control mice at both age groups. There 
was no difference in the extent of fibrosis between levels, with the exception of 
young mdx that had a lower collagen content of the heart apex compared to the mid 
portion and heart base (P<0.001). 
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Fig 2.11 Cardiac collagen in young (6-8 week old) and old 15-17 month old mdx 
and control mice. Interstitial collagen as a percentage of total area was averaged 
from 4 views at 3 different levels of each heart (apex, mid portion and base). In 
addition, averages of the 3 levels is shown as the top stack (with error bars 
corresponding to this mean value only). Collagen increased significantly with age in 
both strains, but the magnitude of increase was greater for mdx mice. Mdx had 
significantly more cardiac collagen compared to age-matched control mice. n=7-8 
mice/age /strain.  *= level of significance between mdx and C57 mice, += level of 





 Examples of picrosirius red stained heart samples are shown in Figure 2.12, 
and Figure 2.13. 
 
Fig 2.12 Photomicrograph of a heart apex from a 17-month-old mdx mouse 
(montage of 4x magnification epifluorescent images). Picrosirius staining, 
representing interstitial collagen, is seen within many regions of this mdx heart, 
however it was also common to find a patchy distribution with dense collagen 
deposition in only one or two areas. There appeared to be no specific predilection 
site for fibrosis in mdx cardiac muscle, unlike the regional fibrosis seen in hearts 








Fig 2.13 Fibrosis in mdx and control mice heart, with images from mid sections of 
left ventricles. The red staining represents cardiac collagen deposition. A= young 
(6-8 week old) C57, B= old (17-18 month old ) C57, C= young mdx, D= old mdx. 
There was significantly more fibrosis in young and old mdx compared to age-
matched control hearts. The collagen of older mdx was dense and infiltrative, 








 The comparison of dystrophin-deficient and wild type mice across their 
lifespan was performed to investigate the progression of cardiac abnormalities with 
age, hence helping to better define the mdx cardiac phenotype, and assess the most 
appropriate age to use it as a model for DMD. There have been few cardiac studies 
in this strain providing quantitative data regarding electrophysiology or cardiac 
fibrosis across the lifespan, despite widespread research into the mdx mouse and the 
high incidence of cardiomyopathy associated with DMD. 
 In the acute skeletal muscle necrosis phase represented by the 3-week-old mice, 
mdx have greatly reduced body weights compared to controls. There was a lower 
total heart weight and lung weights at this age (p<0.05), although as a proportion of 
body weight these values were higher, presumably due to the systemic effects of 
skeletal muscle necrosis causing ill thrift. Body weight curves from older mice 
agree with other studies, where there is a decline in body weight in older mdx, as 
they again become less active and have more difficulty in obtaining food and water 
unaided (Pastoret and Sebille, 1995b), although the magnitude of weight loss in the 
mice in this current study was much less. Differing bodyweights between mdx 
colonies worldwide was highlighted in a recent report, where 3-12 month old mdx 
ranged from 35-50 grams (Murakami et al., 2003). The heaviest mdx at this age 
range bred by the USQ colony was 36.7 grams, with an average of 34.6 ± 0.7g.  
These differences may be due to husbandry factors, intercurrent disease or perhaps 
strain variability. As mdx mice have been widely used for research since 1984 
(Bulfield et al., 1984), and may have been maintained as inbred colonies for long 
periods, it is plausible that some phenotype diversity between colonies has evolved 
(with this diversity possibly extending beyond body weight).  
 Heart weights are reported with organs carefully trimmed of great vessels, 
pericardium and fat. Mdx hearts from 6 weeks of age were smaller than controls 
with a lowered heart/body weight ratio, in contrast to a former study (Bia et al., 
1999). The strain difference in heart weight/body weight ratio at 15 months is a 
reflection of declining and increasing body weights in mdx and C57 respectively, 
rather than altered cardiac size. Heart weights may be less if there is considerable 




of either hypertrophy or individual chamber dilation. Recent echocardiograph 
experiments suggest that dilated cardiomyopathy does occur in mdx at 42 weeks of 
age, resulting in increased LV end diastolic and end systolic dimensions and 
reduced fractional shortening (Quinlan et al., 2004). 
 Lung/body weight ratios are used as a measure of pulmonary congestion, and 
the lowered ratios in mdx indicate that congestive heart failure is not a feature.  
 There is a shortening of APD90 in mdx left atria compared to controls. A 
previous study measured shorter APDs from ventricular cells in mdx older than 6 
months, and in dystrophic canine (xmd) epicardial atrial and ventricular cells 
(Pacioretty et al., 1992). The genesis of the shorter potential may result from 
dystrophin’s role in receptor/channel localisation. Previous work suggests that the 
actin-based cytoskeleton is implicated in regulation of both voltage- and ligand–
gated ion channels such as L-type Ca2+ channels (Sadeghi et al., 2002). In the 
mouse the transient outward K current (Ito) has a prominent role in repolarisation, 
and an enhancement of this current will lead to more rapid repolarisation and shorter 
duration of electrical potential. The longer APD50 at 15 months of age is also 
noteworthy, with possible mechanisms including increased ICa or delayed 
inactivation (as suggested by Sadeghi et al., 2002) 
 It is difficult to draw conclusions about ventricular repolarisation from mdx 
ECG data reported in the literature. Murine T wave terminations and hence QT 
intervals are not always readily identifiable (Danik et al., 2002). This is highlighted 
by 3 studies in mdx: in one the QTc was shorter in conscious 10-12 week old mice 
(C57: 61.6±1.5ms; mdx: 55.5±0.5msecs, P<0.05) (Chu et al., 2002), another found 
longer durations in similarly aged mice anaesthetised with xylazine-ketamine (C57: 
50msecs; mdx: 70 msecs, P<0.003) (Sadeghi et al., 2002), and a third study reported 
no difference in 2, 6 and 12 month old mice anaesthetised with Hypnorm-Hypnovel 
(QT stated as 24msecs in both strains) (Bia et al., 1999). These discrepancies may 
be due to drug effects or methodology and could be clarified with telemetry studies, 
plus isolated and in vivo ventricular action potential experiments. In patients with 
DMD QT dispersion is greater (ie the range between minimum and maximum QT 
intervals, reflecting regional variations in ventricular recovery), however the 
minimum QTs were significantly less than normal subjects, indicating shorter 




 Mdx hearts show reduced contractility compared to control mice at most, but 
not all, ages studied. This is the first report showing that at specific ages mdx 
isolated atria are capable of generating equivalent forces as C57 under the same 
conditions and has been previously observed in our laboratory in other groups of 6-
12 month old mice (unpublished data). These results are contrary to patients with 
DMD, who show deteriorating heart function with time, while in mdx mice a 
progression of pathological changes in skeletal muscle occurs also with age, albeit 
to a milder degree than the acute necrosis period around weaning age (Pastoret and 
Sebille, 1995b; Lynch et al., 2001; Hayes and Williams, 1998). 
 It is clear that young mice represented in this study by the 3 and 6-week-old 
groups, have compromised cardiac function. Basal forces are lower, and 
responsiveness to exogenous Ca2+ is blunted and in addition each level of 
repolarisation (APD20, 50 and 90) is significantly shortened in the 3-week-old group. 
Other reports using 12 week old atria show evidence for differing force-frequency 
relationships, development of diastolic contracture, irregular contractile activity and 
a lowered efficacy to CaCl2 (Sapp et al., 1996; Lu and Hoey, 2000). This weakness 
might be intrinsic to dystrophic cardiac muscle, due to secondary phenomena, or 
resulting from a combination of factors. Dystrophic cardiomyocytes have higher 
intracellular calcium, which initiates proteolysis and consequently tissue necrosis, 
which could affect contractility (Alloatti et al., 1995). Both mdx and DMD 
myocytes lack neuronal nitric oxide synthase (nNOS), which is thought to 
contribute to abnormal muscle function and incomplete myofibre regeneration 
(Brenman et al., 1995a; Chao et al., 1996). Young mdx undergoing generalised and 
severe muscle necrosis may be under considerable stress, and were shown to have a 
significantly lower metabolic rate and food consumption to controls (Dupont-
Versteegden et al., 1994a). It is feasible that a period of relative malnutrition and the 
existence of widespread inflammatory processes resulting from necrosis may 
exacerbate cardiac dysfunction, but whether animals then come out of this period 
with upregulated utrophin or adaptive responses to the calcium overload for a time, 
or if compensatory myocyte regeneration occurs is only speculative. Absences of 
dystrophin (and hence effective dystrophin-glycoprotein complexes) render 
cardiomyocytes more susceptible to mechanical stresses (Danialou et al., 2001a; 




12 weeks) that mdx have relatively normal cardiac function and mild 
histopathology under baseline conditions, and mechanical stress induced via aortic 
banding (Danialou et al., 2001a); (Kamogawa et al., 2001), exercise (Nakamura et 
al., 2002) or pharmacological means such as isoprenaline or dobutamine (Yue et al., 
2004);(Quinlan et al., 2004), is necessary to produce significant functional or 
histological changes. . 
 Older mice (>15 months in this current study) show deteriorating atrial 
function, increased fibrosis, and altered twitch morphology, suggesting progressive 
pathology at the myocyte and organ level as mdx age. A recent echocardiographic 
study did not show differences in chamber dimensions or fractional shortening in 
mdx and control mice until they reached 42 weeks of age (Quinlan et al., 2004). 
 The apparent paradox of shorter APD90 and longer contractile rise and 
relaxation times implies a level of dissociation between the electrical events 
occurring within the cardiac cell and functioning of the contractile machinery. The 
alteration in relaxation and contraction times appears to occur in an age-dependant 
manner, being normal in young mice and greater from 6 months onwards in this 
study and at 12 weeks in another performed at 25oC (which slows contractile 
kinetics) (Sapp et al., 1996). Raised intracellular calcium has been shown to abolish 
excitation-contraction coupling in isolated skeletal muscles in rat and toad (Lamb et 
al., 1995). In addition mdx extensor digitorum longus muscles, with an inherent 
intracellular calcium elevation, also displays these properties (De Luca et al., 2001). 
There is an interplay of events determining lusiotropy, including dissociation of 
calcium from actin-myosin cross bridges, reuptake of calcium by the sarcoplasmic 
reticulum and calcium extrusion which may be affected in dystrophic 
cardiomyocytes. 
 Hydroxyproline values from left atria and left ventricular apex samples indicate 
collagen accumulation begins at a young age in mdx mice. The LV HP 
measurements in the first study do not suggest marked fibrosis in dystrophin 
deficient hearts, but this may be a methodological problem rather than a reflection 
of true values. A total assay volume of 2 mL precluded use of more than 20 mg of 
tissue and, because LV was also stored for confocal microscopy, only the tip of the 
apex was utilised. In the second study samples were taken from mid portions of the 




in this study, with HP significantly greater in young, but not old, mdx compared to 
control right atria. The reason for this is unknown, however this structure usually 
has a dense collagen network, commensurate with its structural and conducting 
function and fibrosis may progress in aging normal and dystrophic mice. 
 There was variation in collagen measured by picrosirius red staining and 
confocal microscopy (Study 1), with large standard error of means for dystrophic, 
but not for control hearts. This phenomenon also occurred in another study, where 3 
times as many dystrophic mice were analysed compared to control mice, yet large 
standard errors were noted in mdx only (Quinlan et al., 2004). There was no 
perceived benefit in using confocal microscopy in this series of experiments, 
particularly as the number of scans was small (3), and given the added costs of this 
technique. In Study 2 improvements included the use of more mice, analysing 3 
levels of the heart instead of only one and ensuring analysis fairly included non 
fibrotic as well as fibrotic regions. Fibrosis may not occur equally in all mdx hearts, 
and this is supported by other studies in mdx (Lefaucheur et al., 1995) and boys with 
DMD. Although the magnitude of fibrosis (up to 8-10%) is less in mdx mice 
compared to DMD patients, it could still impact on contractile function and 
electrical impulse propagation in affected animals. 
 There were several limitations to this study. There were no age matched control 
mice available to enable valid comparisons of functional and electrophysiology data 
at 18 and 24 months. Atrial contractile and electrophysiological data may not be 
commensurate with ventricular function, however isolated left atria were used in 
order to obtain sufficient statistical results in mice of body weights ranging from 6 
to 39 grams. Atrial preparations have been used previously to demonstrate altered 
contractile function in mdx mice (Alloatti et al., 1995), and it is known that 
multifocal dystrophic involvement occurs in all four heart chambers of boys with 
DMD (Sanyal et al., 1978; Sanyal and Johnson, 1982), and was evident from 
increased ventricular and atrial collagen in this study.  Mouse trabeculae or papillary 
muscles have a high frequency (~75%) of geometrically unsuitable preparations for 
working muscle experiments (Gao et al., 1999; Kogler et al., 2001), and it is our 
laboratory’s experience that mdx papillary muscle preparations undergo contracture 




intracellular calcium (see Appendix A for details regarding ventricular experiments 
in mdx). 
 . There have been arguments that the mdx is a poor model of cardiomyopathy 
(Grady et al., 1997) (Megeney et al., 1999), however there is evidence from this 
current investigation, and other previously published work, that significant 
dystrophic changes do occur in mdx hearts which can lead to pathophysiological 
events not identical with, but similar to, the cardiomyopathy of DMD. 
 This study concludes that particular ages of mdx may be more useful than 
others for cardiac experiments. The young mouse less than 6 weeks old, undergoing 
or recovering from widespread muscle necrosis, shows cardiac contractile 
dysfunction. Mice older than 15 months of age demonstrate altered twitch 
properties, deterioration in contractile function and fibrosis indicative of ongoing 
pathology. The inherent dystrophic changes in dystrophin-deficient cardiomyocytes, 
such as altered calcium metabolism, cellular electrophysiological alterations and 
nNOS deficiency may be responsible for these changes. A shortened APD90 and 
hence refractory period, in association with other features of dystrophic cardiac cells 
such as increased intracellular calcium, necrosis and fibrosis can potentially enhance 
the development of arrhythmias, which are evident in many boys with DMD. 
Electrophysiological studies such as the transmembrane action potential 
measurements detailed here, patch clamping or monophasic action potential studies 
as performed in other murine models of cardiomyopathy are important in 





CHAPTER 3. THE AGING MDX MOUSE: DIAPHRAGM 
FUNCTION AND FIBROSIS 
3.1 Introduction 
 The landmark study by Stedman et al was the first to document the severe 
histological changes in mdx diaphragm compared to the control strain, and the 
concurrent functional deficits of isolated diaphragm strips in organ bath experiments 
(Stedman et al., 1991). The discovery of a similar pattern of degeneration, fibrosis 
and severe functional deficits comparable to DMD limb muscles has since extended 
the application of the mdx mouse as an animal model of human disease. These 
authors compared diaphragm muscle by examining them histologically at two ages 
(6 and 16 months), by using hydroxyproline analysis as a measure of collagen 
content (in mice from 12-18 months of age), and by determining functional 
properties (18-month-old mice). At 6 months of age there was wide variation in 
myofibre size and architecture, with evidence of continued necrosis and connective  
tissue proliferation. By 16 months of age they noted extensive myofibre loss and 
replacement by fibrous tissue in diaphragms from mdx compared to C57 mice. 
Older mdx diaphragm strips demonstrated reductions of strength to 13.5% of the 
levels of control mice, in addition to reduced elasticity, twitch speed and fibre 
length. Figure 4.1 shows representative H & E stained sections from 18-month-old 
mdx and control mice (sections prepared by author). 
 
  A range of further studies examined contractility at 6 weeks, 4 months, 6 
months, 8 months, 9 months, 10-13 months, 22-24 months and fibrosis (by 
hydroxyproline analysis or histological stains) at 3 months, 4 months, 6 months, and 
8 months (Petrof et al., 1993b; Dupont-Versteegden et al., 1994b);  (Hartel et al., 
2001); (Krupnick et al., 2003; Coirault et al., 2003; Coirault et al., 1999; Lynch et 
al., 1997; Lynch et al., 2001; Gregorevic et al., 2002). However no single study has 






























Fig 3.1 H&E stained diaphragm sections from A) 18-month-old control mouse and 
B) 18-month old mdx. Dystrophic features of collagen accumulation, inflammatory 
cell infiltration, central nucleation and wide variation in cell size are apparent in the 
mdx diaphragm. (20x magnification) 
 
 A lowered threshold of work-induced injury was postulated as a cause of the 
distinct pattern of dystrophic changes in mdx diaphragm muscles (Stedman et al., 
1991). This was supported by findings of similar but less severe histological 
changes in the accessory muscles of respiration, which, like the diaphragm, have a 




diaphragm suggesting that regeneration of myocytes within this organ still occurs, 
even in old mdx. Further studies have shown 70-80% of limb muscles of mdx mice 
have central nuclei, compared to 35% in diaphragm muscle, and that fibre diameter  
remains smaller in mdx diaphragms compared to controls (Louboutin et al., 1993). It 
has been suggested that the crural diaphragm is subject to more strain, fatigue or 
contraction induced injury than the costal diaphragm, possibly due to a higher 
workload and mechanical strain of these fibres in quadrupedal animal (Anderson et 
al., 1998). 
 In contrast, evidence is accumulating against the work-overload hypothesis. 
The decrease in diaphragm strength in mdx mice is more pronounced than that 
predicted by the area of fibrosis alone (Petrof et al., 1993b, Lynch et al., 1997), 
indicative of alternate causes of diaphragm weakness. There is a strong linear 
relationship between maximum tetanic forces and total number of cross bridges per 
square millimetre, with mdx diaphragm having a 48% reduction in cross bridges 
(Coirault et al., 1999). There is also evidence that the contractile apparatus of 
muscle fibres may be intrinsically dysfunctional in mdx diaphragms (Coirault et al., 
1999), even as young as 6 weeks of age when muscle necrosis and fibrosis remain 
limited (Coirault et al., 2003). These authors found a 37% lower force production in 
6-week-old mdx mice, despite only 2.8% fibre necrosis and 3.6% collagen surface 
area occupied. Their conclusions were that mdx diaphragm muscle is more prone to 
degeneration, as a portion of active cross bridges are forced to carry the ventilatory 
workload. Oxidative damage is a likely contributory factor, with studies showing 
both a reduction in NO-mediated protection against ischaemia and increased cellular 
susceptibility to oxidative damage in mdx (Disatnik et al., 2000; Rando et al., 1998). 
Further evidence against the work-overload hypothesis of muscular dystrophy was 
afforded by tracheal banding experiments, which did not accelerate degeneration in 





To date, few studies have utilised direct administration of therapeutic agents into 
mdx diaphragm muscle, despite this structure showing the greatest similarity to 
DMD skeletal muscles, and being a potential treatment paradigm for gene therapies, 
plasmid or adenovirus delivery, or oligoribonucleotide (AO) administration. 
Efficient introduction of pure recombinant plasmid DNA into C57BL/6J mice 
diaphragms was reported (Davis and Jasmin, 1993), and reporter gene delivery has 
been successful in mouse diaphragms (Liu et al., 2001a; Liu et al., 2001b). It was 
demonstrated that a controlled release device for Leukaemia Inhibitory Factor (LIF) 
based on a calcium alginate rod could be sutured to the abdominal surface of the 
diaphragm to provide LIF for a 3-month period (Austin et al., 2000). These 
experiments utilised normal mice or young (3 month old) mdx mice and it is not 
clear from these studies whether the significant collagen deposition present in mdx 
diaphragms limits the use of direct injections in this strain. Timing of administration 
may be critical, with a balance sought between an age of mouse with a large enough 
body size to make surgery and diaphragm injections practicable, and prior to the 
period of accelerating degenerative changes and fibrosis, which may limit the 
spread of injectate within the muscle, and potential success of dystrophin restorative 
therapies.   
 
3.2 Aims 
 There were 4 aims of the study: a) to gain experience in the dissection and 
mounting of mouse diaphragm strips in organ bath experiments, b) to establish and 
optimise hydroxyproline assays for diaphragm tissue within our laboratory, c) to 
determine the best age range for experiments involving direct administration of AOs 
into mouse diaphragm muscles, using both functional data and measures of fibrosis 
and d) to develop expertise in sub-epimyseal diaphragm inoculations in mice. 
 
3.3 Methods 
3.3.1 Mouse numbers and grouping 
The same animals used for cardiac studies (Chapter 3) were utilised for 
diaphragm contractility experiments. There were 7-8 mice per group, with animals 
aged 3 weeks, 6 weeks, 12 weeks, 6 months, 9 months, 12 months, 15 months, 18 




were utilised, except for 12, 18 and 24 months age groups, where only mdx mice 
were available. A total of 10 C57 and mdx mice of mixed ages were used for post-
mortem practice diaphragm injections, additional to contractility studies. 
Hydroxyproline analyses were performed on diaphragm strips from 6 or 7 control 
and mdx mice per age group. 
 
3.3.2 Organ bath experiments 
The organ bath protocol followed was that used in the laboratory at the time, 
utilising existing equipment.  
Mice were anaesthetised with 50 mg/kg tiletamine/zolazepam (Zoletil, 
Virbac Australia)) by subcutaneous injection. The diaphragm and surrounding ribs 
were removed en bloc and placed in ice cold Krebs solution, bubbled with 95% O2 
and 5% CO2. Strips of diaphragm muscle were prepared for hydroxyproline analysis 
by snap freezing in liquid nitrogen before storing at –80oC.  A single diaphragm 
strip 2-3 mm wide was excised from the right hemidiaphragm for organ bath 
studies.  These were anchored by means of cotton thread to a fixed peg at the rib 
end, and attached to a force transducer at the tendon end, and placed within a 25ml 
glass organ bath maintained at 23oC. Tissues were stimulated via a Grass S48 
stimulator (W. Warwick, RI, USA). Data was collected and analysed using Chart 
4.1.1 software on an iMac computer. A square pulse of 0.2 ms duration was 
dispersed via two platinum plate electrodes positioned at each side of the muscle. 
Preload was set at 5 mN, frequency of tetanic stimulation at 120 Hz and voltage at 
10 volts for all muscle strips. 
Reported data was the average of 3 individual single twitch or tetanic 
stimulations per muscle strip to give an overall mean for that mouse. A fatigue 
protocol (one tetanic stimulation every 5 secs for 5 minutes) was also performed. 
Muscles were measured using a digital micrometer, blotted for 3 secs then weighed 
prior to storage at –80oC for subsequent hydroxyproline assays. Cross-sectional area 
(CSA) and normalisation of forces was calculated as described previously (Lynch et 
al., 2001), where CSA equals weight of tissue divided by length multiplied by 1.06 
(the density of mammalian skeletal muscle).  
Organ bath protocols were changed subsequently (including more stringent 




preamplifier to increase stimulation current intensity added to the experimental 
apparatus. Subsequent diaphragm experiments resulted in greater peak force values 
for these reasons (see Chapters 5- 7), however these early results are included 
because they offer useful functional information for aging mice, complimenting 
hydroxyproline values at the same age groups. 
 
3.3.3 Quantitation of collagen 
Hydroxyproline content was used as a measure of collagen. Tissues were 
thawed then hydrolysed in sealed tubes with 6M HCl overnight at 110 oC. The 
samples were dried to entirety using filtered air under pressure and heat (50 oC). The 
rest of the protocol has been described previously (Stegemann and Stalder, 1967), 
with details of the assay adjusted to a 2 mL total volume provided in Appendix A. 
Values are expressed as  gHP µ/mg tissue wet weight. 
 
3.3.4  Diaphragm injection technique 
Anaesthesia was induced with 70-mg/kg thiopentone sodium 
(Nembutal,Boerhinger Ingelheim Australia) given i.p. Hair was clipped from the 
ventral abdomen of the mouse and a midline laparotomy performed from the 
xiphisternum caudally. Exposure of the abdominal surface of the diaphragm was 
achieved by placing a silk suture through the abdominal musculature on each side, 
then attaching a pair of haemostats to the ends of the threads and holding them away 
from the body. Magnification was performed initially with 3x magnification glasses, 
or later, 7x magnification illuminated lenses (Voroscope). 30 gauge 0.3 mL 
disposable insulin syringes (Omnican 30, Braun, Australia) were used for the 
injections, which for practice purposes were a total of 34µL of 0.9% saline and 6 µL 
histological marking dye (Wak-Chemie Medical, Germany). The needle was 
inserted with the orifice away from the muscle and as much of the length inserted 
into the muscle as possible. 4 injections of 10 µL were administered at sites around 
the diaphragm, two in the right and two in the left hemidiaphragms. Success of the 





Results are expressed as mean ± SEM. Variables were compared between 
experimental groups using Student’s t-tests, assuming equal variances. Differences 




Figure 3.2 shows group mean body weights of mice used for both the aging 
heart study (Chapter 3) and for this study. Significant differences were observed at 3 
weeks of age, when mdx were lighter (P<0.001), at 12 weeks old when mdx were 
heavier corresponding to their muscle hypertrophy stage (P<0.05) and again at 15 
months when mdx mice were moving less freely around their cages and weight loss 
was observed (P<0.01). This weight loss in mdx continued until the end of the study 
(24 months of age). 
 
Body weight of mice (grams)
























Fig 3.2 Body weights of aging mice used for diaphragm study and aging heart 
study. n=7-8 mice per strain per age group, except for 18 months and 24 months 





3.5.2 Diaphragm contractility.  
Peak twitch and tetanic forces are shown in Figure 3.3a and b. Mdx twitch 
values were significantly less at 6 weeks and six months Mdx tetanus values were 
similar to control mice at 3, 6 and 12 weeks of age. After this time there was a 
significant difference between mice strains, with mdx having lower values (P<0.01). 
Twitch to tetanus ratios tended to be greater in mdx mice compared to controls, 
showing significance at 6 months of age (C57, 0.18 ± .004; mdx, 0.23 ± .02,  
P<0.01) and 15 months of age (C57, 0.19 ± 0.02; mdx, 0.29 ± .02, P<0.01).  
Other twitch characteristics measured including time to peak force (TPF), time for 
50% relaxation (TR50) and time for 90% relaxation (TR90) did not differ 
significantly between mice strains (data not shown). Percentage fatigue of 
diaphragm strips was significantly less in mdx mice after 9 months of age (C57, 
53.49 ± 2.3%; mdx, 35.8 ± 5.9%, P<0.01), corresponding to the lower tetanic forces 
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Peak diaphragm twitch force 
Fig 3.3a Peak diaphragm twitch force, normalised to CSA for groups of C57 and 
mdx mice (n= 7-8 mice per strain per age group). There were significant differences 
between strains at 6 weeks and 6 months of age, with mdx showing lower peak 
twitch forces. 
Fig 3.3b Peak diaphragm tetanic force normalised to CSA for groups of C57 and 
mdx mice (n= 7-8 mice per strain per age group). Force was similar in young mice 






























3.5.3 Diaphragm fibrosis  
There was a three to four fold increase in HP in old mdx mice, compared to 
young mdx. Values tended to remain similar in the age groups of control mice 






























Fig 3.4 Diaphragm hydroxyproline values, expressed as µg HP/mg tissue wet 
weight. n=7-8 mice per strain per group. HP values were similar for mdx and control 













3.5.4 Diaphragm injections 
Young mdx mice (< 6 weeks old) and C57 mice of all ages tended to have very 
thin diaphragm muscles, while older mdx had thicker, more opaque muscles that 
were consequently easier to inject. Success of injections was judged by spread of 
blue dye in the muscle around the needle tip. This either resulted in a bleb of 
injectate or sometimes infiltration of dye along the length of muscle fibres, from 
near the costal margin towards the central tendon. Successful injections were aided 
by retraction of the costal margin to flatten the diaphragm surface, positioning the 
mouse on an inclined foam pad to enable the abdominal contents to drop away from 
the diaphragm, and holding the liver away using gauze swabs and blunt forceps. 
Occasional injections resulted in blue dye escaping into the thoracic cavity, however 





   The mdx mouse is a complex model, with differential patterns of dystrophy 
according to age and the muscles examined. The mdx diaphragm is a desirable 
target for dystrophin restoration strategies because of its severe pathology that 
begins early and persists throughout the mouse lifespan. There is, however, little 
available evidence as to the best age to apply such treatments, and only a few 
references document the use of mouse diaphragm sub-epimysial injections (Davis 
and Jasmin, 1993; Petrof et al., 1995; Petrof, 1998b)  
This present study used the parameters of loss of force production and 
collagen accumulation as measures of dystrophic pathology. It was hypothesised 
that success of dystrophin restoring strategies is most likely before significant 
muscle weakness or fibrosis is present (Chapter 5). Whereas young mice (6 weeks 
old) have been used for testing of limb injections of AOs (Lu et al, 2003), the 
thinness of diaphragm muscle in control mice and very young mdx mice may 
preclude the efficacy of this procedure until a larger body size is reached. 
Organ bath studies of mouse diaphragm muscle are well documented and 
performed in many laboratories throughout the world, however a review of the 




et al., 1991; Lynch et al., 1997; Coirault et al., 1999; Stevens and Faulkner, 2000). 
It is essential to optimise procedures within an individual laboratory and for 
researchers to gain expertise in new experimental techniques. It became apparent 
that protocols initially in place in our laboratory were resulting in very low force 
productions (less than 1/3 of those achieved elsewhere), and did not optimise 
conditions for muscle fibre contractions. Changes for subsequent studies included 
the careful determination of preload to obtain optimal muscle fibre length (Lo) and 
hence achieve greatest isometric active tension, determination of the frequency 
resulting in a maximally fused tetanic tension and assessment of optimal stimulus 
voltage. In addition a preamplifier was added to the experimental apparatus to 
amplify field stimulation intensity. Unfortunately much of this preliminary 
experiment was performed before these changes were made, and for comparison 
sake the rest of the diaphragm preparations were treated similarly. As a consequence 
maximal force production was considerably underestimated in this series, as tension 
declines at lengths less than or greater than Lo. However, when taken together with 
hydroxyproline values and information available from published studies, useful 
conclusions could be still be reached. Figure 3.5 shows the approximate decline in 

















































Fig 3.5 Plot expressing both decline in peak twitch force in aging mdx, compared to 
increased fibrosis (measured by hydroxyproline analysis). The two lines show 
averaged values generated by curve fit, and as such represent approximate values 
only. The asterisks show the age at which significant differences between mdx and 
control mice for hydroxyproline and twitch force occurred in this study. 
 
 
 It was felt that determination of diaphragm fatigue did not provide useful 
additional information as muscles showing lower tetanic force production tended to 
fatigue less (older mdx diaphragms). The altered twitch/tetanus ratios could also not 
be interpreted categorically because of the incorrect optimisation procedures used. 
 The success of diaphragm injections was cofirmed by visual confirmation. 
The sites of injections were clearly apparent by the appearance of a raised bleb 
within the diaphragm musculture. Successful injections occurred infrequently at 
first, but with repeated practice these injections were possible at four sites in the 
majority of animals. The dissection of treated diaphragms post mortem also allowed 
examination and assessment of the spread of dye. 
   In conclusion this study provided experience in organ bath techniques and  
highlighted the need for modification and improvements of existing skeletal muscle 




in mice was gained. The reliability of hydroxyproline assays as a measure of 
diaphragm fibrosis was realised. For potential studies employing direct injection of 
AOs into mdx diaphragm muscle it was concluded that such injections should occur 
well before six months of age, when marked dystrophy is evident. As it was thought 
that two administrations of AOs four weeks apart were preferential to one injection 
it was considered that future mice undergo surgery for AO injections at four and 
five months of age, before sacrifice for organ bath studies, hydroxyproline, 






CHAPTER 4. THE AGING MDX MOUSE: 
PROGRESSION OF KYPHOSIS 
4.1 Introduction 
Chest deformity due to scoliosis, kyphosis, lordosis or combined spinal 
curvatures contribute significantly to the morbidity associated with DMD, and often 
leads to a restrictive respiratory pattern with diaphragm and inspiratory muscle 
weakness, ineffective cough mechanisms, mucus plugging of airways and chronic 
alveolar hypoventilation (Rideau et al., 1981; Seddon and Khan, 2003). Vital 
capacity (VC) remains normal in patients with neuromuscular disease if respiratory 
muscle strength is more than 50% of predicted, however when strength is less than 
this VC becomes diminished to a greater extent than expected (De Troyer et al., 
1980; Estenne et al., 1993). This decrease is thought to be associated with a loss of 
compliance of the chest wall and lungs, with stiffening of ribcage tendons and 
ligaments and ankylosis of costosternal and thoracovertebral joints (Estenne et al., 
1993); (Bach and Kang, 2000). As well as exacerbating respiratory dysfunction in 
affected boys, kyphoscoliosis negatively impacts on their quality of life in their 
wheelchair dependant years, with most patients electing surgery for spinal fusion 
and stabilisation and/or experiencing chronic pain due to poor posture and 
prolonged sitting (Smith et al., 1989).  
The natural course of spinal deformity differs between patients and a 
classification scheme has been established based on radiographic indices including 
the Cobb angle, pelvic obliquity, kyphotic index (KI) and sacral angle (Oda et al., 
1993). Pulmonary function (as measured by plateau of vital capacity) correlates 
with the progression of spinal deformity and may be an indicator of the expected 
progression (Yamashita et al., 2001a; Yamashita et al., 2001b). It has also been 
suggested that a particular clinical course may correlate with a specific molecular 
lesion (Hoffman et al., 1989; Hoffman, 1993). 
Thoracolumbar kyphosis also occurs in murine models of neuromuscular 
diseases including the dystrophin deficient (mdx) mouse (Lefaucheur et al., 1995), 
the dystrophin/utrophin deficient (mdx:utrn-/-) mouse (Grady et al., 1997; 
Deconinck et al., 1997a) and the kyphoscoliosis (ky) mouse  (Dickinson and Meikle, 




mice with skin removed. These images show the muscle atrophy present in old 
mdx mice, and the presence of kyphosis of the thoracolumbar region.  
 
Fig 4.1  Whole body photographs of A.Young (3mo) mdx mouse, B. Aged (22 mo) 
mdx, C. Young C57 mouse and D. Aged C57 mouse. Kyphosis is grossly evident in 
both strains of mice, but is more pronounced in mdx. Also evident is the muscle 
hypertrophy in young mdx mice, and the muscle atrophy and weight loss that occurs 
with age in this strain. 
 
Although mdx diaphragm muscle has been shown to most closely mimic the 
pathological changes seen in DMD (Stedman et al., 1991), there is also histological 
evidence of necrosis and fibrosis in postural and paraspinal muscles of mdx and  
mdx:utrn-/- (Lefaucheur et al., 1995; Grady et al., 1997; Deconinck et al., 1997a). 
To date limited respiratory studies have been performed in the mdx mouse model, 
however there is recent evidence of significant attenuation of respiratory responses 
to hypercapnia (a potent ventilatory stimulant) in mdx mice compared to control 
mice, which was thought to be influenced by tumour necrosis factor-α (Gosselin et 





There were three goals in this study: a) Establishment of a novel Kyphotic 
Index (KI) to quantify the progression of spinal deformity in two groups of aging 
mice, mdx and their aged matched controls. b) Evaluation of contractile function in 
paraspinal and respiratory muscles (latissimus dorsi muscles and intercostal strips) 
and comparison to diaphragm muscle as a known standard. The latissimus, a flexor 
of the brachium, was chosen because of its origin from T8-T12 and the 
thoracolumbar fascia in the region kyphosis occurs, and due to its well documented 
contractile properties in other species (James et al., 1997). Functional parameters of 
intercostal muscles have been reported previously in larger species, but not in mice, 
therefore intercostal strips comprising four rib sections and adjoining intercostal 
muscles (external and internal intercostals) were utilised.  c) Measurement of 
fibrosis in the above muscles and longissimus dorsi muscles by means of 
hydroxyproline measurements and picrosirius red stained sections recording 
histological changes to evaluate muscle degeneration and regeneration. It was hoped 
that findings from this study would extend understanding of the mdx phenotype and 
be commensurate with dystrophic changes contributing to thoracolumbar deformity 
in DMD patients. 
 
4.3 Methods 
4.3.1 Mouse numbers and groupings 
  Male C57BL/10ScSn mice (control strain) were purchased from Animal 
Resource Centre, Nedlands, Perth, WA at 7 weeks of age. Male mdx mice were bred 
at the USQ Animal House, Toowoomba, Qld. The mice were housed in groups and 
given free access to laboratory chow and water, and all experiments were conducted 
in accordance with guidelines of the USQ Animal Ethics Committee. 4 mice per 
strain were used for the radiographic study, with one mouse dying during this study. 
An additional 4 mice per strain were also utilised for contractility experiments, 
hydroxyproline assays and histology.  17 month old mice were chosen as the aged 
group because of time restraints of PhD studies, and lack of availability of older 






4.3.2 Radiographic studies and establishment of Kyphotic Index 
  Mice were sedated with Ketamine HCl 50 mg/kg (Ketamil, Troy 
Laboratories, Australia) in combination with Xylazine HCl 10 mg/kg (Ilium 
Xylazil-20, Troy Laboratories, Australia) administered by subcutaneous injection. 
At the end of the procedure atipamezole (Antisedan, Novartis Animal Health, 
Australia) was given at a dose rate of 0.1 mg/kg to reverse α-2 agonist effects of 
xylazine. Mice were lightly taped to the radiographic cassette using clear adhesive 
tape. Each animal was individually identified by tail markings, a radiodense (metal) 
number placed next to them, and a radiographic cassette label indicating date and 
animal grouping. Konica CM-H medical mammography film was exposed using a 
portable X-ray unit (either Showa  Xray Co Ltd Tokyo, Japan or Porta 1030 model, 
Job Corporation, Yokohama, Japan). Optimum exposure with this equipment was 
established at 48KV, 1.8 MAS with a film focal distance of 70 cm. Mice were 
radiographed once monthly from 4 months until 17 months of age. Figure 4.2 
depicts mice undergoing radiography. 
 
Fig 4.2 Mice undergoing radiography for determination of KI. A. Portable x-ray 
machine suspended from a timber beam to ensure correct film-focal distance. B. 
Anaesthetised mice positioned on cassette using clear adhesive tape. A metal 




Equipment and procedures conformed to Queensland Department of Health 
regulations for veterinary radiography, and the correct personal and protective 
equipment (lead gown and gloves) was worn. Although it was necessary to stay in 
the room during film exposure the operator was as far from the x-ray beam as 
allowed by the length of cable. Monitoring of radiation exposure by radiation meters 
was performed regularly. 
Each whole body radiograph was photographed using a tripod mounted 
Ricoh Caplio RR30 digital camera with images analysed using Scion Image 
software Beta 4.0.2 (http://www.scioncorp.com). KI was calculated from a line 
drawn between the caudal margin of the last cervical vertebra, to the caudal margin 
of the 6th lumbar vertebra (usually corresponding to the cranial border of the wing of 
the ilium) (Line AB), divided by a line perpendicular to this from the dorsal edge of 
the vertebra at the point of greatest curvature (Line CD). This correlates as closely 
as possible to those radiographic parameters used to assess KI in boys with DMD, 
and is depicted in Figure 4.3a and b 
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ethod of measurement of KI in boys with DMD (diagram adapted 
t al., 1989)). With patient in sitting position, measurements are made 
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Fig 4.3b.  KI in mice, calculated from radiographs of anaesthetised mice positioned 
in right lateral recumbency. 
Line AB is the length of a line drawn from posterior edge of C7 to the posterior 
edge of L6, usually where it contacts the wing of the ilium (which is more 
consistently identifiable than the sacral border). Line CD is the distance from line 
AB to the dorsal border of the vertebral body farthest from that line. KI=AB/CD 
 
Trial radiographs of the same animals in 3 positions 1) hind limbs and 
forelimbs placed in moderate extension, 2) overextension (stretching) of limbs and 
3) flexion of forelimbs and hind limbs showed there was some differences in 
measured KI, considered to be less than 10%. Care was then taken to avoid 2) or 3), 
and to ensure limbs were only moderately extended. This could be confirmed when 
radiographs were analysed because the femurs and humeri were close to parallel and 
perpendicular to the long axis of the spine. Several radiographs that did not meet 
these criteria or were under or overexposed were excluded from analysis. 
 
4.3.3 Measurement of thoracic area 
 With radiographs photographed using a fixed film-focal distance and 
utilising the Scion Image program draw tool, a line was extended around the inside 
border of the thoracic cavity, from T1 at the thoracic inlet following sternebrae, 
diaphragm and ventral edge of vertebrae to allow an estimation of thoracic area at 
age 17 months (Figure 4.4). This measure was repeated three times and results 
averaged for each animal (n=4 animals per group). Because thoracic area is related 
to body size the calculated area was normalised for body weight to give a value of 







Fig 4.4 Assessment of thoracic area in mice. A freehand line was drawn digitally  
following anterior edge of the first rib, sternebrae, diaphragm and ventral vertebral 
border using Scion Imaging program, and area bound by this line was calculated. 
This measurement was repeated three times for each mouse and results were 
averaged. The mouse shown above had a thoracic area of  3.59 cm2. 
 
4.3.4 Contractility  studies 
  17 month old mice were anaesthetised using pentobarbitone sodium 
(Nembutal, Boehringer Ingelheim, Australia) at 70 mg/kg IP. Cessation of breathing 
occurred when the thorax was entered. The following muscles were dissected and 
placed into ice-cold Krebs buffer solution bubbled with carbogen (95% O2/5% 
CO2); a) diaphragm strip from left midcostal hemi- diaphragm, with placement of 
silk suture material around the central tendon at one end and a small rib section at 
the other. b) latissimus dorsi muscle, which is a fan shaped muscle with an 
aponeurosis originating from the spinal processes of T8-T12 and the thoracolumbar 
fascia, and a distinct tendon of insertion at the proximal humerus. A needle threaded 
with 6/0 surgical silk was passed through the aponeurosis and tied with a loop to 
attach to a force transducer. A short length of silk was also tied at the tendon end to 
anchor to a fixed peg below the stimulating electrodes and c) intercostal section 
comprising 4 ribs and their attached intercostal muscles (internal and external), 




sutures were passed with a needle around each rib at the top and bottom of the 
intercostal strip for mounting.  
Muscles from the right side were collected and stored for histological 
analysis and hydroxyproline assays. Contralateral muscles were mounted in water-
jacketed glass organ baths, maintained at 23oC, using 6/0 silk surgical suture thread 
attached to a fixed peg at one end and a force transducer at the other. Tissues were 
stimulated via a Grass S48 stimulator (W. Warwick, RI, USA) and current intensity 
was amplified using a pre-amplifier (EP500B. Audio Assemblies, Campbellfield, 
Victoria, Aust). Data was collected and analysed using Chart 4.1.1 software. A 
square pulse of 0.2ms duration was dispersed via 2 platinum electrodes positioned 
along the length of the muscle. 
Optimum preload (Lo) was defined as the length eliciting maximal single twitch 
force. Optimal voltage was also determined for each preparation, as was the 
frequency eliciting maximal tetanic force from a range of 50 - 180 Hz.  A total of 7-
8 mice per group were used for contractility studies. Reported data was the average 
of 3 individual single twitch or tetanic stimulations per muscle strip after 25 minutes 
of equilibration and optimisation of conditions. Muscles were measured at Lo using 
a digital micrometer, blotted for 3 secs then weighed. Cross sectional area (CSA) 
and normalisation of force was calculated as described previously for diaphragm 
and latissimus muscles, where CSA equals tissue weight divided by length x 1.06 
(density of mammalian muscle) (Lynch et al., 2001). Intercostal muscle fibre CSA 
was shown to vary topographically (Kelsen et al., 1993) and in our preparations a 
strip comprises both muscle and rib cartilage and internal and external intercostal 
muscle layers consisting of differing fibre orientations and hence lengths. For these 
reasons intercostal forces were normalised to weight only. Time to peak force, 50% 
relaxation time and 90% relaxation time was calculated for each single twitch value. 
 
4.3.5 Hydroxyproline analysis 
   Hydroxyproline content was used as a measure of collagen in diaphragm, 
intercostal muscles, latissimus dorsi and longissimus dorsi muscles. Muscles were 
trimmed of fat, ribs and tendons and stored at -80 oC. Tissue was thawed then 
hydrolysed in sealed tubes with 6 M HCl overnight at 110oC. The samples were 




protocol has been described previously (Stegemann and Stalder, 1967) and 
Appendix A shows details of the procedure for total assay volumes of 2 mLs. 
Values are expressed as µg HP/mg tissue wet weight. 
 
4.3.6 Histology 
  Each tissue (diaphragm, latissimus, longissimus and intercostal muscles) 
was pinned onto cork at optimal length and then fixed sequentially in Telly’s 
fixative (formaldehyde, glacial acetic acid-ethanol fixative, 72 hours), Bouin’s 
solution (formaldehyde, glacial acetic acid-picric acid fixative, 24 hours) and 70% 
ethanol, prior to paraffin embedding, cutting and staining of 10 micron sections 
using 0.1% w/v picrosirius red solution (Sirius Red F3B, Chroma Dyes, Germany in 
saturated picric acid), a collagen specific stain. Additional 5 micron sections were 
stained with haematoxylin and eosin for determination of nuclear position. Analysis 
was performed blinded to the strain of mouse, with sections viewed on a Nikon 
Eclipse E600 light microscope and captured with a Nikon FDX-35mm camera, then 
digitised. A visual grading scheme was applied to the picrosirius stained sections, 
with Grade 1 having minimum interstitial fibrosis (eg <10%), Grade 2 with mild 
fibrosis (10-25%), Grade 3 with moderate fibrosis (25-50%) and Grade 4 with 
marked fibrosis (>50%).   
 
4.4 Statistics 
 Pilot experiments on aged mice were performed to estimate standard 
deviations and suitable sample size. Post hoc tests of power confirmed that an n = 3 
animals for assessment of KI and n=5 animals for contractility experiments were 
adequate (Plummer, 1998). Results are expressed as means ± S.E. Responses 
between mdx and control strain were analysed using Student’s unpaired t-tests, with 
the exception of differences in KI, where ANOVA was employed. P values less 










4.5.1 Gross findings 
 Kyphosis was palpable and clearly evident in all mdx mice at 17 months of 
age.  In addition the control strain showed a degree of thoracolumbar kyphosis 
which was not as pronounced. All animals were ambulatory and in fair-good body 
condition, however the mdx group showed a stiffer gait and moved less freely 
around their cages. 
 
4.5.2 Kyphotic Index 
KI as a measure of spinal deformity remained similar for mdx and control 
mice until approximately 9 months of age, after which a significant difference 
became apparent between mdx and normal mice (P<0.01 at 9 months). There was a 
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Fig 4.5  Kyphosis Index of aging mdx and control mice. Mice were radiographed 
monthly from 4 months to 17 months of age and measurements were made every 2 
months. n=4(mdx), n=3 (C57) *P<0.05, **P<0.01. 
 
Figure 4.6 shows examples of radiographs of young (5 months old) and aged (17 







Fig 4.6  Examples of mouse whole body radiographs used for calculation of  
kyphotic index. A and C = young and aged (5 month old and 17 month old) control 
mouse, B and D=young and aged mdx mouse. The progression of spinal deformity 
results in a decrease in KI, and alteration of thoracic shape and size. 
 
4.5.3 Thoracic Area 
  There was no significant difference in body weights at 17 months of age 
between mdx and C57 mice, however there was a difference (P<0.05) between 
thoracic area and normalised thoracic area in mdx and age-matched controls (Table 











TABLE 4.1 Mean (± SE) of thoracic area, body weight and normalised thoracic 









4.49 ± 0.12 
 
32.2 ± 0.86 
 




3.71 ± 0.25 * 
 
31.65 ± 1.2 
 
0.12 ± .004 * 
 
4.5.4  Muscle contractility  
The characteristics (optimal muscle length (Lo), average width and weight) of 
each isolated muscle strip is listed in Table 4.2.  The latissimus dorsi muscle 
showed greatest variation between mouse strains, with mdx having considerably 
heavier (P<0.001) muscles than C57, despite being no significant differences 
between widths or Lo for these muscle preparations. It is thought that this muscle (in 
addition to many mdx limb muscles) demonstrates considerable hypertrophy during 
their lifespan with the presence of fibrosis contributing to increased weights. A 
difference between strains was also apparent during dissection; the diaphragm, 
intercostals and latissimus muscles of C57 tended to be thin and transparent, while 
in mdx they were thickened and opaque. There was a small difference in average 
diaphragm width selected for mounting, and, although this is unlikely to affect 
















Table 4.2 Mean (± SE) optimum fibre length, weight and width of muscle strips 
from 17-month-old control and mdx mice. n=7(C57), n=8(mdx) ***P<0.001 
*P<0.05 
Muscle 

















































   In vitro isometric contractile properties of these muscles are shown in Table 4.3. 
All mdx muscles examined demonstrated reduced force production (twitch and 
tetanus) compared to control mice, with mdx diaphragm muscle showing the 
greatest reduction in tension generated (approximately two-thirds that of control 
mice, P<0.01). Mdx latissimus dorsi and intercostal strip values were by contrast 
50% of control levels for both twitch and tetanus tensions (P<0.05 except for 
latissimus Po (P<0.01)). Rise times (TPT) were similar, except for the attenuated 
diaphragm twitches of the mdx, which had significantly shorter TPT (P<0.001). 
Relaxation was prolonged in mdx intercostal muscles compared to control levels, 






























































































Table 4.3 Contractile properties of latissimus dorsi muscles, intercostal strips and 
diaphragm strips from 17-month-old mdx and control mice: Time to peak tension (TPT), 
Time to 50% relaxation (TR50), Time to 90% relaxation (TR90), peak twitch force (Pt) and 
maximal isometric tetanic force (Po). n=7 (C57), n=8 (mdx) *P<0.05,**P<0.01, 
***P<0.001. Pt and Po normalised using muscle CSA for diaphragm and latissimus 





4.5.5 Hydroxyproline analysis 
 Four muscles were used for assays of hydroxyproline content, and results 
are shown in Figure 4.7. All mdx muscles had significantly more HP than control 
mice, with the diaphragm HP 2.5 times higher than the other muscles examined. 
Interestingly, control mice also showed a higher level of fibrosis in this organ 
compared to other respiratory or paraspinal muscles, and when relative values were 
compared (control HP as a ratio of mdx HP) the diaphragm and latissimus displayed 
an equal tendency for fibrous tissue deposition (0.66), followed by intercostal 
muscles (0.58) and then longissimus dorsi (0.44). The magnitude of fibrosis may be 


































Figure 4.7  Hydroxyproline content of paraspinal and respiratory muscles in mdx 




 The results of an applied histological grading scheme for muscle sections 
stained with the collagen specific stain picrosirius red are listed in Figure 4.8. The 
percentage of centronucleation of muscle fibres as visible on H&E stained sections 
indicates previous necrosis and degeneration and one or more cycles of 




photomicrographs of all four muscles of mdx and control mice stained for collagen 
are shown in Figure 4.11. It is apparent that mdx muscles demonstrate marked 
heterogeneity in cell size, a high incidence of centrally nucleated fibres, 
inflammatory cell infiltration and fibrous tissue deposition compared to control 
muscles. 
Mdx diaphragm displays the highest scores on histological grading as 
expected, with marked fibre loss and replacement with interstitial collagen. The 
intercostals displayed an intensity of picrosirius staining and high score that is not 
perhaps reflected in measured hydroxyproline content of these tissues. The 
intercostal muscles are a complex mixed tissue when viewed microscopically, 
typically comprised of fibres in both cross and oblique section and containing fat 
and a large blood vessel. The impression in mdx sections was for greater disarray in 
tissue structure, fibre loss, considerable variation in myocyte size, fibrosis and 





























Fig 4.8 Histological score based on interstitial fibrosis, calculated on picrosirius red 
stained muscle samples. Scoring scheme was determined on viewing 10 fields per 
tissue (20X magnification) with a score of 4 indicating greater than 50% fibrosis. 

































Fig 4.9 Frequency distribution of internal nuclei in paraspinal and respiratory 
muscles. Figures are based on counting 100 fibres per muscle on H&E stained 
sections. n=7 (C57), n=8 (mdx) P<0.0001 for all muscles. 
 
Fig 4.10 Photomicrographs of haematoxylin and eosin stained sections. A. Mdx 
longissimus, B. Mdx intercostals, C. Mdx latissimus, D.Control diaphragm. 
20X magnification. The mdx cells show dystrophic features including 
centronucleation, variation in fibre size, inflammatory cell infiltration and interstitial  
fibrosis, indicating cycles of degeneration and regeneration. In contrast the control 






ig 4.11. Picrosirius red stained muscle sections. The dark red stained areas 
E=Grade 3, G=Grade 4.All control mice were considered Grade 1. 







represent collagen. The relative amounts of staining were used to grade samples 
from 1-4, corresponding with the level of interstitial fibrosis. A,C,E,G:mdx.  
B,C,F,H: C57 
A,C =Grade 2, 









 mouse is the most frequently used animal model for research into 
DMD, 
ile a reduction of vertebral support in humans with neuromuscular 
careful positioning of animals it is possible to accurately measure 
naesthesia of mice will affect KI, and early trials 
utilizin
hypertrophy stage) would hinder correct positioning when prone. 
4
The mdx
and much of our understanding of the pathophysiology of dystrophic muscle 
has been gained from studies in this model. They, however, show a milder 
phenotype than boys with DMD or the Golden Retriever Muscular Dystrophy dog 
(GRMD). 
    Wh
weakness can show as thoracolumbar deviation in a dorsal or ventral plane 
(kyphosis or lordosis respectively) or a lateral deviation of the spine due to the 
effect of gravity (scoliosis), the quadrupedal gait of mice results in the development 
of kyphosis. 
    With 
differences between animals not apparent by observation or palpation. A significant 
decrease in Kyphotic Index occurred in a group of mdx mice at 9 months of age, or 
at approximately one third of the mdx lifespan. This differs from mdx:utrn-/-  which 
shows an earlier onset of spinal deformity (Deconinck et al., 1997a; Grady et al., 
1997) This difference is probably attributable to the muscle hypertrophy 
demonstrable in most skeletal muscle of mdx, which for a time maintains whole 
muscle strength, although in vitro organ bath studies of the paraspinal muscles 
indicates that normalised forces (maximum isometric tension per unit cross-
sectional area) are weaker. This is in agreement with experiments conducted on 
limb muscles (Lynch et al., 2001). 
It is likely that the level of a
g only light sedation resulted in animals struggling against the tape restraint 
causing movement blur. Ketamine/xylazine combination provided muscle relaxation 
as well as immobilisation, and offered the benefit of allowing xylazine reversal by 
atipamezole, which may enhance recovery in aged mdx with cardiac impairment. 
Right lateral recumbent views were chosen for ease and consistency, allowing up to 
6 mice per cassette to be radiographed. It is also possible to choose prone 
positioning with cross table lateral views, however this would allow only two mice 
to be radiographed at one time. There was also concern that the heavy shoulder and 








strophic changes as they have an augmentative, though lesser, role than 
    Thoracic area measurements of mdx was less than those of control mice, 
and it is likely that such thoracic deformity in aged mdx will 
function (or contribute to the reduced lifespan of more severely kyphotic mdx:utrn-/- 
(Deconinck et al., 1997a)). Certainly in DMD patients diaphragmatic and 
respiratory muscle weakness coupled with severe thoracic deformity leads to 
hypoventilation and hypoxaemia, sleep abnormalities and susceptibility to 
respiratory tract infections (Sivak et al., 1999; Seddon and Khan, 2003). 
   Certain mdx skeletal muscles show profound dystrophic changes, 
particularly the diaphragm, slow twitch limb muscles and postura
(S an et al., 1991; Lefaucheur et al., 1995; Pastoret and Sebille, 1995b). These 
are muscles with either an obligatory constant workload or a role in resisting 
gravitational forces compared to fast twitch, intermittently active muscles such as 
the extensor digitorum longus. The diaphragm was utilised in these experiments 
because its contractile, morphometric and histopathologic properties are well 
documented (Stedman et al., 1991; Coirault et al., 1999; Anderson et al., 1998) and 
it serves as a useful benchmark for the severity of dystrophic changes in other less 
well-characterised muscles. Mdx diaphragm strips generate significantly lower 
maximum tensions compared to age-matched control mice as reported previously 
(Lynch et al., 1997; Stedman et al., 1991) and there was an inverse relationship 
between twitch force and hydroxyproline content. Histological changes showed 
severe interstitial fibrosis and myocyte disarray typical of this organ in mdx mice.  
 It is apparent that differential levels of dystrophic pathology exist between 
the four mdx muscles examined.  The diaphragm has been shown previously to b
an atypical tissue by virtue of its low percentage centronucleation, despite extensive 
fibrotic infiltration (Boland et al, 1995). These reasons for this are not clear 
(Anderson et al, 1998; Krupnick et al, 2003). There is no published data available 
regarding paraspinal and intercostal  muscle pathology in mdx, or the usefulness of 
counts of incidence of central nuclei in these muscles as a quantitative measure of 
dystrophy.  
    It is perhaps not surprising that intercostal muscles are also subject to a high 
degree of dy
the diaphragm in respiration. During inspiration contraction of the parasternal 




50 and TR90 compared to control mice. Separation of 
interna
 dissected. This muscle also showed centronucleation 
n and extension. It is not amenable to organ bath studies 
diaphragmatic contractions (Farkas et al., 1985). Several of the mdx intercostal 
sections examined scored equally to diaphragm strips (Grade 4, equivalent to >50% 
fibrosis). The discordance between histological scores of fibrosis and 
hydroxyproline levels in intercostal muscles may be a factor of both the extent of 
infiltration and the density of the collagen in this tissue; i.e fibrosis is more 
extensive, but less dense.  
The intercostal muscles showed prolonged relaxation properties, with 
significant increases in TR
l and external intercostal muscle layers was not performed due to the risk of 
damage to individual fibres. The direction of dissection was parallel to external 
intercostal fibres, as external intercostal muscle fibres contribute most to force 
generation during normal respiratory movements. Previous intercostal studies on 
larger species including rabbits (Citterio et al., 1982), dogs (Decramer et al., 1985; 
Farkas et al., 1985) and hamsters (Kelsen et al., 1993 ; Kelsen et al., 1994) utilised 
separated muscles. The preparations spanning 4 ribs were very similar in 
dimensions to these hamster preparations, and were also extrapolated from studies 
in guinea pigs where tracheal segments comprising a series of tracheal rings are 
mounted via silk suture around cartilages in organ bath experiments (Mardini et al., 
1986) (Chitano et al., 2002). 
   The latissimus dorsi is a fan shaped muscle, which because of its superficial 
position on the trunk is easily
and fibrosis, with reduced Pt and Po seen in other skeletal muscles of older mdx. 
Previous contractility studies using rabbit latissimus dorsi confirm its fast twitch 
properties (James et al., 1997). Twitch kinetics from these experiments suggest the 
latissimus dorsi is also a fast twitch muscle in older mice, although this needs to be 
verified by fibre typing. 
    The longissimus dorsi is an important member of the erector spinae group, 
involved in spinal rotatio
because of multiple branching and insertions on many vertebral processes, however 
there was histological and biochemical evidence of dystrophy similar to the other 





  In humans, comparisons have been made between limb muscle and joint 
ce is not as extreme 
iographic 
  
contracture seen in neuromuscular diseases, and the fibrosis and contracture of 
respiratory muscles, stiffening of tendons and ligaments of the rib cage and 
ankylosis of costovertebral and costosternal articulations (Bach and Kang, 2000). 
Failure to fully expand the lungs causes increases in lung tissue and chest wall 
elastance and decreases in compliance (Misuri et al., 2000), alterations that 
contribute markedly to the total mechanical work of breathing.  
    Although the spinal deformity of dystrophin deficient mi
as that seen in patients with DMD, the hallmarks of dystrophy, muscle weakness 
and fibrosis, and not just aging per se, appear to be implicated in the progression of 
kyphosis and thoracic deformity in this model. It is likely also that the relative 
inactivity of aged mdx mice compared to their control strain, noted by ourselves and 
others (Pastoret and Sebille, 1995b), is due in large part to the presence of these 
skeletal malformations and associated muscle contracture and increase in stiffness. 
It is only conjecture at this stage that significant respiratory insufficiency may also 
occur in mdx mice and could be implicated in this failure to move freely.  
    In conclusion, this study demonstrated the application of a rad
index for the measurement of kyphosis in mice, and showed how this index changed 
in mdx mice compared to control mice. The measurement of kyphosis by 
radiographic indices presented here is a method of quantitative comparison between 
mouse strains and may also have application for long-term therapeutic studies or 







CHAPTER 5: ANTISENSE OLIGONUCLEOTIDE 
ADMINISTRATION INTO MDX DIAPHRAGM MUSCLE. 
5.1 Introduction 
DMD is the most common human X-linked genetic disorder. The disease 
remains a prime target for gene therapy because of its monogenic nature, prevalence 
and the distressing and relentless clinical course of those affected, however the 
obstacles in the path of a cure are many. Muscle is a vast organ, representing greater 
than 30% of total body protein, host immune defences are effective against 
transplanted myoblasts, stem cells or vectors, the gene in entirety is too large for 
administration via viral vectors, and finally the complexity of the gene and the 
variety of sites and categories of mutations within the locus itself all hinder progress 
towards an effective, safe and lifelong therapy.  
Antisense oligoribonucleotides (AOs) have been explored as a gene 
correction therapy, aimed at restoring frame-disrupting mutations. They are 
composed of 2’-O-methyl ribonucleotide analogues, which bind to a homologous 
sequence and cause a manipulation (‘exon-skipping’) of primary transcript 
processing. They have the advantage of not undergoing extensive degradation by 
endogenous ribonucleases. 
In mdx cell culture AOs have been shown to induce exon-skipping resulting 
in the production of a truncated, yet still functional protein, coined a ‘Becker-like’ 
protein, due to the similarity between the patchy sarcolemmal distribution and 
shortened dystrophin of patients with Becker Muscular Dystrophy (BMD), a milder 
allelic form of DMD (Mann et al., 2001; Mann et al., 2002). AO mediated skipping 
of multiple dystrophin exons has also been achieved in cultured human muscle cells 
(Aartsma-Rus et al., 2002).  
AO mediated exon-skipping resulted in dystrophin production in mdx limb 
muscles (Mann et al., 2001); (Lu et al., 2003), shown by immunohistochemistry and 
Western blotting. There has been one published study looking at function of AO 
treated mdx muscle which showed partial restoration of function in injected tibialis 
anterior muscles, with significant improvement in force production evident when 




Due to the severity of dystrophy in mdx diaphragm muscle and its 
similarities to the pathology of DMD, it is an attractive target for AO administration 
as a ‘proof of principle’ treatment modality. 
 
5.2 Aims 
The aim of these experiments was to determine the effect of AOs injected  
into mdx mice diaphragms (as a continuation of  work outlined in Chapter 4). 
Contractility studies were undertaken as a measure of efficacy of the AOs in 
restoring (or partially restoring) function. In addition, histological measures of 
degeneration and regeneration (centronucleation and fibre diameter analysis) and 
tissue fibrosis were also used. Hydroxyproline was utilised as a biochemical marker 
of fibrosis in treated diaphragm segments. Finally Western blotting was used to 
measure the level of dystrophin protein production in treated muscles.  
5.3 Methods 
5.3.1 Mouse numbers and grouping  
Male mice were 16 weeks of age at the time of the first surgical procedure, 
20 weeks of age for the second administration, and 25-27 weeks old when 
euthanased. There were six groups of mice: a. mdx AO (n=10), b. mdx sham (saline) 
(n=4), c. mdx sham (lipofectin) (n=4), d.C57 sham (saline) (n=4) and e.C57 sham 
(lipofectin) (n=5). For the purposes of Western blotting an extra group of mice was 
used (n=6), where histology dyes were combined with AOs for more accurate 



























5.3.2 Anaesthesia and surgery 
Anaesthesia was induced with ketamine HCl 50 mg/kg (Ketamil, Troy 
Laboratories, Australia) and xylazine HCl 10 mg/kg (Ilium Xylazil-20, Troy 
Laboratories, Australia). A midline laparotomy was performed under sterile surgical 
conditions to expose the diaphragm. Injections were constituted as described below 
and injected in two sites on both hemi-diaphragms, using 29 gauge needles and 
0.3ml paediatric insulin syringes (Braun Omnican 30).  Sites of AO injections are 
shown in Figure 5.2. 
Muscle and skin incisions were closed with 4/0 Maxon and 5/0 Novafil 
synthetic suture material. After surgery buprenorphine 1 mg/kg (Temgesic, Reckitt 
Benckiser, Australia) and atipamezole 1mg/kg (Antisedan, Novartis Animal Health, 
Australia) were administered for analgesia and reversal of xylazine, respectively. 
Sterile saline (0.5mL) was also injected subcutaneously for maintenance of 
hydration. Mice were monitored post-operatively until ambulatory and were 
examined daily, with the appearance of the surgical wound, appetite, activity and 
weight recorded for 7 days post operatively. All experiments were carried out under 





Fig 5.2 Approximate sites of AO injections. The green ovals represent regions of 
spread of injectate within the diaphragm muscle. X=xiphisternum, V=lumbar 





5.3.3  Oligonucleotides 
The AO used was M23D (+02-18), as defined previously (Mann et al., 
2002) and shown in Figure 5.3. AOs were synthesised on an Expedite 8909 Nucleic 
Acid Synthesiser at the Australian Neuromuscular Research Institute, University of 
Western Australia. The conditions for transfection had been optimised previously 
(Mann et al., 2002). Briefly, complexes of Lipofectin (Life Technologies, 
Melbourne, Australia) were prepared in a 2:1 Lipofectin/AO ratio (w/w) in sterile 
0.9% saline. Lipofectin and AO were incubated separately with saline for 30 
minutes prior to mixing; the AO/Lipofectin complex was then used within 30-45 
minutes. Approximately 1 µg of AO was administered per injection site. Sham 
injections comprised the same volume of Lipofectin or saline. 6 mice were treated 
with AO/Lipofectin as above, with 2 µL histology marker dye added to the 40 µL 
volume (Wak-Chemie Medical, Germany). The dye was autoclaved in cryotubes 
prior to use, with the resultant paste reconstituted in sterile saline. 
 
 
INTRON 23 EXON 23 
 
     +20       +10                         +1       -1                     -10                -20                                -30 
    
5’-ATAAACTTCGAAAATTTCAG   gtaagccgaggtttggcctttggcctttaaactatat-3’
 UC   cauucggcuccaaaccgg 
2’-O-methyl modified antisense oligonucleotide M23D(+2-18) 
Fig 5.3 Representation of the genomic sequence of the boundary between Exon 23 
(upper case letters) and Intron 23 (lower case letters) of the mouse dystrophin gene. 
The numbers above the sequence are used to designate the target homology of the 
AO M23D(+2-18), where M=murine, 23= exon number, D=Donor splice site, (+-
)=annealing coordinates. +2 is the last two exonic bases and –18 represents the first 




5.3.4 Contractility studies 
Mice were anaesthetised with 70 mg/kg thiopentone sodium (Nembutal, 
Boeringer Ingelheim, Australia) by intraperitoneal injection. The diaphragm and 
surrounding ribs were removed en bloc and placed in ice cold Krebs solution, 
bubbled with 95% O2 and 5% CO2. Strips of diaphragm muscle were prepared for 
hydroxyproline analysis and Western blotting by snap freezing in liquid nitrogen 
before storing at –80oC. Another muscle strip was pinned to cork and placed in 
Telly’s solution prior to Bouin’s fixation and eventual storage in 70% ethanol. . 
Three diaphragm strips, each 2-3 mm wide were excised for in vitro studies (two 
strips from the right hemidiaphragm and one from the left). These were anchored by 
means of surgical silk to a fixed peg at the rib end, and attached to a force 
transducer at the tendon end, and placed within a 25 mL glass organ bath 
maintained at 23oC. Tissues were stimulated via a Grass S48 stimulator (W. 
Warwick, RI, USA) and signal current intensity were amplified using a pre-
amplifier (EP500B. Audio Assemblies, Campbellfield, Victoria, Aust). Data was 
collected and analysed using Chart 4.1.1 software on an  iMac computer. A square 
pulse of 0.2 ms duration was dispersed via two platinum plate electrodes positioned 
at each side of the muscle. 
Optimum preload (Lo) was defined as the length eliciting maximal single 
isometric twitch force. Optimal voltage was also determined for each preparation, as 
was the frequency eliciting maximal tetanic force. Reported data was the average of 
3 individual single twitch or tetanic stimulations per muscle strip, with those three 
diaphragm strip values then averaged to give an overall mean for that muscle 
(=Averaged Values) or the maximum force achieved for that diaphragm 
(=Maximum Values). A fatigue protocol (one tetanic stimulation every 5 secs for 5 
minutes) and recovery from fatigue (a single tetanic stimulation 5 minutes later) was 
also performed. Muscles were measured at Lo using a digital micrometer, blotted for 
3 secs then weighed prior to storage at –80oC, and subsequent Western blotting. 
CSA and normalisation of force was calculated as described previously (Lynch et 
al., 2001). 
5.3.5 Hydroxyproline analysis 
Hydroxyproline content was used as one measure of collagen content of diaphragm 




HCl overnight at 110oC. The samples were dried to entirety using air under 
pressure and heat (50oC). The rest of the protocol is described in detail in Appendix 
B. Values are expressed as µg HP /mg tissue wet weight. 
 
5.3.6 Western blotting 
Muscle samples were homogenised in 19 vol. of extraction buffer, and total 
protein was quantified with a Bio-Rad DC Protein Assay Kit. 100 µg of total protein 
from each sample was loaded onto a 4-12% polyacrylamide gel containing 0.2% 
SDS in tris-glycine buffer. Samples were electrophoresed for 5-6 hours at 20-25mA 
(temperature limited to approximately 16oC), before blotting onto a nitrocellulose 
membrane. The membrane was probed with NCL-DYS2 primary antibody (1:100, 
NovoCastra, Newcastle, UK) for 120 minutes followed by 3 washes in TBST 
buffer. The bound primary antibody was detected by horseradish-peroxidase 
conjugated rabbit anti-mouse secondary antibody (1:1000; DakoCytomation, 
Denmark) and Lumi-Light Western Blotting Substrate (Roche Diagnostics, 
Mannheim, Germany). The intensity of the bands obtained from the AO treated 
mice were compared with sham injected mdx and C57 mice. Details of the Western 
protocol used are listed in Appendix B. 
 
5.3.7 Histology of diaphragm samples 
Tissues for histological analysis were paraffin embedded. Blocks were cut at 10 µm 
prior to staining with picrosirius red (F3B, Chroma Dyes, Germany). Analysis was 
performed blinded to the treatment group. Fluorescent microscopy images were 
acquired using a digital camera (Q imaging Micropublisher 5.0 RTV) coupled to an 
epifluorescence microscope (Eclipse E600, Nikon, Japan). Four sections per 
diaphragm were photographed and analysed using the image analysis program 
DocuAnalySIS (Soft Imaging System), then averaged. Results are expressed as 
collagen as a percentage of area. H&E stained sections of 5 µm thickness were 
viewed using bright field, with images acquired and analysed using the same 
equipment. Percentages of muscle fibres with centralised nuclei were determined in 




5. 4 Statistics 
The level of significance of treatment with AOs was determined using t-tests. Data 
was pooled from the sham groups because of a lack of difference between sham 
treatments- ie mdx AO were compared with mdx sham (saline and lipofectin), and 
C57 sham (saline and lipofectin) treated mice. Data is expressed as means ± SE, 
with significance defined as a P<0.001, 0.01 or 0.05 as appropriate. 
5.5 Results 
5.5.1 Mouse survival and evaluation of surgery 
2 mice died within 7 days of the surgical procedure. These were both mdx treated 
with AO/lipofectin complex plus histology marker dye. Affected mice were 
hunched and inappetant, and on post-mortem examination both showed a thoracic 
effusion, with small amounts of blue stain present within the fluid. Wak-Chemie 
product data sheet does not recommend use of the histological marker in living 
subjects, although it has been used successfully in AO treated mice previously 
(Mann et al., 2001). It is also likely that autoclaving of the product causes 
denaturation, manifest as a granular appearance despite retaining its staining 
properties.  It is probable that escape of dye into the thorax occurred inadvertently 
during diaphragm injections. 
The success of the injection procedure was subjective, and gauged by the formation 
of a distinct bleb of injectate at each site, or spread of blue stain along diaphragm 
muscle fibres in mice where marker dye was used. The site of previous injections 
could often be detected as a small area of blood vessel infiltration or grey scar 
tissue. 
5.5.2 Body weight 
Mdx mice were heavier at all time points compared to C57 mice. At the end of the  
experimental period mdx were 35.2 ± 0.63g compared to 30.9 ± 1.32g for wild type 
mice (p<0.01). Weight gain for the 9-11 weeks of the project was 4.1 ± 0.24g (mdx) 
and 2.54 ± 0.65 g (C57). There were no significant differences in body weights 




5.5.3 Contractility studies 
The sham treated mdx group showed force deficits of   52% (twitch force) and 44% 
(tetanic force), compared to wild-type mice, whereas the mdx AO treated mice 
showed a deficit or 35% and 25.2% for twitch and tetanic forces respectively 
(Figures 5.4 and 5.5). Twitch and tetanus forces of the AO treated mdx compared to 
sham-treated mdx were increased by 33.8% and 33.9% respectively. 
.  





























Diaphragm averaged values, single twitch force








Fig 5.4 Twitch force results displayed as : A. The average of 3 diaphragm strips, or 
B. Single maximum value from mice treated with injections of antisense 
oligoribonucleotides (AO) or saline or Lipofectin (sham treated). FOC= Force of 
contraction ***P<0.001, ** P<0.01, * P<0.05.  n= 10 (C57), 9 (Mdx AO) and  8 
(Mdx sham) ** =difference between C57 and Mdx, AO treated. + = difference 





















































Fig 5.5 Tetanic force results displayed as : A The average of 3 diaphragm strips, or 
B Single maximum value from mice treated with injections of antisense 
oligoribonucleotides (AO) or saline or Lipofectin (sham treated).  
 Maximum tetanic contractions for AO treated mdx were closer to wild type mice 
values when analysed by this method. FOC= Force of contraction ** P<0.01, * 
P<0.05.  n= 10 (C57), 9 (Mdx AO) and  8 (Mdx sham). ** =difference between C57 








Twitch:tetanus ratios were identical for mdx AO and sham treated mdx when 
considering averaged values, and these were significantly less than the C57 group 
(Figure 5.6). For maximum forces the twitch/tetanus ratio was significantly higher 
in mdx, AO treated compared sham treated mdx mice ( P<0.05) (Figure 6.5). 
 


















C57 Mdx, AO treated Mdx, sham treated
Mouse group
**
























Fig 5.6 Twitch /tetanus ratio of isolated diaphragm strips from mice treated with 
injections of antisense oligoribonucleotides (AO) or saline or Lipofectin (sham 
treated). A) There was no difference between treated and untreated mdx, however 
there were significant differences between both mdx groups and wild type mice for 
averaged values. B) For maximum force values of mdx, AO treated were closer to 
wild type values, although there was still a significant difference between these 
groups (P<0.05). ** P<0.01, n= 10 (C57), 9 (Mdx AO) and  8 (Mdx sham) * 
=difference between C57 and Mdx, AO treated. + = difference between Mdx, AO 







Fatigue percentage and percentage loss of force (determined by the loss of force of 
single tetanic stimulus after the 5 min fatigue protocol) were similar between groups 





Table 5.1 Percentage fatigue of diaphragm strips, using a 5-minute protocol with 
one tetanic stimulation every 5 secs. Loss of force involved measuring one tetanic 
contraction 5 minutes after the fatigue protocol, expressed as a % reduction in force 
compared to the initial contraction. n= 10 (C57), 9 (Mdx AO) and  8 (Mdx sham) 
 
  Averaged values Maximum values 
 C57 Mdx, AO Mdx,sham C57 Mdx, AO Mdx,sham 




20 ± 6 
 
20 ± 4 
 
24 ± 5 
 
25 ± 7 
 
19 ± 3 
 
31 ± 8 
 
 
5.5.4 Hydroxyproline analysis 
HP values were significantly greater in both sham injected and AO injected mice, 
compared to C57 mice. Mean HP values were greater in AO treated mdx compared 
to sham treated mdx, however these differences were not statistically significant as 

























C57 Mdx, AO treated Mdx, sham treated
Mouse group
**
Fig 5.7 Hydroxyproline values of diaphragm strips. There was no significant 
difference between Mdx, AO treated and Mdx, sham treated mice. ** P<0.01, n= 10 
(C57), 9 (Mdx AO) and  8 (Mdx sham).  
 
5.5.5 Western Analysis 
Western blot analysis of dystrophin expression of diaphragms from wild type mice 
showed a strong expression of full length dystrophin (Figure 5.8). No dystrophin 
was detected in homogenates of AO treated or sham treated mdx diaphragm 
samples. This procedure was repeated multiple times using different muscle samples 





Fig 5.8 Western blot of individual diaphragm strips from C57 and 3 different AO 











Histological determination of fibrosis showed that mdx diaphragms had 
approximately twice the percentage of fibrosis of wild type diaphragms at this age 
(C57; 6.1 ± .6%, mdx; 13.9 ± .6%, P< 0.01). There was no difference in percentage 
fibrosis between AO treated and sham treated mdx (Figure 5.9A). Wild type mice 
showed a low incidence of centrally nucleated muscle fibres compared to both AO 
treated and sham treated mdx. These differences are displayed in Figure 5.9B. 
Photomicrographs of representative sections are shown in Figure 5.10 and 5.11. 
 
 





















C57 Mdx, AO treated Mdx, sham treated
Mouse group























C57 Mdx, AO treated Mdx, sham treated
Mouse group
****
Fig 5.9  Histological analysis of diaphragm muscle from antisense oligonucleotide 
(AO) treated and sham treated mice. A. Collagen (as a percentage of area) 
determined from picrosirius stained sections. B. Percentage of diaphragm fibres 
with centralised nuclei determined from H & E stained sections. Note the similarity 
between mdx AO and sham treated mice in both diaphragm collagen and centralised 




ig 5.10 Representative photomicrographs of picrosirius red stained diaphragm 











treated diaphragms. Interstitial collagen was significantly less in wild type mice 
compared to either AO treated or sham treated Mdx groups.  The dense interstitial 






ig 5.11 H & E stained diaphragm muscle sections (20x magnification). A. C57, B 












fibres was significantly greater in Mdx AO and sham treated muscles compared to 
wild type mice. Other dystrophic features such as marked variation in cell size, 





t studies have shown the potential of AO therapy, both in mdx cell 
ulture and limb muscles (Mann et al., 2001; Mann et al., 2002; Lu et al., 2003). 
rk is novel in applying AOs to mdx diaphragm muscle, an organ at 
greater
mia Inhibitory Factor based on calcium alginate rods 
were su






 risk of dystrophic changes, even in young mice.  It tests the ability of 
injected AOs to restore function in diaphragm muscle and investigates whether 
tissue fibrosis is alleviated. 
The diaphragm is less accessible than limb muscles, and there have been few 
studies determining route, frequency and methods of drug delivery. Controlled 
release devices for Leukae
tured to mdx diaphragms for a three-month period, and this treatment was 
shown to ameliorate dystrophic abnormalities (Austin et al., 2000). Pure 
recombinant plasmid DNA and a lacZ reporter gene was introduced into mouse 
diaphragms without causing significant damage, while proving that 41 ± 3 muscle 
fibres had the potential to be stained from an individual injection site, with fibres 
frequently showing staining along their entire length. These results were superior to 
results obtained with similar injections into hind limb muscles (Davis and Jasmin, 
1993). Adeno-virus mediated gene transfer into mdx diaphragms was successful, 
however contractile function was impaired, thought to be due to direct cytotoxic 
effects of viral proteins (Petrof et al., 1995). Intravenous (tail vein injections) and 
occlusion of the vena cava below the diaphragm allowed reporter gene delivery to 
mice diaphragms, with expression peaking at 6 days and declining slowly (Liu et 
al., 2001a). 
In the current study injections of AO/Lipofectin complex at 4 distinct sites 
improved twitch and tetanic force production in mdx mice diaphragm strips. 
Contractility
d for 3 diaphragm strips, and secondly by consideration of the maximal 
twitch and tetanic forces achieved for each diaphragm (Figures 5.4 and 5.5). The 
two methods were utilised because it is likely that some fibres were more 
successfully transfected than others, with subsequent force production better 
reflected by maximal twitch and tetanus forces as compared to averaged values. All 
3 groups of mice showed increased force production when maximal values were 




re administered at only four sites around the diaphragm, and 
althoug
was no
force and tetanic forces improved 33.9% and 25.3% respectively; when comparing 
AO with sham treated mdx using averaged values. For maximal twitch and tetanus 
values these gains in function were 70.9% and 53%. Regional variations in 
diaphragm dystrophy have been noted previously (Anderson et al., 1998), or 
alternatively the variation in force production may better reflect regions of optimal 
AO delivery and transfection. The benefits were greater for twitch compared to 
tetanic contractions, as it is probable that patchy sarcolemmal distribution of 
dystrophin occurs (similar to BMD), resulting in lesser values for fused tetanic 
contractions where there is recruitment of both dystrophin-positive and negative 
fibres. The twitch/tetanus ratio was also increased and closer to wild-type mice 
when maximal values were analysed, due to the higher twitch forces achieved 
(Figure 5.6). A published observation that dystrophin expression in 17% of mouse 
diaphragm fibres protected all fibres present within the muscle bundle from the 
damaging effects of repetitive lengthening contractions suggests that efficiency of 
transduction need not be close to 100% to obtain significant functional benefits 
(Decrouy et al., 1997) 
There were still significant shortfalls in force values between C57 and AO 
treated mice. The method of delivery and dosage is one possible explanation. Small 
volumes of injectate we
h previous work suggests that there is spread along the length of muscle 
fibres and through the 8-10 cell depth of the diaphragm (Davis and Jasmin, 1993), 
there was no way of assessing whether tissue strips taken for contractility studies 
corresponded exactly with injection sites in this current study. There is recent 
evidence that higher dosages of AOs are required, and persistence of AOs in tissues 
using direct injection techniques is short (Wells et al., 2003). An additional reason 
why force values did not reach those generated by control mice is the degree of 
fibrosis of this organ, with even young mice showing extensive collagen deposition.  
There was no reduction in tissue collagen in AO treated mice compared to 
mdx mice, as determined by hydroxyproline analysis. In the two histological 
parameters examined (percentage centralised nuclei and percentage fibrosis), there 
 difference detected between AO and sham treated mdx mice. At the age of 
euthanasia (6 months) there is already established dystrophy in mdx diaphragms, 




hin expression was short-lived 
or ther
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 comm.). Previous studies have utilised 
the sam
ssion (ie below that detectable using Western blotting). Diaphragm 
stained sections.  In the future it may be preferable to use younger mice for such 
studies, before diaphragm fibrosis is as pronounced. 
There are several possible reasons for the failure to detect protein expression 
by Western blot. The dosage of AO used (1 µg per injection site, total of 4 µg per  
diaphragm) may have been insufficient and dystrop
e was interference with the Western procedure due to the presence of the 
marker dye. The first explanation is the most likely, as more recent work using 3-
µg per injection (Lu et al., 2003) or 8 µg per injection of AO (Wells et al., 2003) has 
shown enhanced transfer and expression The latter authors also suggest that AO-
induced dystrophin expression is transient, possibly due to both the loss of the AO 
and to protein turnover. A recent publication showed that single intravenous 
administration of the same AO bound to the coblock polymer F127, was sufficient 
to induce dystrophin, which was demonstrated by immunohistochemical methods 
but not by Western blots. Three weekly intravenous treatments, however, resulted in 
increased efficiency of dystrophin induction, successfully demonstrated by Western 
blotting in many muscles (Lu et al., 2004).  
The concentration of AO used was based on prior published studies (Mann 
et al., 2001); (Gebski et al., 2003), and advice that higher concentrations of AOs 
may cause tissue necrosis (S. Fletcher, pers
e histology marker dyes in cell culture and in vivo, without hindrance to 
protein detection (Mann et al., 2001).  Much effort was spent optimising the 
Western procedure used, including different membranes, buffers and antibody 
concentrations, which was successful at detecting very low levels of dystrophin in 
diluted homogenates from C57 muscle with as little as 5 µg of loaded protein 
(Appendix B). 
 In conclusion, this study showed that AO injections have the potential to 
improve contractility of mdx diaphragm muscle, even at presumably very low levels 
of protein expre
function, however, is not restored to that displayed by wild-type mice, and in 
addition tissue fibrosis in 6 month old mice is not reduced. Further refinements of 
this study would include the use of younger animals, administration of increased 
AO concentrations, or investigating methods of whole diaphragm delivery, such as 








CHAPTER 6. LONG TERM ADMINISTRATION OF 
ANTISENSE OLIGONUCLEOTIDES INTO THE 
PARASPINAL MUSCLES OF MDX MICE 
6.1 Introduction 
 Antisense oligoribonucleotides have become an attractive tool for the study 
and potential treatment of DMD that results from mutations in the dystrophin gene, 
which interrupt the reading frame and cause a complete loss of dystrophin. 
 AOs alter splicing so that the open reading frame is restored and the severe 
DMD phenotype is converted to a milder BMD phenotype. BMD patients have 
mutations that are not frame-shifting and result in an internally deleted, but partially 
functional dystrophin that retains it’s N- and C- terminal ends (Koenig et al., 
1989).Exon skipping has been successful in cells derived from the mdx mouse 
(Wilton et al., 1999; Mann et al., 2002; Mann et al., 2001; Lu et al., 2003) and 
various DMD patients (van Deutekom et al., 2001; Aartsma-Rus et al., 2002). 
 Functional properties of AO treated muscle were examined 3-4 weeks after a 
single administration into mdx tibialis anterior muscle (Lu et al., 2003). This muscle 
typically undergoes early necrosis but exhibits milder pathology to that seen in the 
diaphragm (Boland et al., 1995; Boland B. et al., 1995), the intercostal muscles, or 
those skeletal muscles involved with postural activity (Lefaucheur et al., 1995). 
Because age-related diminution of efficiency is a common feature of viral and non-
viral gene delivery into skeletal muscle (particularly in dystrophic conditions with 
increased extra-cellular matrix), protein expression was examined in mice of 6 
months of age and was shown to be similar to 2 and 4 week old animals (Lu et al., 
2003). In that study dystrophin persisted for up to 2 months, however another group 
found that AO-induced dystrophin expression is much more transient, possibly due 
to both a loss of AO and protein turnover (Wells et al., 2003).  
There have been no studies documenting AO use in very old mdx mice 
despite their skeletal muscles undergoing cycles of degeneration and regeneration, 
and showing pathology late in life closer to DMD dystrophinopathy (Lefaucheur et 
al., 1995; Pastoret and Sebille, 1995b). There is a need to apply AOs to a range of 
muscles over an extended period of time in order to assess the functional changes in 




current study utilises mice up to 18 months of age, and is also novel for 
administering AOs as deep lumbar injections and assessing respiratory and 
paraspinal muscle function.  
 
6.2 Aims  
The aims of this study were to determine changes in function of intercostal 
muscles and latissimus dorsi muscles following 15 monthly deep intramuscular 
injections of AOs into paraspinal muscles. Diaphragm muscle strips were also 
examined to compare the severity of dystrophy with the paraspinal and accessory 
respiratory muscles. This study follows on from previous work (Chapter 4) 
determining the usefulness of the Kyphotic Index (KI) in measuring kyphosis in 
older mdx. Monthly radiographs were taken for the calculation of KI, which was 
compared in AO and sham treated mice. In addition, hydroxyproline assays and 
histological measures of fibrosis and muscle degeneration and regeneration were 
utilised to evaluate the effects of therapy. Finally Western blotting was used to 
determine expression of dystrophin protein. 
 
6.3 Methods 
6.3.1 Mouse numbers and grouping 
Three groups of mice were utilised; a) C57 mice, sham injected, b) Mdx mice, sham 
injected and c) Mdx mice, AO injected. Mice were males at 8 weeks old at the 
beginning of the experiment and 18 months at the time of euthanasia. 6 mice were 
assigned to each group, however 2 died (one C57 and one sham injected mdx). One 
of these mice failed to recover from anaesthesia and the other died in its cage of 








Fig 6.1 Mouse numbers and groups for long-term administration of Antisense 







6.3.2 Anaesthesia for radiography and administration of AOs 
 Anaesthesia was induced with ketamine HCl 50 mg/kg (Ketamil, Troy 
Laboratories, Australia) and xylazine HCl 10 mg/kg (Ilium Xylazil-20, Troy  
Laboratories, Australia) subcutaneously prior to administration of AOs and 
radiography. 
 The hair over the dorsum was clipped, and the skin cleaned with ethanol prior 
to AO injections. The mice were positioned in ventral recumbency, and firm index 
finger and thumb pressure was applied to elevate and clearly visualise the lumbar 
musculature. 
 At the end of the procedure atipamezole 1mg/kg (Antisedan, Novartis Animal 
Health, Australia) was administered subcutaneously for the reversal of xylazine. 
Mice were kept warm and monitored until ambulatory. 
 
6.3.3 Antisense oligoribonucleotides 
The AO used was M23D (+02-18), as defined previously (Mann et al., 
2002) and represented in Figure 6.2. AOs were synthesised on an Expedite 8909 
Nucleic Acid Synthesiser at Australian Neuromuscular Research Institute, 
University of Western Australia. The conditions for transfection had been optimised 
previously (Mann et al., 2002). Complexes of Lipofectin (Life Technologies, 
Melbourne, Australia) were prepared in a 2:1 Lipofectin/AO ratio (w/w) in sterile 
0.9% saline. Lipofectin and AO were incubated separately with saline for 30 
minutes prior to mixing; the AO/Lipofectin complex was then used within 30-45 
minutes.  
The injection sites were into the paraspinal muscles adjacent and parallel to 
the thoracolumbar vertebrae. The needles were placed deep into the longissimus 
dorsi muscles, orientated in a cranial direction and kept as flat as possible. Evidence 
from preliminary experiments using several cadaver specimens injected with dye 
showed that the majority of the injectate remained within the longissimus dorsi 
muscles, but a small amount spread within the dorsal portion of the latissimus dorsi 
muscle, or sometimes into adjacent intercostal muscles (Figure 6.3). These 




injectate could travel via fascial planes to other muscle regions. This variation in 
distribution was not a concern, as it was likely that each muscle had a contributory 
role in the progression of kyphosis, and the latissimus and intercostals were also 
used in contractility studies. Three evenly spaced injections were administered on 
each side of the spine, to give a total of 6 µg of AO per mouse in a total volume of 
40 µL. Sham injections comprised the same volume of saline. Saline was utilised 
instead of Lipofectin, based on advice from previous studies where there was no 
difference found between saline or Lipofectin sham groups (S Fletcher, pers comm.) 
At the time of the final procedure (18 months of age) the AO treated mdx had 2 µL 
histology marker dye added to the 40 µL volume (Wak-Chemie Medical, Germany). 
The dye was autoclaved in cryotubes prior to use, with the resultant granular paste 
reconstituted in sterile saline.  
EXON 23 INTRON 23 
 
     +20       +10                         +1       -1                     -10                -20                                -30 
    
5’-ATAAACTTCGAAAATTTCAG   gtaagccgaggtttggcctttggcctttaaactatat-3’
 UC   cauucggcuccaaaccgg 
2’-O-methyl modified antisense oligonucleotide M23D(+2-18) 
 
 
Fig. 6.2 Representation of the genomic sequence of the boundary between Exon 23 
(upper case letters) and Intron 23 (lower case letters) of the mouse dystrophin gene. 
The numbers above the sequence are used to designate the target homology of the 
AO M23D(+2-18), where M=murine, 23= exon number, D=Donor splice site, (+-
)=annealing coordinates. +2 is the last 2 exonic bases and –18 represents the first 







Fig 6.3 Photographs showing the spread of antisense oligonucleotide/ histology dye 
 injections in the paralumbar muscles of mdx mice. A. Lateral view of skinned 
mouse, with spread of injectate in longissimus muscle (top) and latissimus muscle 
(below). B. Dorsoventral view showing spread within longissimus muscles. In some 
mice there was clear staining of intercostal segments also. 
 
 
6.3.4 Radiography and determination of Kyphosis Index 
 After induction of anaesthesia and administration of AOs, mice were lightly 
taped to the radiographic cassette using clear adhesive tape. Each animal was 
individually identified by tail markings, a radiodense (metal) number placed next to 
them, and a radiographic cassette label indicating date and animal grouping. Konica 
CM-H medical mammography film was exposed using a portable X-ray unit (either 
Showa  Xray Co Ltd Tokyo, Japan or Porta 1030 model, Job Corporation, 
Yokohama, Japan).  
 Each whole body radiograph was photographed using a tripod mounted Ricoh 
Caplio RR30 digital camera with images analysed using Scion Image software Beta 
4.0.2 (http://www.scioncorp.com). KI was calculated from a line drawn between the 
caudal margin of the last cervical vertebra, to the caudal margin of the 6th lumbar 
vertebra (usually corresponding to the cranial border of the wing of the ilium) (Line 




the point of greatest curvature (Line CD), as described in Chapter 4. Measurements 
for each mouse were repeated 3 times and the results were averaged. 
 
6.3.5 Contractility studies 
18-month-old mice were anaesthetised using pentobarbitone sodium 
(Nembutal, Boehringer Ingelheim, Australia) at 70 mg/kg IP. Cessation of breathing 
occurred when the thorax was entered. The following muscles were dissected and 
placed into ice-cold Krebs buffer solution bubbled with carbogen (95% O2/5% 
CO2); a) diaphragm strip from left midcostal hemi-diaphragm b) latissimus dorsi 
muscle and c) intercostal section comprising 4 ribs and their attached intercostal 
muscles (internal and external), extending from T8-12, adjacent and parallel to the 
longissimus dorsi muscle. Muscle dissections are described in greater detail in 
Chapter 4. 
Muscles from the left side were collected and stored for Western analysis, 
histology and hydroxyproline assays. Contralateral muscles were mounted in water-
jacketed glass organ baths, maintained at 23oC, using 6/0 silk surgical thread to 
attach to a fixed peg at one end and a force transducer at the other. Tissues were 
stimulated via a Grass S48 stimulator (W. Warwick, RI, USA) and current intensity 
was amplified using a pre-amplifier (EP500B. Audio Assemblies, Campbellfield, 
Victoria, Aust). Data was collected and analysed using Chart 4.1.1 software. A 
square pulse of 0.2ms duration was dispersed via 2 platinum electrodes positioned 
along the length of the muscle. 
Optimum preload (Lo) was defined as the length eliciting maximal single 
twitch force. Optimal voltage was also determined for each preparation, as was the 
frequency eliciting maximal tetanic force from a range of 50 - 180 Hz.  Reported 
data was the average of 3 individual single twitch or tetanic stimulations per muscle 
strip after 25 minutes of equilibration and optimisation of conditions. Muscles were 
measured at Lo using a digital micrometer, blotted for 3 secs then weighed. Cross 
sectional area (CSA) and normalisation of force was calculated as described 
previously for diaphragm and latissimus muscles, where CSA equals tissue weight 
divided by length x 1.06 (density of mammalian muscle) (Lynch et al., 2001). 
Intercostal muscle fibre CSA was shown to vary topographically (Kelsen et al., 




internal and external intercostal muscle layers consisting of differing fibre 
orientations and hence lengths. For these reasons intercostal forces were normalised 
to weight only. Time to peak force, 50% relaxation time and 90% relaxation time 
was calculated for each single twitch value. 
 
6.3.6 Hydroxyproline analysis 
Hydroxyproline content was used as a measure of collagen in diaphragm, 
intercostal muscles, latissimus dorsi and longissimus dorsi muscles. Muscles were 
trimmed of fat, ribs and tendons and stored at -80 oC. Tissue was thawed then 
hydrolysed in sealed tubes with 6 M HCl overnight at 110 oC. The samples were 
dried to entirety using filtered air under pressure and heat (50oC). The rest of the 
protocol has been described previously (Stegemann and Stalder, 1967) and 
Appendix B gives details of the procedure for total assay volumes of 2 mLs. Values 





  Each tissue (diaphragm, latissimus dorsi, longissimus dorsi and intercostal 
muscles) was pinned onto cork at optimal length and then fixed sequentially in 
Telly’s fixative (formaldehyde, glacial acetic acid-ethanol fixative, 72 hours), 
Bouin’s solution (formaldehyde, glacial acetic acid-picric acid fixative, 24 hours) 
and 70% ethanol, prior to paraffin embedding, cutting and staining of 10µm sections 
using 0.1% w/v picrosirius red solution (Sirius Red F3B, Chroma Dyes, Germany in 
saturated picric acid), a collagen specific stain. Instead of applying the histological 
grading scheme used in Chapter 4, an image analysis program was utilised to grade 
collagen as a percentage of tissue area. Fluorescent microscopy images were 
acquired using a digital camera (Q imaging Micropublisher 5.0 RTV) coupled to an 
epifluorescence microscope (Eclipse E600, Nikon, Japan). Four sections per tissue 
were photographed and analysed using the image analysis program DocuAnalySIS 
(Soft Imaging System), then averaged. Additional 5 µm sections were stained with 
haematoxylin and eosin and viewed using bright field, with images acquired and 




nuclei were determined in 200 fibres per muscle. Analysis was performed blinded 
to the strain of mouse. 
 
6.4 Statistics 
Pilot experiments on aged mice were performed for a previous experiment to 
estimate standard deviations and suitable sample size (Chapter 5). Post hoc tests of 
power (Plummer, 1998) confirmed that an n = 3 animals for assessment of KI and 
n=5 animals for contractility experiments of the latissimus, longissimus and 
diaphragm muscles were adequate. Results are expressed as means±S.E. Responses 
between mdx and control strain were analysed using Student’s unpaired t-tests, with 
the exception of differences in KI, where ANOVA was employed. P < 0.05 were 
considered statistically significant.  
 
6.5 Results 
6.5.1 Evaluation of long term AO administration 
 All mice tolerated the injection procedure well, with no adverse effects 
noted in surviving animals. At the conclusion of the experiment all mice showed a 
degree of palpable thoracolumbar kyphosis, which was less pronounced in the 
control strain. There were no significant differences in body weights between the 
three groups (C57 30.4 ± 1.03g; mdx sham treated 31.4 ± 0.88g; mdx AO treated 31 
± 0.98g) 
 
6.5.2 Kyphotic Index 
 KI as measure of spinal deformity was initially less for both sham and AO 
treated mdx mice compared to control mice (P<0.01 at 6 months of age). The AO 
treated mdx showed a tendency to a greater KI (and hence less thoracic deformity) 
than sham treated mdx after that age, although this only reached statistical 
significance at 10 months and again by the end of the experiment (18 months of 
age). AO treated mdx mice also had a lower KI compared to control mice from 8 to 
18 months of age, however at 16 and 18 months there was no statistical significance 
between the two groups. The data was also analysed with the inclusion of aging C57 
and mdx from a previous study (Chapter 4). This ensured a greater n number (n= 8 
(C57), 6 (Mdx AO) and 9 (Mdx)), which reduced some of the intergroup variability. 
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This was believed to be acceptable as all mice were x-rayed on the same day each 
month and were of a similar age and weight.  There was again evidence of reduced 
kyphosis in AO treated mdx mice, with statistical significance between treated and 
untreated mdx at 10, 12, 16 and 18 months of age. The AO treated mice however 
still demonstrated a reduced KI at most time points. Measured KI of the 3 mouse 
groups is shown in Figure 6.4.A and B.  
Kyphotic Index of AO and sham injected mice
Age of mice (months)
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Fig 6.4A  Kyphotic Index as a measure of thoracolumbar deformity in antisense 
oligonucleotide (AO) treated Mdx, sham (saline) treated Mdx and C57 mice. 
AO/Lipofectin complex or saline were injected intramuscularly into the paraspinal 
muscles once monthly from 2-18 months of age. KI was calculated from lateral 
radiographs. n= 5 (C57), 6 (Mdx AO) and  5 (Mdx sham). * P<0.05, ** P<0.01 
(comparing AO treated Mdx and C57 mice), and ++ P<0.01 (comparing AO treated 




Kyphotic Index of AO, sham injected and aging mice
Age of mice (months)
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Fig 6.4B  Kyphotic Index as a measure of thoracolumbar deformity in antisense 
oligonucleotide (AO) treated Mdx, sham (saline) treated Mdx and C57 mice and 
additional untreated Mdx and C57 mice. AO/Lipofectin complex or saline were 
injected intramuscularly into the paraspinal muscles once monthly from 2-18 
months of age. KI was calculated from lateral radiographs. n= 8 (C57), 6 (Mdx AO) 
and  9 (Mdx). * P<0.05, ** P<0.01 (comparing AO treated Mdx and C57 mice), and 
++ P<0.01 (comparing AO treated Mdx and sham injected Mdx). There was 
evidence of reduced kyphosis in AO treated Mdx compared to sham injected and 















Fig 6.5 Representative radiographs from 18 month old mice treated with either 
antisense oligonucleotide (AO) injections or sham (saline) injections into the 
paraspinal muscles. The yellow lines represent those constructed for the 
measurement of the Kyphotic Index (KI) = length of line ab/cd. A) C57 sham 
injected mouse. KI= 3.86 B) Mdx sham injected. KI=3.05 C) Mdx AO treated. 
KI=3.65. In the above examples kyphosis is more pronounced in the Mdx sham 












6.5.3 Muscle contractility 
 The characteristics of each isolated muscle (optimal length (Lo), weight and 
width) are shown in Table 6.1. There was a significant increase in weights of all 
mdx muscle preparations (sham and AO treated) compared to wild type mice. This 
weight increase of the latissimus dorsi and diaphragm muscles was attributable in 
part to their greater widths (P<0.05). Diaphragm strips are cut from the entire organ, 
and therefore width could vary from section to section, however the latissimus is an 
entire muscle that has a distinctive fan shape. It is possible that a measurement of a 
long muscle of varying widths was not entirely accurate. It is also likely that 
dystrophic changes, including collagen and fat deposition and muscle hypertrophy, 
also play a role in the increased weight of most mdx muscles. There were no 
significant differences in muscle morphometry between AO and sham treated mdx. 
 
Table 6.1 Mean (± SE) optimum fibre length (Lo), weight and width of paraspinal 
and respiratory muscle strips from 18-month-old sham treated control mice, sham 
treated mdx mice and antisense oligonucleotide treated mdx mice. n= 5 (C57), 6 
(Mdx AO) and  5 (Mdx sham). * P<0.05, ** P<0.01 (comparing AO treated Mdx 
and C57 mice). ++ P<0.01 (comparing C57 and sham injected Mdx). 
Muscle Lo (mm) Weight (mg) Width (mg) 
Latissimus dorsi    
Control 33.04 ± 2.2 77 ± 8.2 2.34 ± 0.2 
Sham mdx 32.7 ± 2.14 121.6 ± 14.2 + 3.02 ± 0.3 
AO mdx 34.4 ±0.69 140.6 ± 8.8 * 3.27 ±0.29 * 
Diaphragm strip    
Control 8.1 ± 0.78 6.08 ± 1.2 1.26 ± 0.12 
Sham mdx 7.94 ± 0.74 10.92 ± 1.85 + 1.92±0.31 + 
AO mdx 7.63 ± 0.28 9.36 ± 0.82 * 2.1 ± 0.13 * 
Intercostal strip    
Control 7.61 ± 0.99 48.2 ± 6.4 5.37 ± 0.55 
Sham mdx 8.05 ± 0.89 79.82 ± 5.5 ++ 6.88 ± 0.89 
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Fig 6.6 Isometric twitch and tetanic forces from latissimus dorsi, diaphragm and 
intercostal strips from 18-month-old sham injected control mice, antisense 
oligonucleotide (AO) injected and sham injected mdx. A) Peak twitch forces of 
latissimus and diaphragm muscles in the three groups of mice. B) Peak tetanic 
forces of latissimus and diaphragm muscles. C) Twitch and tetanic forces of 
intercostal muscle strips. There were significantly greater twitch and tetanus forces 
in control mice compared to mdx for all muscles, however there was no difference 
in force between AO treated and sham injected mice. 
FOC= Force of contraction ** P<0.01, * P<0.05.  n= 5 (C57), 6 (Mdx AO) and  5 















6.5.4 Quantitation of collagen 
 The hydroxyproline content of four paraspinal and respiratory muscles 
(latissimus dorsi, longissimus dorsi, diaphragm and intercostal muscles) is shown in 
Figure 6.7. All mdx muscles demonstrated approximately twice the hydroxyproline 
levels compared to control mice (P<0.05), with the diaphragm showing the greatest 
evidence of fibrosis of the four tissue types. There was a trend for lower 
hydroxyproline levels of diaphragm and intercostal muscles in mdx AO treated 
mice, however this did not reach statistical significance. The greater fibrosis of mdx 
diaphragms was also apparent on picrosirius stained sections of these muscles. Mdx 
AO treated latissimus and diaphragm muscles showed significantly less fibrosis 
than sham treated mdx when analysed by this method (Figure 6.8). Examples of 
histological sections are shown in Figure 6.9. 
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Fig 6.7 Hydroxyproline (HP) content of latissimus dorsi, longissimus dorsi, 
diaphragm and intercostal muscles in control mice, sham treated mdx and antisense 
oligonucleotide (AO) treated mdx mice. Tissue fibrosis, as measured by HP content, 
was significantly greater in all mdx muscles compared to controls. * P<0.05.  n= 5 
(C57), 6 (Mdx AO) and  5 (Mdx sham). 
  
 
































Fig 6.8 Fibrosis of latissimus dorsi, longissimus dorsi, diaphragm and intercostal 
muscles in control mice, sham treated mdx and antisense oligonucleotide (AO) 
treated mdx mice. Tissue fibrosis, as measured by analysis of picrosirius stained 
tissues was significantly greater in all mdx muscles compared to controls. For 
diaphragm and latissimus dorsi muscles there was significantly less fibrosis in AO 
treated mdx compared to sham treated mdx. n= 5 (C57), 6 (Mdx AO) and  5 (Mdx 
sham). * P<0.05, ** P<0.01, P<0.001 (comparing AO treated Mdx and C57 mice). 







































Fig 6.9i) Latissimus dorsi (A,C,E) and longissimus dorsi muscle sections (B,D.F) 
stained with picrosirius red. Mdx mice (C,D) showed significantly greater fibrosis 
than control mice (A,B). In addition to the dense interstitial collagen network of 
dystrophin deficient muscle, there was also irregular myocyte size and fibre 
disarray. In antisense oligonucleotide (AO) treated mice there was a small, but 
statistically significant decrease in percentage fibrosis of the latissimus dorsi 

































Fig 6.9ii) Diaphragm muscle sections (A,C,E) and intercostal sections (B,D,F) 
stained with picrosirius red.  Sham treated mdx mice (C,D) showed significantly 
greater fibrosis than control mice (A,B), demonstrated in these photomicrographs as 
bright red bands of dense interstitial collagen. Antisense oligonucleotide treated 
mice showed a small but significant, decrease in diaphragm collagen (E), but not the 








 The characteristics of dystrophy, including variability in fibre size; centrally 
located nuclei, split and fused fibres, inflammatory cell infiltration and myocyte 
disarray, were apparent in all H&E stained mdx muscles. These changes were more 
pronounced in the diaphragm and intercostal muscles than the latissimus and 
longissimus dorsi muscles. There was a lower incidence of centrally nucleated 
fibres in AO treated mdx latissimus muscles (P<0.05) and intercostal muscles 
(P<0.01), although there was still considerable discrepancy between these treated 
muscles and control mice (P<0.001). The frequency of centrally nucleated myocytes 
is shown in Figure 6.10, and representative photomicrographs in Figure 6.11. 
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Fig 6.10 Incidence of muscle fibres with centrally located nuclei from control mice, 
antisense oligonucleotide (AO) treated mdx and sham treated mdx mice. The control 
mice characteristically showed peripheral nuclei (with their frequency here 
represented by the solid line adjacent to x-axis). There was a reduction in the 
percentage of central nucleation in AO treated latissimus and intercostal muscles.  
n= 5 (C57), 6 (Mdx AO) and  5 (Mdx sham). P<0.001 when comparing mdx and 








Fig 6.11(i) Representative H&E photomicrographs of latissimus dorsi (A,C,E) and 
longissimus dorsi muscles (B,D,F). Control mice muscle (A,B) had peripheral 
nuclei and little interstitial inflammation. Sham injected mdx mice (C,D) in contrast 
showed central nucleation and inflammatory cell infiltration typical of dystrophin 
deficient muscle. Antisense oligonucleotide (AO) injected mdx latissimus dorsi 
myocytes (E) had significantly fewer central nuclei than sham treated mdx. In this 
cluster of cells collagen is still evident but cells show peripheral nuclei, suggestive 
of less degeneration. AO treated mdx longissimus dorsi muscle (F), in contrast 









Fig 6.11(ii) Representative H&E photomicrographs of diaphragm sections (A,C,E) 
and intercostal muscles (B,D,F). Control diaphragm (A) and intercostal muscles (B) 
show homogeneity in size and shape compared to sham treated mdx diaphragm 
sections (C) and intercostal muscles (D).   Diaphragm section from AO injected mdx 
(E) showed no significant difference in central nucleation compared to sham 
injected mdx, however the AO treated mdx intercostals displayed milder pathology. 
This group of mice showed significantly less central nucleation than sham treated 




6.5.6 Western blots 
Western blot analysis of C57 lumbar muscles showed full-length dystrophin at the 
predicted site (427 kDa), however it was not possible to detect dystrophin in AO 
treated mdx muscles. The Western blots were repeated several times with similar 






ig 6.12 Western blot of paraspinal muscles of control mice, sham injected mdx 
.6 Discussion 
e oligonucleotide therapy of DMD is a promising approach to the 




mice and antisense oligonucleotide (AO) injected mdx. Only the C57 dystrophin 
band is evident. Muscles blotted in order were C57 longissimus, sham injected mdx 
longissimus, AO treated mdx longissimus (2 different mice) and AO treated mdx 




disease in those boys whose genetic defect is amenable to forced alternative 
splicing. There are, however, a number of questions raised by this mode of therapy - 
including the safest and most efficacious route of administration, timing, long-term 
efficacy, and level of dystrophin expression required to ameliorate symptoms. There 
is much work still needed using animal models such as the mdx mouse and GRMD 
dog before clinical trials can progress. 
 This project examined the o
ad stered into the paraspinal muscles of mdx mice aged from 2-18 months of 
age. These ages were chosen as, although mdx show the most severe necrosis at 
weaning age, they continue to experience cycles of degeneration and regeneration 
throughout life, with gradual development of severe or moderate dystrophy in 








mN, mdx AO treated : 13.6 ± 1.6mN). 
(Stedman et al., 1991; Pastoret and Sebille, 1995b; Lefaucheur, 1995). In addition, 
other important clinical features of DMD such as thoracolumbar deformity was 
documented previously (Laws and Hoey, 2004). 
 AO injections were well tolerated by the mice, and there w
local swelling, loss of appetite or stiffness of gait following monthly treatments. 
 The KI of the AO treated mice tended to be greater than sham injected m
(indicating less kyphosis) at all time points from 8-18 months of age, however there 
was only statistical difference between groups at 10 and 18 months of age. There 
was incongruity between KI in this series of radiographs (involving a larger n) than 
a previous study (Chapter 4), as the control mice in this study showed a decline in 
KI at 16 and 18 months of age, bringing them closer in value to mdx mice. The KI 
of AO treated mdx mice tended to plateau from 8-18 months of age, compared to 
fluctuating values in the other two groups of mice, making it more difficult to draw 
conclusions on the validity of statistical tests of significance (Fig 6.4A). When 
additional mice were included in the analysis there was less intergroup variabilty 
(and consequently smaller error bars). It was felt that inclusion of the additional 
untreated mdx and C57 mice was statistically valid as there were no significant 
difference in KI between them and sham injected mice. This also indicated that 
using more animals may improve a) the assessment of KI in mdx and control mice 
across their lifespan (despite tests of power suggesting fewer mice were adequate) 
and b) the evaluation of therapeutic interventions measuring this parameter. 
 The contractility data presented in Figure 6.6 shows the specific twi
te forces of control mice was greater than mdx mice, with the exception of 
diaphragm single twitch data (Fig 6.6i). This was an unexpected result and was also 
contradictory to the specific tetanic forces obtained from the same muscle 
preparations, however other authors have noted the discrepancies between forces 
normalised for mass or cross-sectional area in old mice skeletal muscle (Hayes and 
Williams, 1998). When diaphragm twitch forces were normalised for muscle weight 
only they were significantly greater for control mice (C57; 3.15 ± 0.42 mN/mg, mdx 
sham treated; 1.39 ± 0.25 mN/mg, mdx AO treated : 1.48 ± 0.19. P<0.01). Absolute 
twitch forces for diaphragm strips were also greater for control mice, although this 




ared to sham treated mdx. An inadequate 
n results obtained in this study were 
ding adeno-associated 
us v
 There was no significant difference in force production of any examined 
muscle type for AO treated mdx comp
dosage or distribution of AO to the muscles in question is likely to be the primary 
explanation for this result. AO transfection is a local phenomenon, limited by 
concentration, the spread of injectate within tissues and degree of internalisation of 
AO by myocytes. Although evidence of dye was observed within other tissues such 
as latissimus dorsi or occasionally intercostal muscle regions, a dilution of effects 
could also result from this spread, i.e. there was less AO available to transfect fewer 
cells. Tissues with the most staining were reserved for Western blotting to maximise 
detection of dystrophin, but this could mean that the muscles strips used for 
contractility studies were less likely to have successfully incorporated AOs. In 
addition this project examined function at one time point only (18 months old), and 
there may be a diminution of efficacy of AO therapy in dystrophic muscle with age, 
as satellite cell reserves and regenerative ability of muscle wanes and fibrosis 
advances. This latter point may explain the discrepancy between improvement in KI 
and lack of improvement in contractility.  
 The two methods of measuring collagen are complimentary with results 
generally in agreement, however certai
equivocal. There was no significance difference between AO and sham treated 
muscles using HP assays, but significantly less interstitial collagen in diaphragm 
and latissimus muscles when collagen specific stains were analysed. The advantage 
of histological staining methods is the ability to visualise and record the extent of 
fibrosis, however the number of fields of view examined (or the number of levels of 
sectioning) limits the accuracy of analysis. AO therapy is unlikely to influence 
fibrosis in diaphragm muscle because direct injections were not employed, however 
it may have provided benefit in areas of latissimus muscles.  
 Evaluation of central nucleation in mdx myocytes demonstrated the 
attenuation of dystrophic pathology in other studies, inclu
vir ector-mediated gene therapy (Wang et al., 2000; Yoshimura et al., 2004; 
Fabb et al., 2002) and stimulation of calcineurin signalling (Chakkalakal et al., 
2004). The percentage decrease in centrally nucleated fibres in this current study, 
although significant from untreated muscles, is only small. This contrasts to 




estern blotting, despite the presence 
athology in mdx mice, and at many time points 
and consistent fibre sizes and shapes (Wang et al., 2000;  Yoshimura et al., 2004). 
In these studies they injected vectors and min-dys into single muscles rather than 
over a wider area, and accurate localisation of transduced fibres was possible by 
histology and immunohistochemical methods.  
 It was not possible to demonstrate dystrophin expression in longissimus 
dorsi and latissimus dorsi muscle samples by W
of strong dye staining to enable localisation of the sites of AO injection. This is 
most likely a result of low dosage of AO administered, as detailed in the diaphragm 
study (Chapter 5). In the time since both these studies were undertaken other 
researchers have shown that up to 8 fold increased amounts of AO are required for 
in vivo studies in mdx muscles (Lu et al., 2003; Wells et al., 2003). 
Immunohistochemical methods have recently been proved to be more sensitive than 
Western blotting for demonstraing low level dystrophin induction  follwing AO 
administration (Lu et al., 2004).  
 In conclusion, this study did provide some evidence that long term AO 
administration reduced muscle p
significantly altered the dystrophic phenotype of kyphosis present in this strain, 
(comparing AO treated with sham injected mdx). There was still evidence of greater 
kyphosis in treated mice compared to control This study also showed that 
significantly higher levels of AO are needed for in vivo experiments than that which 
achieved transfection of myocytes in cell culture in previous studies. The 
confounding problems of all gene modulating therapies currently considered for 
DMD clinical trails are exemplified here; the need for high efficiency widespread 
transfer, high biological activity, persistent expression and efficient target delivery 












HAPTER 7: CONCLUSIONS AND IMPLICATIONS 
, and that we, or those that come after us, may 
s a prototype disease. It is 








FOR FURTHER STUDY 
Regarding every disease now incurable we may entertain the hope that our 
powerlessness may not be permanent
speak of it in very different terms… 
   Sir William Gowers, Lancet 1879 
 
Duchenne Muscular Dystrophy can be regarded a
c
ystrophin gene, the largest in the human body, has been studied for decades 
and its structure and mutations can now be considered well characterised. There are 
several naturally occurring laboratory animals, and many more man-made ones, that 
are excellent models for different aspects of study. There are research centres 
throughout the world dedicated solely to research into muscular dystrophies. It is 
likely the discovery of a genetic cure for DMD will release the floodgates for 
treatment of many other genetic diseases of lesser prevalence in society.  
Dystrophin’s countless roles are being revealed gradually; it is a strut that 
maintains structural stability and helps to resist the forces of muscular co
integrally involved in those contractions via connections to actin, it binds 
important molecules such as nNOS, calmodulin, dystrobrevin and ion channels, 
either directly or indirectly. These various and vital roles suggest that successful 
treatment can only come about through dystrophin replacement strategies, rather 
than anti-inflammatory drugs, hormone intervention, immune modulators or channel 
blockers, which influence only part of the complex. 
Whilst there is hope for successful treatment in the future for boys affected 
with DMD, the pathways to it are far from clear. Par
ve stem cell therapy, gene transfer via plasmids or viruses, a series of 
injections such as geneticin, or a system of applying molecular ‘patches’ using 
antisense oligonucleotides? The complexity of the gene and variety of mutations 
arising within it also suggest than a standard form of treatment is unlikely, but rather 
that therapy will be customised for every patient, based on individual genotyping 




emonstrated by mdx muscles in vivo 
or 
ly lower 
 Exon skipping strategies utilising AOs hold great promise for those patients 
with point mutations and short deletions, as d
and cultured human muscle cells. The challenges include devising methods for 
widespread delivery, refinement of AO chemistry and ensuring persistence of 
dystrophin expression in all muscle types, including the heart and the diaphragm. 
 This dissertation sought to examine several muscles uniquely involved in the 
dystrophic phenotype and previously either less well characterised, 
uncharacterised, in the mdx mouse model. These included cardiac muscle, accessory 
respiratory muscles and paraspinal muscles. In addition mdx diaphragm muscle was 
utilised as an example of skeletal muscle severely affected by the dystrophic 
process, and most representative of the profound dystrophy seen in DMD. 
Following these characterisation studies strategic administration of AOs was 
performed in diaphragm and paraspinal muscles, and the effects evaluated. 
 Mdx cardiomyopathy varies with the life stage. Young mice (3 weeks of age, 
or corresponding to the acute muscle necrosis stage) showed significant
heart weights and atrial contractility compared to control mice. 3 and 6 week old 
mdx showed blunted atrial responsiveness to increasing concentrations of calcium. 
15-month-old mdx also displayed lower atrial forces compared to C57 mice. 
Isometric twitch characteristics altered with age, with 15-month-old mice showing 
lower basal forces and prolonged rise and relaxation times. Electrophysiological 
differences were evident in dystrophic hearts when action potential durations were 
measured by transmembrane glass microelectrodes. There was a strong trend for 
shorter APD90 in mdx mice (significant at 3 weeks, 9 months and 12 months), while 
APD50 increased in mice over 15 months of age. The apparent paradox of slowed 
twitch properties, shortened APD90 and prolonged APD50 provide evidence for 
dissociation between cell contractile machinery and electrical events, in addition to 
dysregulation of ion channels in mdx cardiomyocytes. These properties, and the 
development of increasing interstitial fibrosis with age in mdx hearts, provide 
insights into DMD cardiomyopathy including ECG disturbances and the tendency 
for arrhythmias. Differences between human and murine disease were noted: mdx 
hearts can show equivalent function to control hearts at many ages, and fibrosis is 
patchy and diffuse, rather than localised and severe, as occurs in boys with DMD. 





 measured from 
commonly in DMD. In conclusion this study showed that young (<6 weeks) and 
old (>15 months) mdx mice were most useful for cardiac studies, when contractile 
dysfunction and electrophysiological disturbances were significant. 
 Spinal deformity is common in DMD, and also occurs in the mdx mouse, in 
the form of thoracolumbar kyphosis. A novel radiographic index ex
the Kyphotic Index used in children, was developed and applied to aging C57 and 
mdx mice. KI remained the same until approximately 9 months of age, after which it 
became significantly less in mdx mice (indicating more severe kyphosis). Muscles 
associated with spinal and thoracic deformity were isolated and used for 
contractility studies, measurements of interstitial collagen, and histological 
measures of muscle degeneration and regeneration. The latissimus dorsi, intercostal 
muscles and diaphragm muscles of the mdx mouse showed reduced twitch and 
tetanic force production, increased central nucleation (indicating myocyte 
regeneration) and increased fibrosis. This study was the first to apply such a 
radiographic index to an animal model, and evaluate the effects of dystrophy of the 
paraspinal and respiratory muscles in the progression of kyphosis. 
 AOs were administered once monthly by intramuscular injection into the 
paraspinal muscles of mice from 2-18 months of age. KI was
monthly radiographs and found to be greater in AO compared to sham treated mdx 
at 10-18 months of age (significant at 10, 12, 16 and 18 months). There was still 
significant discrepancy in KI however, between AO treated mdx and C57 mice. 
There was no improvement in force production of latissimus dorsi, intercostal 
muscles or diaphragm in AO treated mice, but there was some reduction in fibrosis 
measured by histological stains specific for collagen in AO treated latissimus dorsi 
muscles and diaphragm. The frequency of centrally nucleated fibres was 
significantly less for AO treated latissimus dorsi and intercostal muscles. 
Dystrophin expression could not be demonstrated by Western blot.  The conclusion 
from this study was that some benefit to the dystrophic phenotype in the form of 
reduced kyphosis was observed after long-term administration of AOs. The 
concentration of AOs was thought to be too low to result in persistent expression of 
dystrophin, and higher concentrations were indicated. More sensitive dystrophin 





an trials. The proof of principle that AOs 
 The mdx diaphragm shows necrosis and fibrosis from an early age, with the 
histological changes closely mimicing that seen in skeletal muscles of boys wi
DMD. Organ bath studies measuring contractility of diaphragm strips, 
hydroxyproline analysis and histological measures of fibrosis and degeneration and 
regeneration were shown to be reliable indicators of the extent of dystrophy in this 
organ. From preliminary studies using mice from 3 weeks to 15 months of age, it 
was decided to use 4-month-old mice for the administration of AOs directly into 
diaphragm muscle. Two procedures one month apart were performed, involving 
sub-epimyseal injections of AO/lipofectin complex at four sites around the 
diaphragm. Mice were sacrificed one month after the second procedure and 
diaphragm strips were dissected for contractility studies. Twitch and tetanic forces 
were significantly greater in AO treated diaphragms compared to sham injected, but 
fibrosis was not alleviated. The frequency of centrally nucleated fibres was also 
similar between AO and sham treated mdx. Western blotting again failed to 
demonstrate dystrophin production, thought to be due to a low concentration of AO. 
This study was the first to show evidence of functional benefits after AO treatment 
in muscle with a tendency for severe dystrophy, and provides additional evidence 
that this mode of treatment may be a safe and efficacious form of therapy if vectors 
for systemic delivery are developed. 
 From the studies outlined above and consideration of published work, it is 
clear that AO strategies are ready for hum
successfully induce exon skipping in both mdx and DMD cells was followed by 
studies showing improved function in mdx limb muscles, with a lack of 
inflammatory response and toxicity. Long term AO use was safe and well tolerated 
in mdx mice, and alleviated kyphosis compared to sham injected mice. Diaphragm 
function was improved after two injections of AO, albeit of a lower concentration 
than would be considered for future trials. Recent advances including systemic 
delivery via intravenous injections, the feasibility of double or multi-exon skipping 
and the development of viral vectors expressing antisense sequences offer hope. 
Considerable challenges remain, including the effective delivery of AOs that induce 
persistent expression of dystrophin, which is able to provide functional benefits 
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APPENDIX A: DEVELOPMENT OF NEW TECHNIQUES 
A1: CARDIAC MONOPHASIC ACTION POTENTIALS 
A1.1 Introduction 
Boys with DMD show a high prevalence of atrial and ventricular arrhythmias, 
however the mechanisms of disturbed rhythm and conduction are not well understood 
(Sanyal and Johnson, 1982; Perloff, 1984). QT dispersion, a measure of QT interval 
variability, is seen in congenital arrhythmias such as congenital long-QT syndrome, 
torsades de pointes and various cardiomyopathies. A high degree of QT dispersion 
(>60ms) was found in a study of 67 DMD patients (Yotsukura et al., 1999), and these 
authors demonstrated the association between QT dispersion and severity of ventricular 
arrhythmias with a probable relationship  to regional myocardial derangement. 
Abnormal ECGs have been observed in mdx mice, attributed in one study to the 
deficiency in nNOS activity seen in this strain (Bia et al., 1999). There is controversy 
regarding QT intervals in mdx, due possibly to difficulties in determining the termination 
of the murine T wave (Bia et al., 1999; Chu et al., 2002; Danik et al., 2002)). 
Monophasic action potentials (MAPs) are extracellular recordings that can 
replicate the repolarisation time course of transmembrane action potentials (TAPs) with 
high fidelity. MAPs can be recorded from the endocardium and epicardium of in vivo or 
in vitro beating hearts in human and animal subjects. The MAP accurately reflects the 
duration as well as configuration of the repolarisation phase of the TAP, although action 
potential amplitude and upstroke velocity is much less (Franz, 1999). They are hence 
useful as a link between basic and clinical electrophysiology in arrhythmia research, 
including studies of various transgenic mice models of human cardiomyopathy (Casimiro 
et al., 2001; Franz, 1999; Knollmann et al., 2001a ; Knollmann et al., 2001b). 
MAP measurements would be a useful tool to further investigate the 
electrophysiological properties of mdx hearts, thus enhancing both the understanding of 
repolarisation and genesis of arrhythmias in dystrophic cardiac tissue, and helping to 
resolve controversies regarding the mdx cardiac phenotype. 
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A1.2 Methods 
A1.2.1 Langendorff perfused murine heart model 
Hearts were isolated from 6-8 week old and 15 month old mdx and C57 
mice.n=14-15/group 
Mice were anaesthetised with 60 mg/kg sodium pentobarbital administered intra-
peritoneally.  A thoracotomy was performed and hearts were excised into room 
temperature perfusion fluid. The aorta was cannulated under magnification using a blunt 
ended 21 gauge needle, and the coronary circulation perfused at 80 mmHg with modified 
Krebs-Henseleit buffer containing (mM) NaCl 119, NaHCO3 2, KCl 4.7, MgCl 1.2, 
KH2PO4 1.2, EDTA 0.5, glucose 11 and pyruvate 2. The concentration of CaCl2 was 
1.25mM. Buffer was equilibrated with 95% O2 and 5% CO2 at 37oC for 1 hour, giving a 
pH of 7.4, and was filtered inline using 0.45 µm filter to remove microparticles. The left 
ventricle was vented with a polyethylene apical drain, and the heart was then immersed in 
warmed perfusate in a jacketed glass bath maintained at 37oC, where it rested 
horizontally. The temperature of the perfusion fluid was monitored continuously by a 
needle thermistor at the entry of the aortic cannula. The heart was paced by attaching 
electrodes to either the right atrium or ventricle and stimulating via a Grass SD9 
stimulator. Settings= voltage threshold + 20%, (usually 2-3 volts but sometimes requiring 
a higher voltage to capture initially (up to 60 V)), 2 ms duration, frequency 6.9 Hz. This 
frequency achieved a heart rate of 420 bpm. 
Perfusion pressure was also measured and maintained at 80mm Hg. Data was 
recorded at 2 kHz on a PowerLab data acquisition system (AD Instruments, Castle Hill, 
Australia) and 4 kHz for ECG channels. The experimental apparatus for MAP is shown 
in Figure A1.1. 
The organ bath used was a Radnoti water-jacketed glass dish, modified with a 
Perspex insert to support and prevent free swinging of the heart for the purposes of 
recording MAPs. A simultaneous volume conducted ECG was also recorded with the 
recording electrodes and earth electrodes positioned in the perfusion fluid in close 
proximity to the heart. 
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Clip-on Domes for MLT844 (ADI) 
Grass SD9 stimulator 
Temperature pod for thermistor 
Thermistor (ADI) 
Custom made MAP electrodes 
Custom made ECG electrodes 
Suction  
Heated water bath 
Arterial clips and clip applicator, fine forceps and scissors 
. 
A1.2.3  Monophasic Action Potential Recordings 
A 0.25mm MAP recording probe was constructed according to published protocols 
(Knollmann et al., 2001a) and consisted of an elastic strand of twisted double silver wires 
(95% purity), insulated with Teflon sleeves except for the very tips. The ends were 
deflected by 90o for the distal 3mm. Both tips were galvanically chlorinated to eliminate 
DC current offset. The MAP exploring electrode was smoothed to a rounded surface. The 
reference electrode was placed 1 mm proximal from the tip electrode to avoid 
simultaneous contact with the myocardium (Figure A1.2).  The method used for 













Fig A1.2 Experimental setup and detail 
of monophasic action potential 
electrode used in a Langendorff- 
perfused mouse heart. The MAP 
electrodes and four silver/ silver 
chloride electrodes recording the 
surface ECG are shown. 
(Knollmann et al., 2001a) 
















Fig A1.3 Method of galvanically chloriding silver wire to create MAP or ECG 
electrodes. The wire is attached to a 9-volt battery and submerged in a saturated KCl 
solution for 5-10 minutes. Successful chloriding is seen by the formation of a dull grey 
discolouration to the wire. The silver chloride coating is fragile and impermanent, 
requiring the process to be repeated every few days.  
 
The MAP probe was lowered by hand perpendicularly onto the epicardial surface 
of the heart until gentle but stable contact pressure was achieved, resulting in the 
development of MAP signals. 
MAP recordings were made from different aspects of the heart by rotating the 
heart horizontally to expose the right or left ventricle to the MAP electrode. To obtain 
endocardial recordings the electrode was placed on right or left ventricle via a small hole 
in either atrium and made to contact the endocardium by directing the tip against the 
ventricular wall. 
MAP recordings were preamplified with a DC coupled differential preamplifier, 








9 volt  
Battery 
Bath with 3M KCl 
Silver plate 
or wire 
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A1.3  Quality criteria for MAP recordings from murine hearts. 
Table A1 details those criteria that ensure murine MAP recordings are faithful in 
accurately reproducing the wave shape of TAP recordings from mouse hearts. 
Representative murine MAPs are shown in Figure A1.4 
Table A1  MAP quality criteria (adapted from Knollmann et al., 2001a and Franz, 1999) 
________________________________________________________________________ 
1. Fast, clean upstroke (phase 0) 
2. No major contamination by intrinsic deflection or QRS 
3. Stable MAP wave shape with horizontal diastolic baseline 
4. Rapid early repolarisation (APD50 3-11 ms depending on recording site) 
5. No ‘spike and dome’ morphology 
6. An inflection point (plateau) below the 50% repolarisation level 
________________________________________________________________________ 
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Fig A1.4 Transmembrane action potentials (upper panels) compared to monophasic 
action potentials (lower panels) from normal mouse hearts. These traces illustrate the 
regional heterogeneity in waveform duration and amplitude, and marked difference in 
amplitude between MAPs and TAPs (Knollmann et al., 2001a) 
A1.3 Results 
50 mice were utilised while trialling MAP techniques. Expertise was gained in mounting 
hearts in the Langendorff apparatus and achieving good function (manifest as constant 
pressure, strong regular cardiac contractions and pink colour to the tissue). All hearts 
(mdx and C57) continued to beat for the duration of the experiment, which was often 
more than two hours.  
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Fig A1.5 Examples of monophasic action potential recordings achieved from epicardial 
surfaces of mdx hearts. These serve to illustrate the variation in MAP amplitude and wave 
forms experienced during these experiments. A. A typical left ventricular epicardial trace, 
with an amplitude of 4 mV. B. Another left ventricular recording from a different mouse 
recorded on a separate day. The amplitude was 2 mV and APD was also different to 
previous recording. C. This a third mouse reading with a 1mV amplitude, slower upstroke 
velocity and prolonged duration. Also apparent in these traces is the 50-cycle interference 
causing baseline and downstroke fluctuations. 
 
There were three main areas of difficulty encountered during these experiments: 
1.Reliability of MAP recordings 
It was not possible to consistently and reliably obtain MAP recordings, despite efforts to 
replicate conditions and electrodes from previously successful experiments. Sometimes 
MAP recordings were achievable, but of very low amplitude (2-3 mV) making 
comparison between mice difficult. MAP electrodes were re-chlorided, or made again 
from new silver wire when problems were encountered. Two different commercial bio-
amplifiers were trialled (Grass CP511 Amplifier and Animal Bioamp (ADI, Australia), 
and a custom made differential circuit was also made and tested unsuccessfully. 
2.Electromagnetic interference 
50-cycle interference was a significant problem throughout this series of experiments, 
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apparatus was disassembled and rebuilt in another area of the laboratory. An ultrasonic 
flow probe was also thought to be a major source of EMI initially, so its use was 
discontinued. Water baths, computers and amplifiers were moved as far from the heart 
and electrodes as possible. The stage for the tissue bath and the tissue bath itself was 
shielded using aluminium foil. Various combinations of filters were tried, and isolated 
ground amplifiers were chosen (with 50-Hz notch filter). Grounding of the heart was also 
attempted using earth electrodes. 
3. Amplitude and morphology of MAPs 
Variable MAP amplitudes are reported in the literature –for example 11-19mV 
(Knollmann et al., 2001a), 3.5-15.1mV (Danik et al., 2002) and 14.6-22.4mV (Liu et al., 
2004). Action potential amplitudes cannot be used as an absolute measure of cellular 
electrophysiology, but serve as a relative reference for acceptable signals. The maximum 
MAP amplitude achieved was 8.5mV, with the majority falling in the 2-4 mV range. Of 
greater concern than amplitude alone was the fidelity of waveforms, with many showing 
the appearance of Fig A1.5c, where there was not always typical depolarisation spikes 
with rapid repolarisation downstrokes. 
 
A1.4 Discussion 
MAP recordings provide precise information regarding local activation and 
repolarisation of the heart, and there is a need for verifying this information in mdx mice. 
Unfortunately there was a series of technical problems encountered during this 
experiment limiting the usefulness of the results, meaning n numbers were low and 
statistical tests could not be applied. The problem of 50-Hz interference was not 
overcome, despite seeking expert advice on this matter (A. Katchman, pers comm. 
20.4.04). A commercial bioamplifier recommended and subsequently first used (Grass 
CP511) was found not to be a differential amplifier. Advice was also sought regarding 
waveform and amplitudes (B. Knollmann, , pers comm 20.5.04 and M. Franz, pers comm. 
24.5.04) and it was felt that the problems encountered may be a combination of recording 
technique or MAP electrodes, although M. Franz indicated that recordings such as shown 
in Fig A1.5a and b were acceptable. This project was terminated due to inconsistencies in 
results and the time constraints of PhD studies. 
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A2: TRANSMEMBRANE ACTION POTENTIALS AND 
FUNCTION OF VENTRICULAR TISSUE 
A2.1 Introduction 
In recent years mouse trabeculae or small papillary muscle preparations have been 
utilised in studies of contractile function and calcium handling (Stull et al., 2002; Gao et 
al., 1999; Stuyvers et al., 2002). They have the advantage over single cardiomyocytes in 
that intercellular connections are maintained, loaded contractions can be assessed and 
also there is the ability to maintain high pacing rates, similar to physiological frequencies 
(Stull et al., 2002).  Ultra-thin muscles have less diffusion distance compared to thick 
ventricular wall preparations, so core hypoxia or accumulation of metabolites do not limit 
contractility. However, they suffer the disadvantage of a low incidence of geometrically 
suitable preparations (33% in one study (Stull et al., 2002)). 
TAPs are superior to MAPs in providing information on resting membrane 
potentials, action potential amplitudes or upstroke velocity (Liu et al., 2004), however 
achieving stable TAPs at very short cycle lengths can be difficult.  
It was hoped that information gained from successful TAP studies in mdx and C57 mice 
would complement atrial data in aging mice (Chapter 3) and MAP studies in age matched 
mice (Appendix A1). 
 
A2.2 Methods 
Hearts were isolated from 6-8 week old and 15 month old mdx and C57 mice. 
n=14-15/group 
Mice were anaesthetised with 60 mg/kg sodium pentobarbital administered intra-
peritoneally.  A thoracotomy was performed and hearts were excised into room 
temperature perfusion fluid. The aorta was cannulated under magnification using a blunt 
ended 21 gauge needle, mounted onto a Langendorff apparatus and the coronary 
circulation perfused at 80 mmHg with modified Krebs-Henseleit buffer containing (mM) 
NaCl 119, NaHCO3 2, KCl 4.7, MgCl 1.2, KH2PO4 1.2, EDTA 0.5, glucose 11 and 
pyruvate 2. The concentration of CaCl2 was 0.25M. The Krebs buffer was equilibrated 
with 95% O2 and 5% CO2 at 37oC for 1 hour, giving a pH of 7.4, and was filtered inline 
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using 0.45 µm filter unit to remove microparticles. The heart was immersed in a jacketed 
glass bath maintained at 37oC, where it rested horizontally and was perfused in 20mM 
2,3-butanedione monoxime (BDM) to prevent cutting injury. The temperature of the 
perfusion fluid was continuously assessed by a needle thermistor at the entry of the aortic 
cannula. 
The right ventricle was opened from base to apex by cutting parallel to the 
interventricular septum. Blood clots were washed out and a thin, uniform, nonbranched 
trabeculae or small pap muscle was carefully dissected leaving a block of tissue at one 
end from the RV free wall, and a small part of the tricuspid valve at the other end to 
facilitate mounting. Muscles were mounted between a stainless steel cradle glued to a 
force tranducer (Sensor Nor beam) and snared at the valve end by 9/0 monofilament 
nylon suture material (Ethilon brand) threaded into a 50 µm hollow stainless steel tube 
(Goodfellow, Cambridge,UK), according to published protocols for rat trabeculae (Ward 
et al., 2003). Muscles were perfused initially with the same buffer as above (with the 
exception of BDM) at 37oC, and stimulated at 0.5 Hz. Calcium and frequency was 
increased incrementally each 10 minutes over a 40-minute period until baseline 
conditions were reached (37oC, 1.25 mM Ca2+, 6.9 Hz.). Voltage was set at 20% greater 
than threshold, field stimulated at a pulse duration of 5 ms and perfusate flow rate at 8 
mLs per minute. 
Force development was determined at slack length (with no preload applied) and 
optimal length where force development is slightly below maximal (corresponding to an 
approximate sarcomere length of 2.2 µm (Stull et al., 2002)). 
Experimental apparatus was similar to that detailed in B4.2 (microelectrode 
apparatus) and A1.2.2 (Langendorff apparatus). 
When muscles were equilibrated, force recordings were measured for 5 minutes, and a 
glass microelectrode was impaled into the tissue using a 3M KCl filled microelectrode of 
10-50 mΩ resistance. Stable TAP recordings (at least 10 beats at 3-4 sites) were sought. 
The muscles were measured at optimum length using a calibration reticule in the ocular 
of the dissection microscope after mounting. Cross-sectional areas were calculated 
assuming an ellipsoid shape (CSA=πab x length, where a= ½ minor diameter and b= ½ 
major diameter). 
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A2.3 Results 
Ventricular preparations from 32 mice were used while attempting to optimise 
experimental conditions. Experience was gained in the dissection and mounting of 
papillary muscles or trabeculae under magnification. Figure A2.1 shows force recordings 
and action potential recordings. 
 
 
Fig A2.1 Force recordings (above) and action potentials (below) achieved at a frequency 
of 6.8 Hz, or over 400bpm. These preparations were subjected to a temperature of 37oC, 
and field stimulated at 5 ms pulse width and 30 volts. 
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The following observations were made regarding these experiments: 
1.There was a low incidence of suitable linear, non-branched trabeculae necessitating the 
use of papillary muscles in most cases. The broad apical end of mouse papillary muscles 
made it difficult to mount these in the cradle of the force transducer, and the use of this 
cradle restricted contractions. Later in the experiment a fine (6/0 silk) noose was used to 
attach muscles to a hook glued onto the force transducer. 
2. There was poor contractile function in many preparations. Rapid deterioration in 
function was encountered in mouse trabeculae at 37oC in another published study, forcing 
these investigators to using non-physiological room temperatures for the remainder of 
their experiments (Gao et al., 1998). 
3. Achieving stable sequences of TAPs at high frequencies was very difficult. 
4. Some technical difficulties were encountered including preload drift, and signal noise 
at high frequencies. This made measurement of small increments in force difficult. 
This project was not pursued at the time because of difficulties in consistently achieving 
good ventricular function, making comparisons between strains problematical. 
 
A2.4 Discussion 
There are few reports that characterise fundamental cardiac physiology in mdx 
mice, and some are performed under non-physiological conditions (Sapp et al., 1996) or 
in atrial preparations only (Sapp et al., 1996; Lu and Hoey, 2000a; Lu and Hoey, 2000b;). 
There is a need to further explore electrophysiological properties of mdx ventricular 
muscle as undertaken in transgenic mouse models of human cardiomyopathies. There is 
now an emphasis on replicating physiological temperatures and frequencies as far as 
possible (Stull et al., 2002; Ward et al., 2003) and ensuring optimum sarcomere length 
(Stull et al., 2002; Stuyvers et al., 2002). While these guidelines were adhered to as much 
as possible in this study it was unfortunate that statistical comparisons could not be made. 
Further improvements of apparatus and technique could include miniaturising the tissue 
bath further and use of laser diffraction techniques to accurately measure sarcomere 
length, rather than relying on optimal force production alone. It is possible that mouse 
trabeculae or papillary muscles are highly sensitive to stretch and are readily damaged. 
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APPENDIX B: RECIPES AND PROTOCOLS 
B1: HYDROXYPROLINE ASSAY 
B1.1 Equipment 
2 mL flat based polypropylene tubes with lid 
Spectrophotometer, semi-micro cuvettes (1.5-3 mL tapered) 
Heating block or oven for heating at 1070C  overnight. 
Timer 
Pippetors and tips, beakers, heat resistant tube rack. 
Shaking water bath at 600C 
Manifold for bubbling off HCl (either a series of Silastic tubing and Y connectors with 18 
gauge needles on ends, or custom made manifold (see Fig A.1)) 
Filter (Sartorius Midistart 0.2 µm) and tubing to connect from air tap to manifold 
B.1.2 Reagents 
1.Hydroxyproline Standards 
Stock of 1 mg/mL hydroxyproline (trans-4-hydroxy-L-proline, Sigma, Australia) 
prepared in distilled water. 
Aliquot standards into 150 µL amounts and freeze. 
Thaw prior to use for dilution into a standard series. 
Require range of 0-20 µg HP, in assay vol of 500 µL. Mix reagents well. 
 
2.Buffer Stock solution (pH 6) 
Dissolve 50 g citric acid.1H20 (analytical grade), 12 mLs acetic acid (96%), 120 g sodium 
acetate.3H20 and 34 g of sodium hydroxide in dH20 and bring up to 1 litre. Ten drops of 
toluene added as preservative. 
The buffer is used in colour reaction by taking 500mLs and adding 100mLs water and 
150mLs n-propanol= Working Solution. Stable for several months. 
 
3.Chloramine T reagent (0.056 M) (keep in dark at 4o for 3 weeks) 
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Dissolve 1.41g of Chloramine T in 10 mL water; add 10 mLs n-propanol and 80 mLs 
buffer at pH 6 (this is stable for several weeks, then discard) 
 
4.Erlich’s Reagent  
Dissolve 15 g p-dimethylaminobenzaldehyde (Sigma, Australia) in 60 mLs n-propanol 
and 30 mLs perchloric acid, (2:1 n-propanol:perchloric acid) (or the amount required for 
that day’s assays). 
This is light sensitive and unstable, so needs to be prepared freshly. 
This volume is enough for approx 360 samples (250 µLper sample) 
Use fume hood with waterfall for preparation. 
Perchloric acid and n-propanol can be mixed together and stored. 
 
B1.3 Sample Preparation 
Weigh tissue after trimming tendons, fat or capsular tissue. Place sample of tissue (or HP 
standard) in 6 N HCl. Use approx 10-20 mg tissue in 0.5 mL HCl in a cryotube. Tissue 
can be homogenised or cut into smaller pieces with scissors. Vortex thoroughly. 
Seal tubes and hydrolyse at 107oC for 18 hrs. 
Next morning, open tubes and dry hydrolysed samples (blow off HCl with filtered 
compressed air in fume hood). This takes 1-2 hours, and results seem better if bubbling is 
not too vigorous, as this causes dried sample to adhere to walls of tube making them 
difficult to reconstitute. If tube rack is placed on heater block at 50oC it speeds up drying 
process by evaporation also. Replace lids with fresh ones to avoid traces of HCl affecting 
assay. 
Reconstitute dried sample with 500 µL dH20. Vortex thoroughly, and get as much of 
dried sample from wall of tube. Despite the hydrochloric acid being  removed in totality, 
the hydrolysate remains acid (pH 1-2). 
 
B1.4 Assay Procedure 
Use 0.5 mL reconstituted sample or standard 
1.Add 250 µL of Chloramine T reagent. Ensure samples and chloramine T at room 
temperature.  Vortex and incubate for 20 minutes at room temperature. (=oxidation step) 
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2.Add 250 µL Ehrlich’s reagent to each sample and vortex. Incubate at 60oC for 20 
minutes (chromophore development stage) Cool tubes under tap water 
3.Read absorbance of each sample at 550 nm using spectrophotometer. 
Curve tends to plateau out, and some samples may be obviously dark red, but show HP in 
flat area. If too concentrated dilute sample with n-propanol and repeat absorbance 
reading. (Fig B.2) 
4.Construct standard curve (determine curve fit and equation by entering values into 
KaleidaGraph v 3.5, Synergy Software, Reading, USA ). Calculate µg hydroxyproline in  
samples (Fig B.3). 
 
Fig B1.1 Custom made manifold for drying hydrochloric acid from samples. The 




Taps for closing off  
air - flow to half of tubes 
Manifold base 
AIR
20uL  pippette  tips 
screwed into manifold base 
Aluminium  heater block,  
drilled to fit tubes 
Heater 
Stand for manifold, 
when not in use 
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Fig B1.2 Hydroxyproline standard series with dilutions from 1-20 µg hydroxyproline. 









Hydroxyproline standard curve 
υg hydroxyproline
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B2: HISTOLOGY RECIPES AND PROTOCOLS  
Histology protocols and recipes were courtesy of Assoc Prof Lindsay Brown’s laboratory 
and Paul Addison, histologist, Department of Physiology and Pharmacology, University 
of Queensland. Procedures were adapted from hand processing to automatic processing to 
suit the equipment available at USQ. 
 
 









Steps in preparing histological slides
1.PRESTAIN AND FIXATIVE
2. TISSUE PROCESSING AND WAX EMBEDDING
3. CUTTING AND MOUNTING OF SECTIONS
5 µm sections 10 µm sections
Dewaxing and hydration
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B2.1 Prestain and fixative recipes 
1. Telly’s fixative 
870 mL of 70% ethanol 
44 mL CH3C00H (glacial acetic acid) 
87 mL formaldehyde 
2. Modified Bouins’s solution 
850 mL picric acid 
100 mL formaldehyde 
50 mL glacial acetic acid 
 
Pin tissue onto cork, especially if thin tissue such as diaphragm or limb muscles 
Place tissue in Telly’s fixative for 3 days. 
Remove Telly’s and cover tissue in Modified Bouin’s fluid for 24 hours. 
Perform 3 changes of 70% Ethanol every 24 hours. 
Store with tissue well covered by 70% Ethanol 
 
B2.2 Tissue processing and wax embedding. 
Equipment: 
Shandon Elliot Duplex processor or Histokinette tissue processor with 9x 1L flask for 
ethanol and toluene 
Fume hood 
Tissue cassettes and baskets 
Fisher Histo-Centre tissue embedding station 
Simport embedding rings and plastic moulds 
Paraplast Extra paraffin beads 
Forceps 
Toluene 
Ethanol 100%, and beakers, measuring cylinders and funnel for diluting 
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Automatic processor times: 
Beaker   Solution   Time 
1.   70% ethanol   30 mins 
 
2.   90% ethanol   30 mins 
 
3.   95% ethanol   30 mins 
 
4.   95% ethanol   30 mins 
 
5.   Absolute ethanol  30 mins 
 
6.   Absolute ethanol  30 mins 
 
7.   Absolute ethanol  30 mins 
 
8.   Toluene   30 mins 
 
9.   Toluene   30 mins 
 
10.   Wax (A)   30 mins 
 
11.   Wax (B)   30 mins 
B2.3 Cutting and mounting 
Equipment: 
Leica manual microtome 
Feather brand disposable blades  
Menzel- Glaser Polysine microscope slides 
Heated water bath and heated trays 
Paintbrushes, pencil 
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Sections cut at 5 µm (H&E) and 10 µm (picrosirius red) 
B2.4 Staining 
Haematoxylin and Eosin recipes: 
Mayer’s Haematoxylin: 
0.5 g Mayer’s Haematoxylin powder 
500 mL dH2O 
Heat at 50-60oC on magnetic heater stirrer until dissolved. 
Add 25 g aluminium potassium sulphate, mix until dissolved. 
Add 100 mg sodium iodate - this oxidizes haematoxylin and changes colour to reddish. 
Cool solution (preferably overnight) 
Adjust pH by adding 0.5 g citric acid. 
Add 10 g chloral hydrate to preserve solution. 
Filter before use. 
Do trial staining to determine the best staining times - 6.5 mins usually gives good 
nuclear staining. 
This volume is usually sufficient for 500 slides, and is getting low in volume by 6-8 
months. 
Store at 4 oC  when not in use. 
Eosin stain: 
Eosin used is Eosin yellowish (eosin Y) which is alcohol and water soluble. 
Stock solution: 2 g powder, 40 mL dH2O, 160 mL 95% EtOH 
Working solution: Add 1 vol Stock solution : 3 vol 80% Ethanol (150: 450mL) 
Store at 4 oC   
Adequate for 200 slides. 
Scott’s solution 
4.5 g magnesium sulphate, 3.75 g sodium bicarbonate 
Make up to 1 litre with dH2O 
Store at 4 oC, can also keep solution in staining pots at RT, however discard regularly 
 
Picrosirius Red stains: 
Phosphomolybdic Acid 
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0.2% solution is used (ie 100 mg/100 mL dH2O) 
0.01M HCl solution 
1mL 10 M HCl to 999 mL dH2O 
Discard after use. 
1% Lithium carbonate solution 
Add 5 g Li Carbonate to 500 mL dH2O 
0.1% Picrosirius red stain 
0.1 g Sirius Red F3B (Chroma, Germany) in 100 mL dH2O 
 
Staining procedure, Picrosirius red 
Place slides in racks in 56 oC oven for 1 hour 
Dewaxing: 
1.XYLENE 5 mins 
2.XYLENE 5 mins 
3.XYLENE 5 mins 
Hydration: 
4.100% ETHANOL 3 mins 
5. 100% ETHANOL 3 mins 
6. 90% ETHANOL 3 mins 
7. 70% ETHANOL 3 mins 
8. Water bath 2 mins 
9. Distilled water 1 min 
10. PHOSPHOMOLYBDIC ACID 5 mins 
11. Brief rinse in water bath 
Stain: 
12. PICROSIRIUS RED STAIN 90 mins 
13. 0.01 M HCl 2 mins 
Dehydration and rinse: 
14. 70% ETHANOL 30 secs 
15. 90% ETHANOL 30 secs 
16. 100% ETHANOL 30 secs 
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17. 100% ETHANOL 30 secs 
18 100% ETHANOL 30 secs 
Mounting: 
19 XYLENE 5 mins 
20 XYLENE 5 mins 
21 XYLENE 5 mins 
22. Coverslip with Depex. 
 
Staining procedure, Haematoxylin and eosin 
Place slides in 56oC oven for 1 hour 
Follow dewaxing and rehydration as for Picrosirius Red staining protocol until step # 7 
Omit Lithium Carbonate (step # 8) 
Running water bath 2 mins 
9. Distilled water 1 min 
H&E staining 
10 HAEMATOXYLIN STAIN  7 mins 
Water bath 1 min 
11 SCOTT’S SOLUTION  0.5-1 min 
Water bath 4 mins 
12 70% ETHANOL  1 min 
13.  EOSIN STAIN 11 mins 
14.  95% ETHANOL  30 secs 
15. 100% ETHANOL 30 secs 
16. 100% ETHANOL 30 secs 
17. 100% ETHANOL 30 secs 
MOUNTING 
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B2.5 Photography and analysis 
Equipment either: 
A) Biorad MRC 1024 confocal scanning microscope with a krypton/argon laser and 
subjected to a Rhodamine/Texas Red filter of 568nm wavelength. Images were 
captured using a Biorad Lasersharp 2000 program.  
Photomicrographs of 4 sections per heart were analysed and averaged for saturated pixel 
intensity corresponding to collagen fibres, using Scion Image software Beta 4.0.2 
(http://www.scioncorp.com) density slice tool. 
 
B) Nikon Eclipse E600 microscope, images captured with Q Imaging Micropublisher 
5.0 Docu AnalySIS 
Skeletal muscle regeneration was assessed by counting centronucleation (manual 
counting of 100 fibres per muscle). Cell diameters were calculated from digital 
photomicrographs and Scion Image software. 















                                                                                                                                     A-  28
B3 :WESTERN BLOT  
Protocols courtesy of Renee Cornford-Nairn (USQ), Russell Johnsen and Kaite 
Honeyman (UWA) 
B3.1 Recipes: 
Protein Treatment Buffer/ Protease Inhibitor/PMSF 
1 mL Protein treatment buffer (PTB) and 30 uL Protease Inhibitor (Sigma, Australia) and 
2.5 µL PMSF solution. 
PMSF= 0.5 mM phenylmethylsulfonyl fluoride in isopropanol (17.25 mg/0.5 mL) 
Transfer buffer (5X concentration) 
Tris base 30 g 
Glycine 144 g 
Sodium dodecyl sulfate (SDS) 0.5 g 
adjust to pH 8.3 with concentrated HCl 
Double distilled H20 to make up to 1 L 
SDS is used to enhance the transfer of large molecular weight proteins such as 
dystrophin. 
Loading (treatment) buffer 
125 mM TrisHCl (pH 8.8) 5 mLs 
4% SDS   8 mL 
40% glycerol   20 mL 
d H20  17 mL 
2 M urea was added as a denaturant, because samples are not sonicated. Range of urea= 
2-8 M. 2 M= 6g urea in 50 mL 
 
TBST Buffer (Western washing buffer) 
 Concn (X1 
solution) 
1X working 
soln (1litre vol) 
10X stock (2 L 
total volume) 
Trizma base 10 mM 1.21 g 24.22 
NaCl 150 mM 8.76 g 175.2 g 
Tween 20 0.05% 500 µl x 
Adjust pH to 7.6 using HCl. Use Trizma not Tris HCl as base. 
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TBS Buffer 
 Concn (X1 
solution 
1X working 
soln (1L vol) 
10X stock (2 L 
total volume) 
Trizma base 10 mM 1.21 g 24.22 g 




 100 mL TBST 
 5 g skim milk powder 
Place in beaker with magnetic flea. Stir to dissolve. Store in Schott bottle in 
fridge. 
 
    SUMMARY OF WESTERN TRANSFER 
 1. Protein Extraction  
 
 2. Protein Quantitation  
   
 3. Mini Gel Electrophoresis  
 
4. Western Transfer  
 
5. 1o Antibody incubation 
 
6. 2 o Antibody incubation 
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B 3.2 Protein extraction 
Prechill porcelain six-well mortars by placing in freezer. Chop tissue finely with scissors. 
Weigh tissue samples (10-30 mg tissue is optimum). Record weights. Place muscle tissue 
trimmed of tendons into labelled 1.5 mL eppendorf tube. Add 19 volumes of Protein 
Treatment Buffer/Protease Inhibitor/PMSF mix to frozen muscle sample on mortar- eg if 
tissue weighs 10 mg add 190 µL of mix. Use porcelain pestle to grind tissue, while 
keeping samples as cold as possible (use crushed ice or dry ice under mortar). Wash 
pestle thoroughly with distilled water after use to avoid contamination. Grinding takes 
some time and some tissue such as diaphragm is more difficult- grind as finely as 
possible. Pippette ground sample back into eppendorf tube and vortex thoroughly. 
Store at -20oC until needed. 
 
B3.3 Protein Quantitation 
This assay uses the scaled Lowry assay for protein estimation using a commercial kit 
(BioRad Protein Assay Kit) with concentrations (rather than µg of total protein 
calculated). (Note that this protocol will not work using buffers containing 2-
mercaptoethanol). Aim of assay is to determine the concentration of total protein present 
in the tissue sample prior to loading the gel, with an optimum of 10 µg total protein 
loaded per lane. 
Prepare a standard curve: 
(Note the kit manual uses 4 mL plus volumes. ¼ suggested volumes are adequate for 1 
mL microcuvettes) 
Prepare 2mg/mL Bovine Serum Albumin (BSA) stocks and aliquot and freeze -20oC until 
use. 
Concentration µl BSA stock µl PTB 
Blank 0 25 
0.2mg/mL 2.5 22.5 
0.5mg/mL 6.25 18.75 
1.0mg/mL 12.5 12.5 
1.5mg/mL 18.75 6.25 
2mg/mL 25 0 
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Prepare dilutions of samples. 
Dilution µl Sample µl PTB 
1/5 5 20 
1/10 2.5 22.5 
 
Other dilutions can be used (eg ½ and undiluted), however these may fall outside linear 
range of graph and are probably unnecessary. 
Protocol for protein estimation:  
Use freshly autoclaved tips, and wear gloves to avoid protein cross contamination. 
Turn on spectrophotometer (750 nm). 
Prepare a solution containing 125 µL of Reagent A per sample, and 20 µL Reagent S per 
mL of Reagent A. Dispense into a 15 mL Falcon tube or similar. Mix thoroughly. This 
mix is stable for 1 day. 
Dispense 1 mL of Reagent B per sample into a 50 mL Falcon tube. 
Briefly centrifuge thawed samples and standards (5000RPM) 
Add 125 µL Reagent A-S mix into each tube. Vortex. 
Add 1 mL Reagent B. DON’T MIX, STIR OR INVERT. Incubate for 15 minutes at room 
temp. 
Read absorbance at 750 nm. 
Use graphing program (eg Kaleidograph) to calculate total protein concentration 
(mg/mL) of unknown samples. Average both dilution readings. 
 
B3.4 Mini Gel Electrophoresis 
Uses Invitrogen NuPage Novex 4-12% Bis-Tris gradient gels and Invitrogen NuPage 
MOPS-SDS running buffer. Loading dye =4 µL mercaptoethanol + 1 µL bromphenol 
blue. 
For C57 muscle samples load approximately 100 µg protein and make up volume of 35 
µL with PTB and 5 µL loading dye to give 40 µL total volume/well. Add loading dye in 
fume hood due to use of mercaptoethanol. 
For AO treated mice and mdx can use 35 µL of protein to maximise detection (dystrophin 
will be present in very low concentration) 
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Standard= Invitrogen E-Page SeeBlue pre-stained standard. Use 5 µL volume. No need to 
heat prior to electrophoresis. Standard extends from 20-260 kDa protein range. 
Briefly centrifuge samples. 
Denature proteins by heating at 95oC for 10 minutes in heating block. 
Remove gels from plastic bag (care with liquid inside bag as it contains sodium azide 
which is toxic.) 
Rinse gels well in distilled water and remove white plastic strip from base. 
Assemble gel apparatus. Pour 1 x MOPS-SDS running buffer into each compartment 
until ¾ full. 
Place gel with writing facing towards you and comb facing away. If using 2 gels place 
back to back. Lock gel tension wedge in place to hold gels firmly. Fill inner chamber first 
and check for buffer leakage into outer chambers. Fill chambers to almost full. 
Remove combs gently. See Figure B.3.1 for view of electrophoresis tank used. 
Use a plastic transfer pipette to flush buffer into wells to wash them out thoroughly. 
Load protein marker in left hand well. 
Load other samples. Leave empty well between C57 sample and mdx if possible to avoid 
contamination. Use gel loading tips to fill wells. 
Turn power unit on, adjust current to 20-25 mAmps. Run for approximately 3 hours  for 1 
gel or 5-6 hours for 2 gels, or until marker runs nearly to bottom of gel. Use water bath 
set with dip cooler at  15-18 oC and heat exchange coil into tank to limit temperature to 
approximately  16oC.  
Can proceed to transfer immediately or alternatively leave gels in plastic soaked in buffer 
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Fig B3.1 Mini Gel Apparatus 
View of the Invitrogen XCell SureLock™Mini Cell  
 
 
Preparation for Transfer: 
Remove gel cassettes from electrophoresis unit and place in labelled plastic containers 
Cover in transfer buffer. Soak for 10-20 minutes. 
Soak Scotch Brite pads in transfer buffer for a minimum of 4hours. 
 
B3.5 Western Transfer 
Have the following available: 
BioRad unit for transfer (BioRad Mini-Protean II Cell Model and BioRad 
PowerPac3000) 
1L Transfer Buffer 
Container with transfer buffer to fit size of BioRad blot module components 
Soaked blotting pads 
Transfer membranes (Hybond-P membranes, Amersham Biosciences, Buckinghamshire 
UK). These membranes contain polyvinyldiflouride (PVDF), which have a high binding 
capacity compared to nitrocellulose membranes. 
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 Use forceps to remove blue backing sheets after clipping top right hand corner of 
membrane for orientation (2 clips for second membrane). Dip in methanol for 10-20 
seconds to activate, the give a 5 minute wash in distilled water. 
Filter paper, soaked briefly in transfer buffer 
Invitrogen NuPAGE gel cassette. This is opened by gently prising one side with plastic 
spatula to crack open cassette and expose gel while leaving it sitting on the larger plate. 
Trim below wells with edge of spatula. Discard gel waste into acrylamide waste bin. 
The sandwich is assembled in container with transfer buffer using roller to roll out air 
bubbles. To turn out gel, place bottom layers onto cling film and turn gel face down onto 
wet filter paper layer. Cut foot of gel from unit using plastic spatula. Slide spatula 
carefully along gel to release. Finish preparing sandwich (Figure B 3.2). 
Note that the gel is positioned closest to the black plate, and after sliding the plastic clasp 
closed to hold the sandwich together the module is inserted into the BioRad unit with the 









Fig B 3.2 Order of transfer sandwich: 
 
Fig B3.2 Order of components of gel sandwich 
 
Insert a frozen ice block into the back of the unit, and fill with transfer buffer. Insert a 
cooling coil to maintain temperature at 12oC. 
Place a magnetic flea into bottom of unit and position lid and electrical leads 
Have a magnetic stirrer beneath this to facilitate mixing and cooling of buffer with 
magnetic flea. 
WHITE PLATE OF BLOT MODULE >ANODE 
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Turn power pack on to a constant current of 300 mA at 15-18oC overnight. 
With 40 minutes of transfer time remaining, make up Blocking Buffer. Have TBST ready 
also and a shaking platform available. 
With 10 minutes remaining make up Primary Antibody (Novocastra Laboratories Ltd, 
Newcastle upon Tyne, UK NCL-DYS2 mouse monoclonal antibody). 
Antibody is diluted 1:100 (can be up to 1:33) with blocking buffer. 
 
B3.6 Antibody incubation 
Disassemble transfer apparatus and remove nitrocellulose membranes using forceps. 
Cut off the lower half of the membrane below orange myoglobin marker. 
Place each upper membrane is a small plastic container just big enough to fit membrane. 
Wash 2 x in distilled water for 5 minutes each wash.  
Incubate in Blocking Buffer for 60 minutes. Agitate gently on shaker for 1 hour. 
Incubate membranes in antibody for 2 hours at room temperature. Add prepared DYS2 
(Novocastra Laboratories, UK) diluted in blocking buffer. 
Wash 3 x in TBST for at least 10 minutes. Place in blocking solution for 15 minutes. 
 
B3.7 Antibody detection 
Make up Secondary Antibody (Peroxidase-Conjugated Rabbit Anti-Mouse 
Immunoglobulins, DakoCytomation, Denmark) Dilute 1:1000 in Blocking Buffer. 
Incubate for 120 minutes at room temperature. 
Wash membranes twice in TBST and once in TBS each for 10 minutes. Make up 
chemiluminescent substrate during the last 10 minute wash 
 
B3.8 Chemiluminescence and film development 
Use Lumi-Light Western Blotting Substrate (Roche Diagnostics, Mannheim, Germany). 
Mix 3mL each of Reagent 1 and 2 per membrane in a Falcon tube. Use fresh tips for each 
solution. 
Place Lumi-light on top of membranes for 1 minute only. Drain off excess substrate. 
Place membranes between 2 pieces of transparency film or plastic folder inserts. Use a 
tissue to gently wipe over plastic to remove air bubbles. Place in radiographic cassette. 
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In darkroom pour developer and fixer into shallow trays. Use photographic safelight only 
and remove piece of Amersham Bioscience radiographic film and cut to size. Cut one 
corner to orientate where protein marker is positioned. Film exposure time is variable, 
with C57 mice only needing 10 seconds exposure, and mdx requiring 5 or 10 minutes to 
maximise detection. Develop film for 30 secs with agitation, then wash, then fix for 2-3 
minutes with gentle agitation. Give a final wash and hang in drying cupboard for a short 
period. 
 
B3.9 Results of Western blotting for dystrophin  
It was possible to consistently demonstrate the 427 kDa protein dystrophin in C57 
muscle, whereas it was absent in mdx muscle (as expected) and antisense oligonucleotide 
(AO) injected mdx mice. Many repeat experiments were performed to improve detection 
of low levels of AO. Modifications such as the addition of PMSF to the Protein 
Treatment Buffer, using a methanol free Transfer Buffer, adding SDS to the Transfer 
Buffer to enhance transfer of large proteins and utilisation of the high binding capacity 
PVDF membranes were made. The low dose of AO used may have resulted in this failure 
to detect dystrophin in AO treated mice (see Chapters 6 and 7). Clear expression of 
dystrophin is shown in Figure B.3.3, where six dilutions of C57 extracted protein was 




Fig B.3.2 Detection of dystrophin in C57 limb muscles. Six dilutions of extracted protein 
were used to test for the sensitivity of the Western blotting procedure. Lane1 corresponds 
to 60 µg total protein, 2= 40 µg, 3=20 µg,, 4=15 µg, 5=10 µg and 6=5 µg. 
 
    1  2  3        4  5   6
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B4: SKELETAL MUSCLE ORGAN BATH PROTOCOL 
B4.1 KREBS PHYSIOLOGICAL SALINE SOLUTION (Krebs PSS) 
Stock solutions (make up in 1 L volumes with dH20): 
Stock A: 
NaCl 118 mM 
KCl  4.7 mM 
MgSO4.7H2O 1.16 mM 
KH2PO4 1.18 mM 
Stock B: 
NaHCO3 25 mM 
Stock C: 
CaCl2.2H20 2.5 mM 
Store at 4oC 
Working solution 
Add 100 mL each of Stock A, B and C in MilliQ. Add 4.0 g glucose and make up to 2 L. 
Make fresh working solution each day. 
 
 
B4.2 Experimental equipment and protocol 
Carbogen (95% O2 and 5% CO2) was bubbled through Krebs PSS for 30 minutes prior to 
experiment to bring buffer to correct pH (7.4). Ice-cold Krebs was used for dissections. 
Mice were anaesthetised with 70 mg/kg thiopentone sodium (Nembutal) by 
intraperitoneal injection. The skeletal muscles of interest were removed and placed in the 
Krebs PSS. Muscles were anchored by means of surgical silk to a fixed peg at one end, 
and attached to a force transducer at the tendon end, and placed within a 25 mL glass 
organ bath maintained at 24oC (Figure B4.1). Tissues were field stimulated via a Grass 
S48 stimulator (W. Warwick, RI, USA) and current intensity was amplified using a pre-
amplifier (EP500B. Audio Assemblies, Campbellfield, Victoria, Aust). Data was 
collected and analysed using Chart 4.1.1 software on an i Mac computer. A square pulse 
of 0.2 ms duration was dispersed via two platinum plate electrodes positioned at each 
side of the muscle. 
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Optimum preload (Lo) was defined as the length eliciting maximal single twitch force. 
Optimal voltage was also determined for each preparation, as was the frequency eliciting 
maximal tetanic force. Reported data was the average of 3 individual single twitches or 
tetanic stimulations per muscle strip, with those three values then averaged to give an 
overall mean for that muscle. A fatigue protocol (one tetanic stimulation every 5 secs for 
5 minutes) and recovery from fatigue (a single tetanic stimulation 5 minutes later) was 
sometimes performed also. Muscle dimensions were measured at Lo using a digital 




















Fig B4.1 Row of water-jacketed organ baths used for skeletal muscle contractility 
studies. The computer is to the right of the organ baths, and above it is positioned the 
stimulator and preamplifier. Recordings showing a) twitch b) tetanus and c) fatigue of 
representative diaphragm strips. 
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B5 MICROELECTRODE STUDIES 
B5.1 TYRODES PHYSIOLOGICAL SALINE SOLUTION (TPSS) 
Stock solutions (make up in 1 L volumes with dH20): 
Stock A: 
NaCl 136.9 mM 
KCl  5.4 mM 
MgCl2.H2O 1.05 mM 
NaH2PO4. H2O 0.42 mM 
Stock B: 
NaHCO3 22.6 mM 
Stock C: 
CaCl2.2H20 1.8 mM 
Store at 4oC 
Working solution 
Add 100 mL each of Stock A, B and C in MilliQ. Add 2.0 g glucose, 0.2 g Ascorbic acid, 
and 0.4 mL of 9.5% Na2EDTA solution. Make up to 2 L. 
Make working solution up freshly each day. 
B5.2 Experimental equipment  
Thermometer 
STIMULATOR   Microelectrode & 
     Micromanipulator 
POWERLAB 
Chart 4 
ELECTROMETER     Ag/AgCl 
     electrode 
                    -ve                                        TPSS 
      O2/CO2            
    
                                     Organ chamber  
                 heater 
         +ve   
      Platinum electrodes  
    
Gilson 
pump 
Fig B5.1 Diagram of microelectrode apparatus used for atrial microelectrode and 
contractility studies. 
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Pipette puller- WPI microprocessor controlled vertical pipette puller. Microelectrodes of 
10-50 MΩ  resistance used. 
Perfusion pumps- Gilson minipuls 3, set at 3 mL/minute. 
Stimulator- Grass SD9 stimulator 8-10 V usually (can increase<20 V), Freq 1 Hz, pulse 
width 0.5 msecs, 
Determine threshold voltage that elicits a contraction, add 20 %. 
During an experiment it may be necessary to increase voltage to maintain contractions. 
WPI motorised micromanipulator DC 3001R, MS 314 step arm controller 
WPI Electrometer-Cyto 721 
Thermometer-Fluke 50S K/J  Temp =35+/- 0.5oC 




 +       -        Earth  
AE-801 SensoNor 
Sensor element   
-Header 
 
     Pins 
Resistors 
     Beam  
  
Fig B5.2 Transducer consists of Wheatstone Bridge and crystal silicon beam with a 1000 
Ohm resistor implanted each side, surrounded by 4 pins. An entomology pin was used as 
hook and a Plexiglass cover gave protection of transducer hook when not in use. 
 
Figure B5.3 shows a photograph of the microelectrode apparatus enclosed in a mesh 
Faraday cage. Representative left atrial recordings and transmembrane action potentials 
are shown. 
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Fig B5.3 Microelectrode stage holding tissue bath and left atria and microscope used for 
visualising impalements (A). The traces on the right show examples of left atrial 
transmembrane action potentials (B) and basal contractions at 1.8mM calcium (C). 
 
 
B5.3 Experimental protocol for Transmembrane action potentials and contractility 
of isolated atria 
The heart was quickly dissected in ice cold pre-carbogenated (95% O2/5% CO2) TPSS. 
The right atrium, right ventricular free wall and left ventricle and septum were dissected, 
blotted for 3 seconds and weighed. The left atria (LA) was removed and a stainless steel 
hook was positioned into the pulmonary vein opening, before transferring into a 1 mL 
Perspex organ bath. The LA was pinned onto a small rubber mat, and the hook connected 
to the force transducer (model AE801, SensoNor, Horten, Norway). The tissue was 
perfused continuously with carbogenated TPSS at a flow rate of 3mL/min and a 
temperature of 35±0.5oC. The LA was held at an optimum preload of 3.5±0.5 mN 
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throughout the experiment, and field stimulated via platinum electrodes at 0.5 ms pulse 
width and 1 Hz, 25% above threshold (Grass SD9 stimulator, W. Warwick, RI, USA).  
After a 30 minute equilibration period the LA was impaled 4-5 times at different sites 
with a 3 M KCl filled glass microelectrode (World Precision Instruments, New Haven, 
CT, USA, 150F glass, 10-50 MΩ resistance). Data was recorded using a PowerLab and 
Chart 4.1.1 software (A.D. Instruments, Castle Hill, Australia), at 1000 samples/sec and 
then an average of the 4-5 recordings was calculated. A concentration response curve 
(CRC) to CaCl2 was generated following transmembrane action potential (TAP) 
recordings. 
 
 
 
 
 
 
